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Key variables such as trauma exposure (TE) and internalizing symptoms (e.g., posttraumatic stress 
disorder [PTSD]) have been shown to correlate with non-medical use of prescription drugs 
(NMUPD); however, the temporal associations between these phenotypes remain poorly 
understood. Moreover, there is a paucity of research that incorporates the influence of genetic 
factors in the etiology of NMUPD.  Although it has been demonstrated that drug use disorders are 
moderately heritable, research aimed at identifying the specific genes conferring risk is virtually 
non-existent for NMUPD. Therefore, determining the contribution of genetic and environmental 
factors associated with risk is critical to understanding NMUPD. To this end, the aims of the 
present study included a) examination of the prevalence and longitudinal relationships between 
TE, probable-PTSD, and NMUPD (experimental lifetime use [E] and repeated use of 6 or more 
occasions [R]) via crosslag autoregressive models; and b) identification of genetic variation 
associated with NMUPD and PTSD via genome wide analyses (i.e., genome wide complex trait 
analysis [GCTA], and genome wide association analysis [GWAS]) within a sample consisting of 
7,579 college students (61.1% female; Mage at baseline=18.53, SD=.65).  Follow-up analyses were 
additionally conducted focused on interpersonal violence.  
 The findings from the present study lends support to the extant literature suggesting that the high 
risk model (i.e., substance use precedes TE/PTSD) plays an important role in the longitudinal 
associations between NMUPD (-E, -R) and TE/probable-PTSD (prior NMUPD associated with 
heightened risk of TE/probable-PTSD at later time points).  The h2SNP estimate derived from the 
meta-analysis of GCTA results for NMUPD-E was .15 (SE = .01) and for NMUPD-R was .22 (SE 
= .01).  The h2SNP estimate for TE was .02 (SE = .01).  Due to concerns regarding power, GWAS 
were conducted only with NMUPD-E, probable-PTSD, and IPV phenotypes.  Genetic variants 
associated with NMUPD-E (rs73241778, rs138647543, rs142738451, rs74901044, and 
rs9578774) and suggestive variants associated with probable-PTSD (rs10024355) were identified 
following GWAS analyses.  Overall, although the model suggesting that TE/PTSD precedes 
substance use and the role of genetic factors received limited support within the present study, it 
is critical to note that each of these pathways is likely important yet partially dependent on a 
multitude of other factors including developmental period and class of NMUPD substance being 
examined.  Moreover, continued efforts within better powered samples are warranted to better 
understand the contribution of genetic factors. 
 
 
 
 
 
 
 
 
 
 
 
 1 
Etiological Contributions of Genetic and Environmental Factors to Nonmedical Use of 
Prescription Drugs among Young Adults 
 
Introduction 
Young adulthood is a critical period associated with high risk of trauma exposure (TE), 
posttraumatic stress disorder (PTSD), and substance use behaviors, including aberrant use of 
prescription drugs (i.e., non-medical use of prescription drugs [NMUPD]). The following section 
begins with an overview of the prevalence of NMUPD and negative correlates associated with use.  
Next, concerns regarding definitional variability and delineating NMUPD from other forms of 
substance use are reviewed.  Following, demographic (sex, ethnicity/race, age) and environmental 
factors (i.e., TE) are discussed prior to describing models of comorbidity between TE, PTSD, and 
NMUPD and the extant longitudinal literature regarding these phenotypes.  Genetic factors 
associated with NMUPD, TE, and PTSD are then reviewed within the domains of behavioral (i.e., 
family and twin studies) and molecular genetic studies (i.e., candidate gene studies and genome 
wide association studies [GWAS]). Moreover, more novel molecular approaches with be discussed 
(i.e., genome-wide complex trait analysis [GCTA]) prior to review of the aims of the present study.  
Non Medical Use of Prescriptions Drugs (NMUPD) 
NMUPD is defined by the National Survey on Drug Use and Health (NSDUH) as using a 
prescription drug “even once, that was not prescribed to you, or that you took only for the 
experience or the feeling it caused” (Substance Abuse and Mental Health Services Administration 
[SAMHSA], 2013) and is an umbrella term frequently applied to the most commonly misused 
categories of prescription medications: stimulants, sedatives, and opioids (Volkow, 2005). In 2015, 
18.9 million individuals (7.1%) reported NMUPD within the past year (SAMHSA, 2016).  
Prevalence of NMUPD has been rising since the 1990’s and NMUPD is the second most common 
illicit substance of misuse after marijuana (SAMHSA; 2010).  Rates of such misuse have been 
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shown to vary significantly by prescription medication type with rates of past year opioid misuse 
being the highest (4.7%) followed by stimulants (2%) and sedatives (.6%; SAMHSA, 2016).  
Misuse also differs by developmental period assessed with young adults (18 to 25 years of age) 
being more likely to report past year misuse (15.3%) relative to youths (12 to 17 years of age; 
5.9%) and adults (26 years of age or older; 5.8%; SAMHSA, 2016). 
Aberrant prescription drug use has been associated with a number of negative 
psychological and physical outcomes (e.g., depression, anxiety [Cai, Crane, Poneleit, & Paulozzi, 
2010], emergency room visits [Warner, Chen, & Makuc, 2009], and overdose deaths, [Becker, 
Sullivan, Tetrault, Desai, & Fiellin, 2008]). A four-fold increase in opioid misuse was noted 
between 1998 and 2008 among treatment admissions (2.2% to 9.8%; Mental Health Services 
Administration, 2008). Moreover, in 2008, opioid overdose surpassed automobile accidents as the 
leading cause of accidental death with the majority of overdoses being associated with prescription 
opioid misuse (18,893 prescription opioid related deaths compared to 10,574 heroin related deaths; 
Center for Disease Control and Prevention, 2015). Given growing use and potential negative 
correlates, NMUPD has been cited as a growing public health concern and significant economic 
burden with approximately $50 billion in estimated economic loss associated with health care, 
legal, and workplace costs (Birnbaum et al., 2011; for review: Oderda, Lake, Rüdell, Roland, & 
Masters, 2015). 
NMUPD definitional and assessment variability. As NUMPD has received increased 
attention, researchers have noted a number of methodological concerns within the burgeoning 
literature (Boyd & McCabe, 2008). NMUPD is a blanket term, and there is significant 
heterogeneity in how individual research studies operationalize it. The variability in how 
investigators define NMUPD, as well as differences in assessment of NMUPD are of significant 
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concern. The formal definition provided by SAMHSA in the 2013 NSDUH stated the any use 
within an individual’s lifetime could be considered NMUPD (SAMHSA, 2013). Not only does the 
focus on lifetime misuse with the SAMHSA definition complicate our understanding of temporal 
relationships between NMUPD and other variables, but “any use” may not capture problematic 
use worthy of clinical attention.  For instance, as identified with other substances, a pattern of 
experimental use may not be as relevant to the aforementioned negative correlates as a pattern of 
repeated substance use (Young et al., 2002).  On the opposite end of the misuse continuum, DSM-
IV-TR criteria for abuse and dependence are thought to more accurately identify those with 
problematic use (American Psychiatric Association [APA], 2000).  Although DSM-IV-TR may 
better capture clinically significant misuse, the use of strict diagnostic criteria as a means of 
determining NMUPD may not aid in identification of individuals exhibiting problematic but 
subthreshold use. Much less empirical attention has been placed on misuse existing between these 
two extremes. However, the DSM-5 has embraced this consideration of continuous symptoms with 
the transition to drug use disorders and classifications of mild, moderate, and severe substance use 
(APA, 2013) but few studies have yet to implement these criteria in the assessment of NMUPD.  
Given the potential for variability in correlates associated with this continuum of use, additional 
examination of both experimental and repeated aberrant use of prescription medications is 
necessary. 
In addition to concerns raised regarding “any use”, the portion of the definition referencing 
use for “the feeling it may cause” was considered problematic given that some individuals may 
indeed be using the medication for its intended purpose (e.g., pain relief; Huang et al., 2006).  Thus, 
such use may not be necessarily problematic. Given the definitional concerns surrounding 
NMUPD, SAMHSA (2016) has attempted to refine the definition by shifting from “non-medical 
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use” to “misuse.”  Moreover, the definition has shifted to defining “misuse” as using a prescription 
medication “any way that a doctor did not direct you to use them, including (1) use without a 
prescription of the respondent's own; (2) use in greater amounts, more often, or longer than the 
respondent was told to take them; or (3) use in any other way a doctor did not direct the respondent 
to use them.” However, it remains unclear whether this alteration in definition is associated with 
more refined assessment or has potentially created more complexities with regard to identifying 
individuals that may be using for intended purpose (e.g., pain relief) albeit without a doctor’s 
guidance (e.g., may be using for intended purpose [pain relief]; however, if they do not have a 
medical background it may be less likely that they would be able to correctly gauge appropriate 
medication/dose for the pain experienced). Given that the extant literature frequently utilizes the 
term “non-medical use of prescription drugs” which also encompasses use of a medication for the 
feeling it may cause, discussion of this form of substance use will be referred to as NMUPD 
throughout the present manuscript. 
 Many of the aforementioned concerns regarding the operationalization of NMUPD within 
the literature has been reviewed in detail by Barrett and colleagues (2008).  Although SAMHSA 
has undergone attempts to refine the definition, differing views on what constitutes NMUPD 
remain and this lack of consistency within the literature creates challenges in interpretation across 
studies.  As this literature continues to rapidly evolve, continued efforts to view findings within 
the context of these differing definitions will be necessary.  
Delineating NMUPD from other forms of substance use.  Despite rising concerns 
regarding NMUPD and the consequences associated with use, a paucity of research exits 
examining NMUPD independently relative to other substances (e.g., alcohol).  NMUPD is 
frequently binned with other forms of illicit drug use although some evidence suggests that 
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examinations of these substances independently is critical.  Given the binning, it remains unclear 
as to whether specific substances are driving the associations with risk correlates and outcomes.  
Limited attempts have been made at delineating NMUPD from other forms of substance misuse 
(particularly other forms of illicit drug use); however, the extant literature suggests that different 
risk correlates and outcomes may be affiliated with NMUPD specifically (Bohnert et al., 2012).  
However, given the binning, it remains unclear as to whether specific substances are driving the 
associations with risk correlates and outcomes.  For example, depression and anxiety symptoms 
were shown to be more strongly associated with overdose via medication relative to other 
substances (alcohol and illicit drugs; Bohnert et al., 2012).  Moreover, Ford & Arrastia (2008) 
demonstrated differential associations between sex, race, marital status, sexual activity, marijuana 
use, and social bonding based on form of substance use (NMUPD versus other forms of illicit 
substance use).  The authors suggest that given these differences, NMUPD may be a unique form 
of substance use; however, they strongly encourage additional research regarding differential 
associations based on substance type (Ford & Arrastia, 2008).   
Reasons for engaging in NMUPD rather than other substance types may be associated with 
differing means of access and misperceptions regarding safety. Prescription drugs are frequently 
considered “soft” drugs in comparison to “hard” drugs like heroin (Quintero, Peterson, & Young, 
2006).  In viewing prescription medications as “soft” drugs, the consequences associated with use 
are frequently minimized.  Moreover, prescription medications may be viewed as safer than other 
illicit drugs and easier to obtain from friends and relatives (Friedman, 2006). Arria and colleagues 
(2008) noted that low perceived risk was significantly associated with misuse when controlling for 
demographic characteristics and sensation-seeking.  
Aggressive marketing by pharmaceutical companies has also been linked with heightened 
 6 
misuse, particularly opioids (Van Zee, 2009; Maxwell, 2011). The increased exposure may also 
contribute to the evolving misperceptions of safety and social acceptability of NMUPD (Quintero 
et al., 2006). This marks a complex issue, given the benefits of direct to consumer marketing (e.g., 
greater awareness of potential medication options; Ventola, 2011). Thus, attempting to achieve a 
balance whereby increased access to information is available while the potential influence on 
misuse is minimized marks a critical area in need of additional attention.  
In sum, although NMUPD falls broadly under the category of substance misuse, the risk 
correlates of misuse (i.e., motivations, misperceptions regarding safety, perceived social 
acceptability) may differ substantially from those identified for other substances.  Given these 
putative constellation of differences, it is critical to consider etiological factors and correlates that 
may be unique to NMUPD. The extant literature on other substance use phenotypes is quite 
developed, and in comparison, the etiologic literature on NMUPD is in its infancy. Thus, the 
independent examination of NMUPD will only serve to further refine the field’s understanding of 
this particular category of misuse and provide greater opportunities to create targeted prevention 
and intervention programs that may prove more effective than more broadband approaches to 
reduce substance use. 
Demographic correlates of NMUPD. Due to the heightened concern regarding NMUPD, 
recent focus has been placed on identifying putative risk and protective factors.  On the 
demographic level, previous research has identified sex, race/ethnicity, and age as key variables 
associated with variability in NMUPD.  For example, men are more likely to report NMUPD 
overall (i.e., clustered across drug classes) relative to women (McCabe et al., 2006; Johnston, 
O’Malley, Bachman, & Schulenberg, 2005).  However, differential associations have been 
identified among men and women when the broad NMUPD classification of misuse is parsed into 
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independent categories (i.e., opioids, stimulants, sedatives) with women reporting greater 
nonmedical use of opioids relative to men (SAMHSA, 2011).  However, more recent research 
suggests that prevalence of misuse is greater among men for each category with the exception of 
sedatives (SAMHSA, 2016).  NMUPD patterns have also been examined for racial/ethnic 
differences. Overall, the highest rates of use were among non-Hispanic individuals reporting two 
or more races (11.7%; SAMHSA, 2016).  Similar rates were identified among non-Hispanic White, 
American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and Hispanic 
individuals (SAMHSA, 2016).  The lowest prevalence rates were identified among non-Hispanic 
Blacks or African Americans and Asians (SAMHSA, 2016).  
NMUPD among college students.  In addition to the aforementioned demographic 
variables, age has been linked with NMUPD variability. Prescription misuse is particularly 
prevalent among young adults with approximately 4.4% of individuals within the 18-25 age group 
reporting current NMUPD (i.e., past 30 days; SAMHSA, 2014) in comparison with the 12-17 age 
group and 25+ age group which endorse 2.6% and 2.1% current use, respectively.  Moreover, a 
growing literature suggests that college aged students may be a particularly vulnerable population 
for NMUPD (McCabe, West, & Wechsler, 2007; Tapscott, B. E., & Schepis, 2013). NMUPD is 
more prevalent among young adults relative to other age groups and is particularly prevalent 
among college students (SAMHSA, 2016). Additional research also suggests that stimulants use 
is the most common form of NMUPD among college students (less expensive and more readily 
available on campuses), followed by benzodiazepines and opioids (Parks et al., 2015).  For 
example, previous research suggests that college students relative to their non-collegiate peers 
report greater Ritalin misuse (Johnston et al., 2005). 
Several potential factors may contribute to the elevated risk of substance misuse present 
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within this time period including heightened stress associated with the period of transition, 
increased access, and lower levels of parental monitoring (Gfroerer, Greenblatt, & Wright, 1997).  
Additionally, college students have been found to overestimate the prevalence of NMUPD among 
peers (McCabe, 2008) which may influence perceived norms and potentially increase misuse 
behavior (McCabe, West, & Wechsler, 2007). Moreover, permissive views on use among students 
and overestimation of peer misuse have been linked with increased risk of misuse (Perkins, 2012).  
Thus, college students may be a particularly at-risk group relative to non-collegiate same age peers, 
making them a fitting group for further study. 
Environmental Factors (i.e., Trauma Exposure) Associated with NMUPD 
In identifying demographic variables associated with heightened risk, the ability to 
implement intervention efforts may be improved. In addition to demographic factors, a growing 
literature suggests that TE and PTSD may confer increased risk of aberrant prescription drug use 
(Walsh et al., 2014; Ham et al., 2016) thereby potentially representing an important modifiable 
risk factor.  If individuals with histories of TE/PTSD are at heightened risk for NMUPD, targeted 
interventions aimed at TE/PTSD may reduce the risk of NMUPD. 
TE is a common occurrence with approximately 70% of individuals being exposed to at 
least one traumatic event within their lifetimes (Benjet et al., 2016). Although TE is prevalent, 
trajectories of symptoms experienced post trauma are frequently characterized by resilience 
(Bonanno et al., 2012). However, an estimated 6.1% of Americans meet lifetime diagnostic criteria 
for DSM-5 PTSD which pertains to a constellation of symptoms (i.e., intrusion, avoidance, 
negative alterations in cognitions and mood, alterations in arousal and reactivity) that may occur 
post trauma (APA, 2013) and 4.7% meet past year criteria (Goldstein et al., 2016) although 
estimates can vary greatly depending on sample characteristics and method of assessment (Breslau, 
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2001).  TE is particularly relevant among young adults (16 to 20 years of age; Breslau et al., 1998).  
This age group is additionally at heightened risk of experiencing exposure to interpersonal violence 
(IPV; e.g., physical assault, sexual assault; Breslau et al., 1998).  This has become a growing focus 
of concern across college campuses with such violence being identified as particularly prevalent 
(Azimi & Diagle, 2017).   
Correlates of TE and PTSD.  Previous research has identified several demographic 
variables which may influence the association between TE and PTSD.  Although men report 
greater exposure to any traumatic event, the prevalence of IPV is higher among women (Tolin & 
Foa, 2006; Cromer, & Smyth, 2010). Women additionally have higher rates of PTSD relative to 
men (Breslau, 2001).  In regard to other demographic variables of race/ethnicity, previous research 
suggests that the lifetime prevalence of PTSD was highest among African Americans relative to 
other racial groups (Roberts et al., 2001; Breslau, Davis, & Andreski, 1995).  However, rates of 
TE varied by event with African Americans being exposed to trauma more interpersonal in nature 
(e.g., child maltreatment, witnessing domestic abuse; Roberts et al., 2001).  Other studies have 
identified mixed results regarding prevalence of TE by race/ethnicity (Breslau et al., 1991; Hanson 
et al., 1993; Kilpatrick et al., 1997).  Age has also been identified as a critical variable to be 
considered when examining the associated between TE and PTSD.  Specifically, college represents 
a time in which the likelihood of TE is at its peak (i.e., college students represent the age range at 
highest risk for trauma exposure [Breslau, et al., 1998]).  
Aspects of the trauma itself, including trauma type, have also shown differential 
associations with PTSD.  Specifically, IPV has been associated with increased post exposure 
psychopathology relative to trauma considered more accidental or non-assaultive (e.g., natural 
disasters, transportation accidents; Breslau et al., 1991).  Moreover, IPV has been frequently 
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associated with problematic substance use (Ouimette, Kimerling, Shaw, & Moos, 2000; Back et 
al., 2001; Hedtke et al., 2008).  Few studies have thoroughly examined the NMUPD risk affiliated 
with TE type, but the extant research indicates that witnessing violence and sexual assault are 
significantly related to past year NMUPD (McCauley et al., 2010, 2011).  Given these findings, 
the potential influence of trauma type when examining the associations between TE/PTSD and 
NMUPD is a critical consideration. 
Associations between PTSD and NMUPD.  Although extensive literature exists 
regarding the relationship between PTSD and other forms of substance use (Hawkins, Catalano, 
& Miller, 1992; Newcomb & Felix-Ortiz, 1992), examination of the associations between PTSD 
and NMUPD remains in a relatively nascent stage.  However, within the extant literature a 
significant association between PTSD and NMUPD is typically found (Cochran et al., 2015; 
McCauley et al, 2009; Rhoades & Wenzel, 2013; Saha et al., 2016; White et al., 2009; Smith et 
al., 2016; Bohnert et al., 2012; Liebschutz et al., 2010; McCauley et al., 2010; Mackesy-Amiti et 
al., 2015) although not consistently (Kennedy et al., 2015; Wilsey et al., 2008; Hall et al., 2016; 
Berenson & Rahman, 2011; Becker et al., 2008).  Several factors may contribute to the lack of 
significant findings between PTSD and NMUPD.  Kennedy and colleagues, 2015 did not 
demonstrate a significant association between PTSD and stimulant misuse. The authors did not 
provide detailed information regarding PTSD assessment and created a dichotomous “mental 
health” variable, although a large proportion included participants diagnosed with PTSD. Thus, 
poor reporting regarding PTSD measurement and the binning of several mental health disorders 
into a single dichotomous variable make it difficult to discern the association between PTSD 
specifically and NMUPD. Wilsey et al., 2008 examined the relationship between PTSD and opioid 
misuse within a chronic pain sample but did not control for pain in the final model. Moreover, 
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state anxiety was included in the final model which may have accounted for the variance in 
NMUPD associated with PTSD (e.g. potential multicollinearity issues). Hall et al., 2016 also 
focused on a very specific population, examining a traumatized sample of women on probation or 
parole which limits generalizability. Moreover, although a fairly comprehensive list of covariates 
(i.e., pain, substance use, mental health disorders) were included, trauma load/type was not 
controlled for. The other two studies that did not demonstrate associations between PTSD and 
NMUPD included several important covariates, however, had limitations in regard to assessment 
of each variable (Berenson & Rahman, 2011; Becker et al., 2008 adapting items from the NSDUH 
survey and DSM-IV-TR, respectively). Lack of standardized assessment may have influenced the 
findings. 
Although biases were present in each of the studies that did not suggest a significant 
association, it is critical to note that many of these same limitations and additional problematic 
sources of bias are also present in the studies that did identify an association. For example, 
McCauley and colleagues (2010) did not correct for multiple testing, thus, although a significant 
finding was identified, it would unlikely remain significant upon application of corrections. Thus, 
it is difficult to determine the true relationship between PTSD and NMUPD and to quantify 
whether the biases within the five studies were more or less problematic than those identified 
within the other studies. However, the pervasiveness of these conceptual and methodological 
issues warrant considerable attention. 
 NMUPD and TE/PTSD models of comorbidity.  Although associations have been noted 
between TE, PTSD, and NMUPD, the causal relationship among these phenotypes is unknown. 
However, multiple models of comorbidity have been hypothesized including the self-medication 
model (i.e., TE/PTSD precedes NMUPD which is used as a method of coping with PTSD 
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symptoms), substance use increasing risk of TE and thus PTSD (i.e., individuals misusing 
prescription medications may engage in behaviors putting them at heightened risk for trauma [e.g., 
transportation accident] and post trauma symptoms), and shared risk liability to both disorders 
(i.e., a third factor [e.g., genetic factors] contributes to comorbidity). 
The self-medication hypothesis is frequently used to describe the mechanism potentially 
underlying the association between post-trauma distress and substance use broadly which has been 
conceptualized under negative reinforcement models of comorbidity (Keane & Kaloupek, 1997). 
This hypothesis posits that the psychoactive effects of substances aid in alleviating distress 
following trauma, at least for a short period of time (Miranda, Meyerson, Long, Marx, & Simpson, 
2002). The numbing effect or altered state created by substances thereby serves as a negative 
reinforcer (i.e., removes psychological distress) and acts as an effective short term strategy for 
reducing distress. However, although reinforcing in the short term, it does not allow the individual 
to recognize that they are indeed capable of experiencing and tolerating distress without the use of 
substances and can contribute to the development of substance abuse/dependence.  The 
relationship between PTSD and misuse as a means of self-medication has been noted among 
several forms of substance use (Ouimette et al., 2010; Hawkins et al., 1992; Newcomb et al., 1992).  
Although the association between PTSD and substance use is often explained by the self-
medication hypothesis, alternative models regarding the relationship between traumatic stress and 
substance use also exist. It has been hypothesized that substance use may increase risk of trauma 
exposure and PTSD (e.g., lowered inhibitions could increase participation in risky behaviors 
and/or unsafe situations; Cottler, Compton, Mager, Spitznagel, & Janca, 1992). The high-risk 
hypothesis suggests that misuse of substances may be related to a broader cluster of other high risk 
behaviors which could heighten risk for TE and thus, indirectly, PTSD (Chilsoat & Breslau, 1998). 
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Although this model is less frequently referenced within the literature, there is some research that 
suggests that substance use increases IPV risk and IPV in turn confers heightened risk of substance 
use thereby creating a “vicious cycle” (Kilpatrick et al., 1997) 
Additionally, a shared etiological factor (e.g., genetic influences) may increase 
vulnerability to both PTSD and substance use (Sartor, McCutcheon, Pommer, Nelson, & Grant, 
2011). Multiple genetically informed studies suggest that substance use and PTSD are influenced 
by common genetic contributions (Xian et al., 2000; Sartor et al., 2011; Wolf et al., 2010).  
However, the shared liability hypothesis has not received as much empirical attention as the self-
medication hypothesis and the lack of temporal assessment within the NMUPD and PTSD 
literature further diminishes the field’s understanding of how each of these variables may influence 
one another. 
Longitudinal examination of NMUPD, TE, and PTSD.  The research examining the 
relationship between TE and NMUPD has been predominately cross-sectional in nature thereby 
reducing the ability to determine causal influences.  Although a longitudinal study design was not 
utilized, Sturza & Campbell (2005) noted that a large proportion of rape victims reporting misuse 
stated they were using the medication “to deal with” their rape experience.  Given the theorized 
perceived safety and social acceptability of NMUPD, individuals may be at increased risk of 
NMUPD as a means of coping with PTSD. Another pathway by which these TE/PTSD may 
increase risk of NMUPD includes access to prescription medications following a potentially 
traumatic experiences.  Fortuna and colleagues (2010) noted increasing trends in prescribing of 
opioids for non-injury and injury related visits since 1994.  In instances of pain management 
following an injury, an individual may be prescribed an opioid.  The opioid may serve dual 
purposes in that the patient could use the medication for both pain management and perhaps to aid 
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in PTSD symptom reduction post injury. This may also be further complicated by psuedoaddcition.  
Psuedoaddiction refers to the misuse of medications for treatment of underlying undiagnosed 
physical pain rather than emotional distress associated with traumatic experiences (Passik, Kirsh, 
& Webster, 2011). This is a complex concern, particularly among veterans. Many returning 
veterans report pain symptoms and are also at heightened risk of PTSD given the risk of trauma 
exposure while deployed. Therefore, an important balance must be achieved whereby the pain is 
being treated adequately while also considering the potential impact of PTSD on risk of misuse.   
The confluence of these aforementioned factors may contribute to heightened risk of 
NMUPD rather than other forms of substance misuse when experiencing PTSD. Although it is 
assumed that NMUPD is used to cope with TE/PTSD (Miranda et al., 2002), it remains merely an 
assumption given the scarcity of data to validate this claim. The relationship between TE/PTSD 
and NMUPD is likely bidirectional in nature; however, the relative risk associated with TE/PTSD 
and NMUPD across time has not been investigated.  Thus, there is a need for large-scale 
longitudinal studies to examine the relationships between TE/PTSD and NMUPD at a phenotypic 
level.  Elucidating the causal association among these variables is critical given the clinical 
implications.  If TE/PTSD influences NMUPD it could prove to be a beneficial assessment point.  
Moreover, TE/PTSD prevention efforts could effectively reduce NMUPD.  However, this may be 
a misguided effort if the reverse is the case and NMUPD increases risk of TE/PTSD.  
Genetic Factors Associated with NMUPD 
Although environmental factors (i.e., TE) are thought to confer risk for NMUPD, 
understanding of the etiology of NMUPD would be incomplete without consideration of genetic 
factors.  Thus, a model that would most appropriately capture the associations among these 
variables would integrate both environmental factors and the underlying genetic risk that may 
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impact each phenotype.  Previous research within the PTSD and alcohol use disorder literature 
suggests a ~55% overlap in the genes contributing to each disorder (Sartor et al., 2011; Xian et al., 
2000).  Shared genetic effects have also been identified between PTSD and other forms of 
substance use including nicotine dependence (63%; Koenen et al., 2005) and drug use disorders 
(i.e., meeting DSM-III-R criteria for marijuana, sedatives, stimulants, heroin/opioids, 
PCP/psychedelics; Xian et al., 2000). These findings lend support for a shared liability model of 
comorbidity characterized by a third factor (e.g., genetics) that may explain the aforementioned 
documented associations between PTSD and NMUPD.   
Behavioral genetics studies. 
Family and twin studies of NMUPD.  Several methods exist to examine the potential 
genetic influences associated with TE/PTSD and NMUPD.  Early behavioral genetics studies 
consisted of family studies and derivatives (i.e., adoption studies; Plomin et al., 2013).  Family 
studies determine the inter-generational transmission of traits by examining familial aggregation 
(i.e., a higher rate of the trait among family members when compared to the general population; 
Gelenter & Kranzler, 2010).  Family studies regarding the transmission of substance use have 
shown that it runs in families (Merikangas et al., 1998). Previous literature has examined illicit 
substance use more broadly (Agrawal & Lynskey, 2008); however, family studies of NMUPD 
independently have not been conducted.   
Family studies provide an opportunity to determine if a particular trait runs in families, 
usually by demonstrating that there is a higher incidence of the trait the closer in relation 
individuals are to the proband (i.e., affective individual).  However, determining the genetic 
influences alone can become difficult, especially as multiple factors could be contributing to the 
trait in question (i.e., genetic influences, shared environment).  Thus, twin studies have emerged 
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as a method to determine heritability or the proportion of phenotypic variance that can be attributed 
to genetic factors. Twin models provide an opportunity to partition the variance of the trait 
according to: additive genetic factors (A), common environment (C), and unique environment (E).  
Additive genetic effects (A) refer to the “sum of the average effects of the individual alleles 
(variant form of a gene)” (Neale & Maes, 2004).  Common environment (C) refers to the shared 
environment that is assumed to be the same for all family members (e.g., happens to both twins 
such as socioeconomic status; Jang, 2005).  Unique or non-shared environment (E) refers to unique 
experiences that one twin may experience while the other may not (e.g., trauma exposure) (Jang, 
2005).  Measurement error in twin models is also captured under the umbrella of unique 
environmental component. The ability to partition the variance and covariance between twins into 
A, C, and E rests on the fact that monozygotic twins share 100% of their genes while dizygotic 
twins share on average 50%. Thus, if intra pair correlations among MZ twins are more than twice 
the size of DZ intra correlations, additive genetic effects play a role in the trait of interest.  It is 
critical to note that estimates of heritability derived from twin studies are to be viewed on a 
population level rather than an individual level (i.e., would not be appropriate to claim that 60% 
of a particular trait within an individual is attributable to genetic factors as heritability is referring 
to differences among individuals and averages). By estimating heritability, previous twin models 
have highlighted the relative influence of genetics and laid a foundation for specific investigation 
of genes exerting a potential influence.  Thus, as Afifi et al. (2010) stated, twin studies serve as a 
guide for future molecular genetics research.   
Similar to family studies, relatively few twin studies have treated NMUPD as an 
independent phenotype. Rather, previous studies have clustered NMUPD with other forms of illicit 
drug use and/or not made the explicit distinction as to whether these substances were used against 
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a doctor’s order (Agrawal et al., 2005; Lynskey et al., 2012).  However, one twin study that did 
examine NMUPD independently identified a modest heritability estimate for stimulants (23%) and 
much smaller estimates for sedatives (6%) and opioids (3%); however, the authors report that this 
is likely due to low sample (499 MZ pairs and 327 DZ pairs; Karkowski et al., 2000).  Another 
twin study examining a common genetic factor associated with various types of substance use 
suggests that a common genetic pathway may be shared across several forms of use, including 
NMUPD, rather than substance specific (Kendler et al., 2003). 
Twin studies have been more extensively used in the examination of other forms of 
substance use and have identified moderate to strong heritability estimates for alcohol use 
disorders (Verhulst et al., 2015), licit substance use (e.g., nicotine dependence, Vink et al., 2005), 
and illicit substance use (e.g., cocaine, opioid dependence, Gelertner et al., 2010).  Rates of 
heritability vary greatly depending on sample assessed, form of illicit substance use being 
examined, and severity of use. McGue and colleagues (2000) identified a heritability estimate of 
25% among a sample of adolescent twin pairs for illicit substance use (e.g., marijuana, 
amphetamines). Moreover, just as some evidence suggests that common genetic influences may 
be associated with various forms of substance misuse (Young et al., 2006; Kendler et al., 2006; 
Palmer et al., 2015), shared genetic factors may also influence other forms of psychopathology.  
Xian and colleagues (2000) findings suggest that genetic influences associated with alcohol and 
substance use account for approximately 40% of the variance identified in PTSD, highlighting the 
genetic overlap across disorders.  However, additional examination is warranted specifically with 
regard to NMUPD. 
Family and twin Studies of TE and PTSD.  Family studies regarding TE and PTSD have 
additionally demonstrated that PTSD runs in families with biological relatives of individuals with 
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PTSD having high rates of PTSD, relative to other trauma exposed individuals (Yehuda et al., 
2001; Nugent et al., 2008).  Moreover, despite views of TE as an entirely environmental 
phenomenon, twin studies examining the heritability of trauma exposure have identified a 
moderate genetic influences (Sartor et al., 2012).  For example, genetic effects have been found to 
account for 35-47% of the variance in exposure to combat related trauma (Lyons et al., 2003).  
Moreover, exposure to TE (i.e., assaultive) has been linked to certain individual (e.g., history of 
depression) and familial (e.g., maternal depression) level factors (Koenen et al., 2002).  However, 
the literature regarding the influence of genetic factors associated with non-assaultive forms of TE 
is mixed.  The majority of twin studies have not identified a genetic contribution to non-assaultive 
forms of TE (e.g., natural disaster; Afifi et al., 2010) while one study noted a genetic impact on 
“low risk traumas” which could be attributable to methodological differences (e.g., inclusion of 
both twins and siblings rather than twins alone, Sartor et al., 2012).  Gene by environment 
correlation (rGE), which refers to the influence of genes on environment (e.g., genotype influences 
selection and interaction with one’s environment), has also been identified as a factor contributing 
TE.  Specifically, personality may influence selection of environments that may be associated with 
heightened risk of TE exposure (Nadar, 2016).   
Genetic influence additionally appears to influence PTSD development following TE.  
Approximately 24-72% of the variance in PTSD has been accounted for by genetic factors (for 
review see Afifi et al., 2010; Lyons et al., 1993; Sartor et al., 2012; Stein et al., 2002).  Moreover, 
the moderate heritability of PTSD symptoms has been identified among both male and female 
samples (Sartor et al., 2012).  Given the genetic contribution to TE in addition to PTSD and that 
TE is a necessary, but not sufficient, component contributing to risk to PTSD, it is necessary to 
account for this when attempting to determine the heritably of the PTSD.  Even while controlling 
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for the genetic influences associated with TE, the literature examining the heritability of PTSD has 
continued to find moderate estimates of heritability (True et al., 1993). 
  Twin studies have determined that the genetics effects associated with PTSD symptoms 
overlap with several forms of substance use including alcohol consumption (McLeod et al., 2001), 
alcohol dependence, cannabis dependence, and tobacco dependence (Koenen et al., 2003).  The 
genetic liability to PTSD post-TE appears to be shared with the liability for substance use 
disorders. Stated another way, some of the covariation between these disorders appear to be 
attributable to the same underlying genetic liability (Sherrer et al., 2008). 
Molecular genetics studies.  Given the identified heritability of these phenotypes, growing 
effort has been placed into identifying specific genetic variants associated with risk.  Although 
twin studies provide an opportunity to determine the degree of heritability associated with specific 
traits, advances within the past thirty years have allowed us to investigate the contribution of 
genetic variants, mostly commonly in the form of specific single nucleotide polymorphisms 
(SNPs), to complex traits (McCarthy et al., 2008).  Molecular studies examine how specific 
variants in the genome are associated with risk for various phenotypes.  Although such 
examination began with linkage studies, which were useful in the identification of areas of specific 
chromosomes that may be associated with the phenotype of interest; Lander & Schork, 2004), 
growing emphasis has been placed in determining if certain polymorphisms are associated with 
cases vs. controls (i.e., those that have the disorder [PTSD] vs. those that do not) or degree of 
association based on a quantitative trait.  Candidate gene studies, which test theorized genes of 
influence in an association with a specific variable of interest, have demonstrated inconsistent 
results within the literature (Tabor, Risch, & Myers, 2002). Thus, growing emphasis has been 
placed in utilizing more agnostic approaches to examining the molecular genetic influences 
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including genome wide association studies (GWAS; Wilkening, Chen, Bermejo, & Canzian, 
2009). Moreover, growing emphasis has been placed on the polygenetic contribution to complex 
phenotypes such as mental health disorders (Hirshorn & Daly, 2005).  Candidate gene studies do 
not take into account the small contribution of many genes to the trait of interest. Moreover, given 
our limited knowledge regarding the relationship between specific genes and certain traits, it may 
be overly ambitious to narrow in on a single trait before associations within the genome have been 
established (Nussbaum et al., 2007).  Additional disadvantages of candidate gene studies include 
lack of adjustment for population stratification (i.e., differences in allele frequencies based on 
ancestry), less coverage relative to genome-wide studies, and frequent use of smaller sample sizes 
which results in less power to detect effects and increases the likelihood of false positives if an 
effect is found (Zhu & Zhao, 2007; Hirshhorm & Daly, 2005).  Thus, testing for genome wide 
associations without a priori assumptions is a more powerful method of identifying variants 
associated with a specific trait.  This is not to say that use of candidate gene studies are not fruitful 
(particularly given the the potential utility in validating GWAS findings via candidate gene 
studies); however, following evidence of association present in GWAS and an understanding 
regarding biological pathways contributing to risk may better position researchers in examining 
genes of significance (Amos et al., 2010).   
Given the interest in identifying genes associated with specific traits with a more unbiased 
approach, GWAS have become more frequently used.  GWAS determine if certain SNPs occur 
more frequently based on case status or severity of the trait in question (Risch & Marikangas, 
1996). These analyses are completed by taking into account linkage disequilibrium (LD), which 
refers broadly to the non-random association of alleles at different loci, within a given population 
(Reich et al., 2001). After generations of assortative mating, linkage equilibrium will occur 
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whereby each allele is independent.  However, those linked together are considered to be in LD.  
Some groups have lower LD such as African ancestral groups because there have had more 
opportunities for recombination over the passage of time.  Other groups such as Europeans and 
Asians have higher LD because of factors including founder effects.  The concept of LD is 
important given that most chips use “tag” SNPs that are in high LD with other SNPs, thus thereby 
allowing for the examination of neighboring alleles (Need & Goldstein, 2006). LD is also 
important to consider, since molecular studies can be confounded by population stratification, 
which occurs when there is a systematic difference in allele frequencies between subpopulations 
within a population (Price et al., 2010). An additional benefit includes the capability to examine 
the overlap between two constructs whereby certain SNPs may be relevant in both phenotypes 
(e.g., TE and NMUPD). 
 GWAS test the “common disease, common variant” hypothesis which suggests that 
common diseases are attributable to common variation occurring within at least 1-5% of the 
population (Wessel, 2013).  But to date, there is a discrepancy between the amount of variance 
that SNPs identified as associated with a certain traits account for via GWAS and those suggested 
by twin studies although this gap is closing as samples sizes increase (Gratten et al., 2012). This 
discrepancy likely reflects the multifactorial contribution of many SNPs to complex traits and 
given the small contribution across many variants, large sample sizes are necessary to have enough 
power to detect an effect (Psychiatric GWAS Consortium Coordinating Committee, 2009).  The 
discrepancy regarding heritability estimates identified in twin studies and the amount of variance 
in a trait accounted for by additive contribution of SNPs identified via GWAS could also be due 
to other factors including: rare variants (those occurring in <1% of the population), epistasis (gene 
by gene interaction), and gene-by-environment interactions (Korte & Farlow, 2013).  The progress 
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of GWAS in accounting for more of the variance as suggested by twin studies and the growing 
interest in other methods which may address some of the shortcomings associated with behavioral 
genetic methods and GWAS demonstrate further promise. 
Molecular studies of NMUPD. To date, no molecular studies exist explicitly examined 
NMUPD.  Hundreds of candidate gene studies have been conducted with regard to substance use 
disorders both licit and illicit (please see reviews: Dick & Foround, 2003; Agrawal & Lynskey, 
2009; Bousman et al., 2009).  Broadly, findings have consistently identified associations between 
genes associated with alcohol metabolism (ADH and ALDH; Dick & Agrawal, 2008) and alcohol 
use.  Moreover, dopamine receptor genes (DRD2, DRD3, DRD4) have demonstrated associations 
with both licit and illicit substance (Du et al., 2011).  Additionally, several candidate genes have 
been linked with variation in opioid use variation.  The most consistently identified genes include 
DRD2, OPRM1, OPRD1, and BDNF which are thought to play a role in encoding receptors and 
signaling molecules (for review please see Mistry et al., 2014). Although several candidate genes 
of interest have shown associations with substance use phenotypes, no candidate gene studies to 
date have examined NMUPD specifically.   
Similar to the paucity of candidate gene studies, no GWAS of NMUPD has been 
conducted; however, there have been GWAS of other forms of illicit substance use.  GWAS for 
opioid dependence have identified multiple loci of potential influence including a genome-wide 
significant SNPs in NCK2 (rs2377339; protein associated with growth factor receptors; Liu et al., 
2013), KCNG2 (rs62103177), and KCNC1 (rs60349741; both potassium voltage-gated channel 
genes; Gelertner et al., 2014).  Gelertner and colleagues (2014) additionally identified associations 
between the APBB2 (rs115368721) and PARVA (rs73411566) genes and opioid dependence 
symptom count.  A GWAS conducted by Nelson et al. (2016) additionally noted an association 
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between CNIH3 (rs10799590) in opioid dependent individuals. With regard to other illicit 
substances, a recent GWAS also identified a SNP in FAM53B (rs2629540), which is potentially 
associated with regulating cell proliferation, associated with cocaine dependence (Gelernter et al., 
2014).  Uhl and colleagues (2008) identified two markers CDH13 and CSMD1 that almost reached 
genome-wide significant for methamphetamine dependence.  Despite molecular studies of licit and 
illicit substances, continued molecular examination of these phenotypes is needed to identify 
additional variants and replicate previous findings.  Moreover, given that there has yet to be a 
GWAS of NMUPD, a large gap within the literature remains present. 
Molecular studies of TE and PTSD.  Over 100 candidate gene studies have been 
conducted specifically targeting SNPs in over 52 different genes and their associations with PTSD 
(Sheerin et al., 2017).  Given the large number of candidate gene studies, meta-analyses have been 
conducted and have identified multiple significant findings including DRD2 (rs1800497), SLC6A3 
(three prime untranslated region variable number tandem repeat; both in the dopaminergic system; 
Li et al., 2016) and the BDNF (rs6265) gene (when sample is limited to TE individuals; Bruenig 
et al., 2016). 
To date, ten GWAS have been conducted and multiple novel loci have reached genome-
wide significance.  Logue and colleagues (2013), in the first PTSD GWAS, identified the retinoid-
related orphan receptor alpha (RORA [rs8042149]; involved in neuroprotection) as associated with 
PTSD.  Additional PTSD GWAS have also identified novel loci including a genome-wide 
significant SNP on chromosome 7p12 (rs406001; associated with protein expression in the 
hippocampus; Xie et al., 2013) and lincRNA AC068718.1 (rs1611133; potentially a non-coding 
RNA gene with regulatory function; Guffanti et al., 2013).  Xie and colleagues (2013) additionally 
identified a nominally significant hit in the Tolloid-Like 1 gene (rs6812849).  This particular gene 
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is thought to be associated with protein expression in the hippocampus and may be influenced by 
stress hormones (Xie et al., 2013).  Genome-wide significant variants have also been identified at 
chromosome 4p15 (rs717947), which the authors suggest may be associated with methylation 
(Almli et al., 2015), and ANKRD55 (rs159572; associated with autoimmune and inflammatory 
disorders) and ZNF626 (rs11085374; potentially involved in RNA transcription regulation) in two 
separate samples (Stein et al., 2016).  A meta analyses across four ancestral groups conducted by 
Nievergelt et al., 2015 identified a novel variant in the PRTFDC1 gene (rs6482463; putative 
tumor-suppressor gene), a finding which was also replicated in another independent sample.  
Powers and colleagues (2016) identified a significant variant in the IL2RA gene (rs6602398; a pro-
inflammatory cytokine associated with inflammatory response) associated with PTSD diagnosis.  
However, this finding was only present among males and no genome-wide significant hits were 
identified among females (Powers et al., 2016).  Another study demonstrated a significant 
association between a novel variant in the NLGN1 gene (rs6779753; encodes the protein 
neurologin 1) and PTSD diagnostic status among a civilian population (Kilaru et al., 2016).  Two 
studies (Wolf et al., 2014; Ashley-Koch et al., 2015) were unable to find genome-wide significant 
variants which is likely due to low sample size (<2,000 participants).  Recognizing low power as 
a difficulty within the field and interest in improving gene finding efforts, Duncan and colleagues 
meta-analyzed data from Freeze 1 of the Psychiatric Genetics Consortium – PTSD which included 
20,070 participants.  No variant reached genome-wide significance with the exception of a variant 
in the KLHL1 gene (rs139558732) within the African ancestral group.  However, it is critical to 
note that this finding is likely spurious in nature given that, when meta-analyzed with results from 
another sample, genome-wide significance for that variant decreased (Duncan et al., 2018).  
Recognizing limitations associated with low sample size, Freeze 2 of the Psychiatric Genetics 
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Consortium – PTSD increased the sample significantly by including 206,655 participants 
(Nievergelt et al., 2018).  Six loci were identified as being associated with PTSD at a genome-
wide level, including rs34517852, rs9364611, rs148757321, rs571848662, rs115539978, and 
rs142174523.  The identification of these variants upon inclusion of significantly greater number 
of participants (ten times the amount of previous work), highlight the importance of power in 
determining the impact of influence of genetic factors in PTSD (Nievergelt et al., 2018).   
Aggregate molecular genetic methods.  Although family and twin studies have been 
historically used as methods of partitioning sources of variance associated with genes.  Growing 
popularity has been placed on utilizing genome wide complex trait analysis (GCTA) which is a 
SNP based method of estimating the heritability of a particular trait among unrelated individuals.  
This is accomplished by creating a genetic relatedness matrix whereby correlations are created 
among individuals and then regressed on the phenotype of interest (Yang et al., 2011).  Similar to 
other genetic methods, GCTA has limitations with regard to not accounting for rare variants and 
also being sample dependent.  However, there are advantages in that a smaller sample size can be 
utilized relative to other genetic methods.  Bivariate analyses can also be conducted to examine 
the covariance between two traits, thereby, aiding in determining if the genetic influences 
associated with one trait are shared with the other (Lee et al., 2012). 
SNP based heritability of substance dependence/drug problems ranges from approximately 
25 to 36% (Palmer et al., 2015).  Moreover, the authors suggested that the SNPs across various 
forms of substance use are likely common given the high correlation identified (Palmer et al., 
2015).  Another study examining the SNP based heritability of cannabis use disorder identified an 
estimate of 21%; however, this finding was not significant (Agrawal et al., 2014) while a 
significant finding with regard to age of cannabis initiation was identified by Minica et al., 2015 
 26 
(25% heritability estimate).  GCTAs conducted by Vrieze and colleagues (2013) identified 
aggregate heritability estimates ranging from 10-30% for drug use, alcohol consumption, alcohol 
dependence, nicotine use, and nicotine dependence.  Taken together, these findings suggest that 
this novel molecular approach may provide another method of determining heritability estimates 
of substance use among unrelated individuals.  Limited examinations of the SNP based heritability 
regarding TE and PTSD have been conducted.  However, the extant literature suggests a moderate 
heritability of IPV (47%; Palmer et al., 2016).  Palmer and colleagues (2016) additionally noted 
that the genetic effects associated with IPV was also shared with drug dependence which supports 
previous research suggesting a potential common liability to both disorders.  With regard to the 
heritability of PTSD, a recent GCTA conducted by Stein et al., (2016) do not identify a significant 
heritability estimate.  However, in the recent PGC-PTSD freeze (Freeze 2), SNP-based heritability 
estimates largely fell within the 10-20% range across ancestries and studies (Nievergelt et al., 
2018).  Moreover, Duncan and colleagues (2017) identified a significant SNP based heritability 
estimate for European-American females (29%) although a significant heritability estimate was 
not identified among European-American males within the sample.  
Summary of literature regarding environmental and genetic factors associated with 
NMUPD. The NSDUH reports that 7.1% of individuals 12 years or older in the United States have 
engaged in NMUPD within the past 12 months (SAMHSA, 2016) and college aged students may 
be a population that is particularly at risk for NMUPD (McCabe et al., 2006). College also 
represents a time in which the likelihood of TE an important risk factor for NMUPD (McCauley 
et al., 2011), is at its peak (Breslau, et al., 1998). Further, TE confers risk for internalizing 
psychopathology (e.g., PTSD) which may increase risk for NMUPD (Young et al., 2012), perhaps 
via a self-medication pathway (Walsh et al., 2014). Thus, there is a need for large-scale studies of 
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college students to examine the relationships between TE/PTSD and NMUPD at a phenotypic 
level to help inform prevention and intervention programming (e.g., enhance our ability to deliver 
targeted prevention/intervention efforts in the wake of trauma that may prevent/decrease NMUPD 
and PTSD development).  
Moreover, despite the demonstrated high prevalence of this problematic form of substance use, 
the genetic contributions of NMUPD remain unclear. This is in contrast to phenotypes like alcohol 
dependence, where numerous quantitative genetic studies and gene finding efforts have been 
conducted (Treutlein et al., 2009; Yan et al., 2014). Environmental factors including TE and PTSD 
may influence aberrant prescription drug use; however, limited research to date has thoroughly 
examined this putative association although it is well established within the broader substance use 
literature as a while (Ouimette, Read, Wade, & Tirone, 2010).  Thus, there is a critical gap in the 
literature needing to be filled. In contrast to the paucity of genetically informative research on 
NMUPD, quantitative genetic studies have demonstrated a heritable influence on TE and 
subsequent internalizing symptoms (i.e., PTSD) and substance use (Stein et al., 2002, True et al., 
1993, Lyons et al., 1993; Xian et al., 2000). In fact, previous research suggests that the genetic 
contribution to risk for TE/PTSD and substance use is overlapping (Sartor et al., 2011; Xian et al., 
2000).   Although some literature suggests that TE/PTSD are associated with NMUPD on a 
phenotypic level and both phenotypes are likely genetically influenced, to date, there have not 
been any efforts to examine the genetic underpinnings of these conditions concurrently to 
determine the degree to which they overlap or are distinct.  
Aims of the Present Study 
The aims of the present study were divided broadly into phenotypic and genotypic aims and 
will be discussed in turn.   
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Phenotypic aims.  The first phenotypic aim was to determine the prevalence of TE/probable-
PTSD and NMUPD (experimental and repeated use, which will be referred to as NMUPD-E and 
NMUPD-R, respectively, throughout the remaining manuscript) in a large representative sample 
of undergraduate students (N = 7,579).  The second aim was to investigate the longitudinal 
relationship between TE and NMUPD (-E, -R) in an attempt to clarify specific associations across 
time (e.g., does TE before college increase risk of NMUPD later in college [self-medication 
model], or conversely does NMUPD before college increase risk of TE in college [high risk 
model]). A supplementary aim included examining the longitudinal relationship between 
probable-PTSD and NMUPD to further elucidate whether it is the distress rather than the 
experience of TE that contributes to NMUPD.  In accordance with existing literature regarding the 
self-medication model (Leeies, Pagura, Sareen, & Bolton, 2010), it was expected that TE would 
significantly prospectively predict NMUPD (-E, -R).  Finally, also in line with the self-medication 
hypothesis, it was hypothesized that probable-PTSD would predict NMUPD (-E, -R) over time. 
Genotypic aims.  The genotypic aims were three fold and included conducting genome wide 
analyses, specifically GCTA and GWAS, to establish SNP-based heritability and identify genetic 
variation, respectively, associated with: (a) TE, and (b) NMUPD (-E, -R).  This set of analyses was 
additionally conducted to estimate SNP-based heritability and identify specific genetic variation 
associated with probable-PTSD.  It was hypothesized that each phenotype would be modestly 
heritable (lower than those identified within the twin literature for these phenotypes) and it was 
also expected that some unique variants would be identified within each phenotype. 
Methods 
 The present study included data from the first three cohorts of Spit for Science (S4S; N = 
7,579).  The first three cohorts were included in the present analyses given that they had been 
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genotyped and were enrolled in the study across all three time points (prior to college, freshman 
year, and sophomore year) at the time the present study was proposed.  From 2011-2014, all 
incoming freshman age 18 or older were invited to participate in a university-wide research study 
on college behavioral health, which included an online survey of a variety of factors including 
childhood experiences, personality, and college experiences. First year students who did not 
participate in the fall were sent additional e-mail invitations in the spring, thereby providing 
another opportunity to complete the baseline survey and become part of the study. Participants 
who were enrolled in the fall completed follow-up surveys in each spring beginning their first year 
while those enrolled in the spring completed follow-up surveys beginning spring of their 
sophomore semester. The new spring survey asked participants to retrospectively report on the 
items from the fall survey. The present study includes data collected during the first three time 
points (i.e., survey conducted fall of freshman year [pre college], survey conducted spring of 
freshman year [freshman year], and survey conducted spring of sophomore year [sophomore 
year]).  The pre-college survey pertained to events occurring prior to college, the freshman year 
survey assessed events occurring since beginning college, and the sophomore year survey assessed 
events occurring within the past 12 months (i.e., time period since freshman spring survey). 
Participants received $10 and a t-shirt for their involvement. Additional detailed information 
concerning recruitment can be found in Dick et al., 2014.   
 Invitations were sent to 11,328 individuals, with a 67% response rate.  Participants were 
representative of the broader university student population in terms of sex and race/ethnicity.  The 
university Institutional Review Board approved all study procedures; informed consent was 
obtained from all study participants. Study data were collected and managed using REDCap 
(Research Electronic Data Capture), hosted at the university (Harris et al., 2009). REDCap is a 
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secure, web-based application designed to support data capture for research studies, providing 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data downloads to statistical 
packages; and 4) procedures for importing data from external sources. 
Sample Characteristics 
The sample was comprised of 7,579 participants (cohort 1:  n = 2,707, cohort 2:  n = 2,481, 
cohort 3: n = 2,391, across cohorts: 61.1% female; Mage at baseline=18.53, SD=.65).  With regard to 
demographic variables, self-identified race of those that responded to the item (n = 7,458) was as 
follows:  White (50.3%), Black (19.6%), Asian (16.3%), and Other (13.9%) which included 
American Indian/Native Alaskan (.5%), Hispanic/Latino (6%), Native Hawaiian/Other Pacific 
Islander (.7%), more than one race (6.3%), and unknown (.4%). 
Phenotypic Assessment (Appendices I-III) 
NMUPD-E. Participants were asked “Have you ever used any of the following drugs for 
non-medical use? Non-medical use means on your own, without a doctor's prescription, in greater 
amounts than prescribed, or for reasons other than your doctor recommended.”  Participants 
reported as “yes” or “no” to each substance category: opioids (heroin, opium, other), sedatives 
(Ativan, Dalmane, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, other), and stimulants 
(ecstasy, amphetamines, crystal meth, other).  A response of “yes” to any category was used as 
indication of experimental NMUPD. 
NMUPD-R (6+ Use[s]).  An additional item was used to distinguish between experimental 
and repeated use.  Participants answered “yes” or “no” within each drug class (i.e., opioids, 
sedatives, stimulants) to the question “Have you used 6 or more times in your life?” and a positive 
response to this item was used as an indicator of repeated use. 
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 TE. TE was assessed via an abbreviated version of the Life Events Checklist (Blake et al., 
1995; Gray et al., 2004).  Participants reported on the occurrence of five different TE events: 
transportation accident, natural disaster, physical assault, sexual assault, and other unwanted or 
uncomfortable sexual experience. Participants completing the survey in the fall or retrospectively 
in the spring of their first year were given the response options of “yes” or “no” to items regarding 
whether each stressful event occurred “before the past 12 months”, “during the past 12 months”, 
or “never happened to me”. Participants completing the survey retrospectively in the spring were 
given the response options of “yes” or “no” to items regarding each stressful event occurred “since 
starting VCU”, “before starting college”, or “never happened to me”. Follow-up surveys conducted 
in the spring of freshman year and sophomore year included a single item asking participants 
whether they had experienced an TE event since college or within the past 12 months, respectively 
(“yes” or “no” response options). A positive response to any TE event prior to college (“before the 
past 12 months”, “during the past 12 months”) was considered a report of TE at the fall time point. 
If a participant retrospectively completed the survey in the spring of their freshmen year and 
reported any TE prior to college (“before starting VCU”) it was also considered a report of TE at 
the fall time point. A positive response to any TE event “since starting VCU” or within the past 12 
months at the freshman and sophomore time points, respectively, was considered a report of TE.  
The same aforementioned method was used to create the interpersonal violence (IPV) variable, 
only restricted to report of sexual assault, physical assault, and other unwanted and/or 
uncomfortable sexual experience. 
 Probable-PTSD. If a participant reported TE at any time point they were asked to respond 
to a probable-PTSD screener item. The probable-PTSD screener item was derived from the 
Primary Care PTSD Screen (PC-PTSD), which has previously been used in screening of PTSD 
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symptoms in primary care settings (Prins et al., 2004). The item asked whether the participant had 
experienced “nightmares, attempts to avoid thoughts or reminders of the potentially traumatic 
experience, hypervigilence, and feelings of detachment.” Endorsement of this item was used as 
indication of a positive report of probable-PTSD.  The same item was utilized at freshman and 
spring follow-up time points and a positive endorsement of probable-PTSD prior to college 
(“before the past 12 months”, “during the past 12 months, “since starting VCU”), and within the 
past 12 months, depending on time point, was also used as an indication of a positive report of 
probable-PTSD. 
Genotypic Procedures 
DNA was collected via an Oragene kit and isolated via standard procedures. 6,534 samples 
passing DNA and initial genotyping quality control (QC) were genotyped on the Axiom BioBank 
Array, Catalog Version 2 at the Rutgers University Cell and DNA Repository (RUCDR). The array 
is designed to assay 653K SNPs and InDels including a) 296K common variants that serve as grid 
for imputation and genome wide association studies (GWAS) and b) 357K likely functional 
variants from exome studies including non-synonymous, loss of function, known disease, splice 
altering, eQTL, and pharmacogenetics-related loci. Many of the ‘functional’ variants are low allele 
frequency. Therefore, the array allows testing of both common and rare variants.   
Given that the present study utilizes data from a large university grant funded resources, a 
project specific pipeline was created to process all samples (please see Webb et al., 2017 for full 
description).  The present study used the established pipeline for genetic analyses. Rigorous quality 
control measures (e.g., missing genotype rates, deviations from Hardy-Weinberg equilibrium 
(HWE), inbreeding, cryptic relatedness), analyses of ancestry, and suggested best practices for 
genetic analyses have been implemented.   Per protocol set forth by the Psychiatric Genomics 
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Consortium (PGC), off target variants identified via SNPolisher, SNPs missing >5% of genotypes, 
samples missing >2% of genotypes, and SNPs missing >2% of genotypes post sample filtering 
were removed, thus, resulting in a pre-imputation sample of 6,325.  Imputation was then conducted 
using the following programs SHAPEIT2 and IMPUTE2 and the 1000 genomes reference panel 
(phase 3; n = 2,504).  Variants within the 1000 Genomes Project (1KGP, phase 3) found to be in 
common with the filtered S4S genotypes were merged together.  Following exclusion of regions 
with high LD and pruning (r2 < .1) via PLINK 1.9, 109,259 variants were identified for ancestry 
analyses.  
Principle components analyses (PCA) was then conducted within the 1KGP phase 3 
reference panel to establish SNP weights for each eigenvector and projected onto the S4S data to 
create 10 principle components. Participants were assigned to 1KGP based ancestry super 
populations based on Mahalanobis distance (Mahalanobis, 1936) identified between each sample 
and each 1KGP population.  Participants were assigned to the 1KGP population with the minimum 
Malahanobis distance.  Finally, each participant was classified into their respective super 
population resulting in five ancestral groups African descent (AFR), American descent (AMR), 
East Asian descent (EAS), European descent (EUR), and South Asian descent (SAS).  To adjust 
for potential fine structure within each super population, within ancestry group PCA was 
conducted. Again, EIGENSOFT and smartPCA were used to perform PCA for each super 
population. Ten distinct within ancestral group PCs were generated for each super population.  
Additional filtering by HWE, minor allele frequency, and relatedness was conducted within each 
super population.  As a result, 274 samples were also excluded, resulting in 6,239 as the final 
sample for genotypic analyses. 
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Additional filtering based on ancestry specific HWE and sample size based MAFs was 
conducted following each GWAS. Minimum observed minor allele count (MAC) was used instead 
of a MAF threshold based on the recommendation of existing literature (Bigdeli, Neale, & Neale). 
GWAS results were then meta-analyzed using METAL (Willer, Li, & Abecases, 2010), which 
uses a fixed effect model and inverse variance weighting based on sample size. Genomic inflation 
(λ and λ1000) was determined within each ancestral group GWAS and meta-analyses, which were 
performed in R 3.5.0. False Discovery Rate (FDR) analysis was performed using the “q-value” 
package (https://github/jdstorey/qvalue) using Bioconductor 3.221.  
Data Analytic Plan 
Phenotypic analyses. To address aim 1 of the phenotypic aims regarding the prevalence 
of TE, probable-PTSD, and NMUPD (-E, -R) descriptive statistics were computed for each time 
point.  Additionally, given the extant literature suggesting that sex and cohort may be confounding 
variables when examining substance/trauma related variables (McCabe et al., 2006, Cromer, & 
Smyth, 2010) and more broadly in studies utilizing cohort design (Prentice, 1995), chi-square 
analyses were conducted to examine associations between each phenotype and both sex and 
cohort.  To address aim 2 regarding the temporal association between TE and NMUPD, cross lag 
autoregressive models were utilized to estimate the association between TE and NMUPD across 
time.  Autoregressive path weights account for stability within each measure across time and the 
correlations among both measures were also estimated.  This model provides the opportunity to 
estimate the effect of TE on NMUPD-E across time and alternatively the influence of NMUPD-E 
on TE across time. Two sets of models were conducted: (1) a model examining longitudinal 
associations between NMUPD-E and TE, and (2) a model examining the longitudinal associations 
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between NMUPD-R and TE.  A detailed description of the analyses is provided below only for the 
NMUPD-E model, as the same analytic framework was used for both substance use variables. 
To examine the longitudinal associations between NMUPD-E and TE, first a saturated 
model including all paths was established (Model 1; Figure 1) and two additional models were 
compared to the saturated model to determine the best fitting longitudinal model examining 
NMUPD-E and TE. The fit of each model was evaluated by the Akaike information criterion (AIC) 
and change in -2 log likelihood compared to the saturated model. The two models compared to the 
saturated model examined the self-medication and the high risk models (i.e., Longitudinal Effects 
Models).  In Model 2, cross lag paths from TE to NMUPD-E across time points (h, l, and k paths) 
were constrained to zero to test the self-medication model across time (i.e., TE serves as a 
significant predictor of future NMUPD-E).  In Model 3, cross lag paths from NMUPD-E to TE 
across time points (i, j, and m paths) were constrained to zero to test the high risk model across 
time (i.e., NMUPD-E serves as a significant predictor of future TE).  
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Figure 1:  Saturated autoregressive cross lag model examining the longitudinal association between trauma exposure and experimental 
non-medical use of prescription drugs controlling for sex and cohort.   
 
Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore 
year.  Double headed arrows indicate correlation and single headed arrows indicate regression. 
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In order to determine if the associations above held when considering distress experienced 
(e.g., probable-PTSD) rather than exposure to a TE itself, two additional sets of models were 
conducted to examine the temporal association between probable-PTSD and NMUPD (i.e., -E, -
R).  First a saturated model was established (Model 1; Figure 1).  Next, cross lag autoregressive 
models were utilized to examine the influence of probable-PTSD on NMUPD (-E, -R) across time 
(Model 2, self-medication model).  Conversely, this model also provides the opportunity to 
examine the influence of NMUPD (-E, -R) on probable-PTSD longitudinally (Model 3, high risk 
model).   
Thus, in total, four sets of two cross lag autoregressive models (i.e., Longitudinal Effects 
Models) were conducted examining the longitudinal relations among (a) TE and NMUPD-E, (b) 
TE and NMUPD-R, (c) probable-PTSD and NMUPD-E, and (d) probable-PTSD and NMUPD-R. 
Genotypic analyses. Genetic analyses were conducted separately within homogenous 
ancestral subgroups and then meta-analyzed to increase statistical power, which is the “best 
practice” that has been implemented by the Psychiatric Genetics Consortium (PGC; 
https://github.com/Nealelab/ricopili). Super population PCs (African descent [AFR], American 
descent [AMR], East Asian descent [EAS], European descent [EUR], South Asian descent [SAS], 
sex, and cohort were included as covariates in all genetic analyses. First, in order to establish the 
heritability of NMUPD (-E, -R) and TE independently, a univariate GCTA was conducted for each 
phenotype. GCTA estimates the heritability of a trait based off of the additive effect of all SNPs. 
This method creates a genetic relationship matrix (GRM) based on SNPs for all individuals in the 
sample. The GRM is then used to predict phenotypic relatedness in an estimate of the variance in 
the trait that is due to each phenotype independently.  Following, three GWAS analyses (one for 
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each form of NMUPD and TE) were run using SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) to identify specific 
variants associated with each phenotype. The genomic inflation factor λ was estimated and the 
quantile-quantile (QQ) plots were used to determine and adjust for bulk inflation and excess false 
positives. False discovery rate (FDR) were used to adjust for multiple testing in all analyses and 
to determine what p-values are significant or suggestive. An additional set of exploratory analyses 
(GCTA, GWAS) were conducted to establish the SNP-based heritability and to identify specific 
variants associated with probable-PTSD and IPV. 
Results 
Phenotypic Results 
Prevalence of phenotypes of interest.  The prevalence of NMUPD (-E, -R), TE, and 
probable-PTSD are presented in Table 1.  Approximately 16% of participants reported NMUPD-
E prior to college and 7% reported NMUPD-R during that same time frame.  Rates of NMUPD (-
E, -R) remained relatively stable over the three time points (Table 1). Moreover, when collapsed 
across all time points, 25.2% (1890/7500) of the sample reported NMUPD-E and 12.4% 
(933/7502) reported NMUPD-R.  Stimulants were the most frequently reported substance used 
non-medically, followed by sedatives, and then opioids. This pattern applied to both experimental 
and repeated use forms of NMUPD at each time point.  Across all time points and each form of 
NMUPD, males had significantly higher report of use relative to females (Table 1).  
TE was prevalent with 83.3% of participants reporting at least one lifetime exposure prior 
to college. Freshman and sophomore year prevalence of TE were lower than prevalence identified 
prior to college and prevalence of probable-PTSD ranged from 26.6% to 37.5% across the time 
points (Table 1).  Prevalence of TE types and probable-PTSD differed significantly by sex.  
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Overall, probable-PTSD was more prevalent among females, as were multiple forms of TE 
including sexual assault and any other unwanted and/or uncomfortable sexual experience.  
However, physical assault was more prevalent among males.  Transportation accidents and natural 
disaster prevalence did not significantly differ by sex with the exception of transportation accident 
during sophomore year with females reporting more accidents relative to males (Table 1).  Across 
all of the assessment periods, 85.5% (6405/7489) of the sample reported at least one TE, 44.6% 
(3323/7452) reported IPV (sexual assault, physical assault, other unwanted and/or uncomfortable 
sexual experience), and 39.1% (2476/6336) reported probable-PTSD.   
Outcome variables of interest (NMUPD-E, NMUPD-R, TE, and probable-PTSD) across 
each time point also consistently differed by cohort (with the exception of NMUPD-E and 
NMUPD-R during sophomore year [ps = .24, .07, respectively], Table 2).  Broadly, cohorts 2 and 
3 reported greater NMUPD (-E, -R) with the exception of cohort 3 during sophomore year which 
exhibited lower prevalence of NMUPD-R relative to cohorts 1 and 2.  With regard to TE, 
prevalence was highest among cohort 1 across time.  However, prevalence of PTSD was highest 
in cohort 3. 
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Table 1. Prevalence of non-medical use of prescription drugs (experimental, repeated use, 
sedatives, stimulants, and opioids), trauma exposure, and probable posttraumatic stress disorder 
across time points by sex. 
 Prior to College (Y1F) Freshman Year (Y1S) Sophomore Year (Y2S) 
 % (n) X2(p) % (n) X2(p) % (n) X2(p) 
NMUPD       
NMUPD-E 
16.7 
(1238/7424) 
19.35*** 
16.5 
(947/5743) 
30.49***  
17.9 
(655/3653) 
22.16*** 
    Females 
15.2 
(690/4552) 
- 
14.4 
(520/3515) 
- 
15.8 
(381/2417) 
- 
    Males 
19.1 
(542/2841) 
- 
20.0 
(418/2089) 
- 
22.1 
(268/1212) 
- 
  Sedatives 
8.2 
(606/7400) 
22.54*** 
5.7 
(327/5713) 
12.48*** 
5.3 
(194/3631) 
7.71* 
    Females 
7.0 
(317/4538) 
- 
4.8 
(174/3599) 
- 
4.6 
(111/2405) 
- 
    Males 
10.1 
(286/2831) 
- 
7.1 
(147/2075) 
- 
6.8 
(82/1202) 
- 
  Stimulants 
13.5 
(980/72691) 
19.47*** 
14.3 
(817/5713) 
34.48*** 
15.8 
(570/3617) 
21.57*** 
    Females 
12.1 
(540/4473) 
- 
12.4 
(439/3541) 
- 
13.7 
(329/2396) 
- 
    Males 
15.7 
(435/2768) 
- 
18.2 
(368/2027) 
- 
19.7 
(236/1197) 
- 
  Opioids 
5.6 
(409/7367) 
46.98*** 
3.7 
(209/5648) 
35.48*** 
4.3 
(155/3635) 
25.97*** 
    Females 
4.1 
(186/4531) 
- 
2.5 
(91/3576) 
- 
3.0 
(73/2409) 
- 
    Males 
7.9 
(221/2807) 
- 
5.7 
(115/2033) 
- 
6.7 
(80/1202) 
- 
NMUPD-R 
7.0 
(523/7429) 
13.99*** 
7.2 
(412/5745) 
26.18*** 
8.8 
(320/3657) 
14.85*** 
    Females 
6.1 
(279/4555) 
- 
5.8 
(210/3616) 
- 
7.4 
(179/2420) 
- 
    Males 
8.4 
(239/2843) 
- 
9.4 
(197/2090) 
- 
11.2 
(136/1213) 
- 
  Sedatives 
2.6 
(191/7291) 
.78 
2.4 
(140/5715) 
5.82* 
1.9 
(68/3655) 
.39 
    Females 
2.5 
(111/4488) 
- 
2.1 
(74/3599) 
- 
1.8 
(42/2400) 
- 
    Males 
2.8 
(78/2772) 
- 
3.1 
(64/2078) 
- 
2.2 
(26/1200) 
- 
  Stimulants 
5.6 
(405/7263) 
16.35*** 
5.9 
(333/5602) 
17.95*** 
7.4 
(268/3613) 
8.99** 
    Females 
4.7 
(209/4471) 
- 
4.3 
(159/3741) 
- 
6.4 
(154/2394) 
- 
    Males 
6.9 
(191/2764) 
- 
6.8 
(148/2183) 
- 
9.2 
(110/1195) 
- 
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  Opioids 
1.9 
(138/7360) 
22.35*** 
1.1 
(61/5643) 
9.25** 
1.5 
(54/3641) 
9.19** 
    Females 
1.3 
(58/4529) 
- 
.8 
(27/3574) 
- 
1.0 
(25/2411) 
- 
    Males 
2.8 
(79/2802) 
- 
1.6 
(33/2030) 
- 
2.3 
(28/1206) 
- 
Any TE 
83.3 
(5802/6963) 
17.25*** 
50.0 
(2826/5723) 
22.85*** 
37.8 
(1364/3613) 
10.45*** 
    Females 
84.8 
(3631/4283) 
- 
52.4 
(1882/3592) 
- 
39.6 
(951/2400) 
- 
    Males 
81.0 
(2146/2651) 
- 
45.8 
(960/2095) 
- 
34.1 
(405/1189) 
- 
  Sexual Assault 
9.8 
(583/5922) 
116.07*** 
3.8 
(219/5714) 
27.10*** 
4.2 
(152/3619) 
14.14*** 
    Females 
13.0 
(478/3667) 
- 
4.9 
(175/3592) 
- 
5.1 
(122/2397) 
- 
    Males 
4.4 
(99/2230) 
- 
2.1 
(44/2084) 
- 
2.4 
(29/1198) 
- 
  Any other    
  unwanted/uncomfortable   
  sexual experience 
24.4 
(1477/6059) 
285.30*** 
13.5 
(768/5693) 
95.84*** 
14.2 
(513/3615) 
50.21*** 
    Females 
31.6 
(1193/3781) 
- 
16.9 
(605/3581) 
- 
17.1 
(410/2395) 
- 
    Males 
12.3 
(276/2252) 
- 
7.7 
(159/2075) 
- 
8.4 
(100/1196) 
- 
  Physical Assault 
28.4 
(1764/6210) 
63.26*** 
7.8 
(446/5736) 
12.16*** 
7.8 
(282/3625) 
6.27* 
    Females 
24.8 
(941/3800) 
- 
6.8 
(245/3605) 
- 
7.0 
(169/2401) 
- 
    Males 
34.1 
(814/2385) 
- 
9.4 
(196/2095) 
- 
9.4 
(113/1200) 
- 
  Transportation Accident 
48 
(3119/6496) 
.11 
11.9 
(683/5729) 
1.19 
13.7 
(496/3630) 
7.14* 
    Females 
47.8 
(1917/4013 
- 
11.5 
(416/3605) 
- 
14.8 
(355/2406) 
- 
    Males 
48.2 
(1184/2457) 
- 
12.5 
(261/2086) 
- 
11.5 
(138/1199) 
- 
  Natural Disaster 
67.8 
(4567/6732) 
1.10 
38.3 
(2199/5747) 
6.79 
18.3 
(664/3622) 
.04 
    Females 
68.3 
(2840/4158) 
- 
39.6* 
(1430/3612) 
- 
18.4 
(442/2402) 
- 
    Males 
67.1 
(1709/2548) 
- 
36.1 
(758/2099) 
- 
18.1 
(217/1196) 
- 
Probable-PTSD 
36.0 
(1683/4671) 
168.12*** 
26.6 
(920/3459) 
70.45*** 
37.5 
(503/1341) 
46.72*** 
    Females 
42.9 
(1269/2959) 
- 
31.2 
(699/2243) 
- 
43.5 
(405/932) 
- 
    Males 
23.9 
(405/1693) 
- 
17.9 
(214/1196) 
- 
23.7 
(95/401) 
- 
Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use 
of prescription drugs, TE = trauma exposure, probable-PTSD = probable posttraumatic stress disorder, Y1F = fall 
assessment period in reference to NMUPD, TE, and probable-PTSD prior to college, Y1S = spring assessment period 
in reference to NMUPD, TE, and probable-PTSD freshman year, Y2S = spring assessment period in reference to 
NMUPD, TE, and probable-PTSD sophomore year. 
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Table 2. Prevalence of non-medical use of prescription drugs (experimental, repeated use, 
sedatives, stimulants, and opioids), trauma exposure, and probable posttraumatic stress disorder 
across time points by cohort. 
 Prior to College (Y1F) Freshman Year (Y1S) Sophomore Year (Y2S) 
 % (n) X2(p) % (n) X2(p) % (n) X2(p) 
NMUPD       
NMUPD-E 
16.7 
(1238/7424) 
24.26 *** 
16.5 
(947/5743) 
6.54 * 
17.9 
(655/3653) 
2.89  
  Cohort 1 
13.8 
(367/2635) 
- 
15.6 
(336/2147) 
- 
18.1 
(237/1307) 
- 
  Cohort 2 
18.5 
(446/2407) 
- 
15.7 
(297/1891) 
- 
19.1 
(225/1175) 
- 
  Cohort 3 
18.0 
(425/2364) 
- 
18.4 
(314/1705) 
- 
16.5 
(193/1171) 
- 
NMUPD-R 
7.0 
(523/7429) 
6.70 * 
7.2  
(412/5745) 
11.17 ** 
8.8  
(320/3657) 
5.42  
  Cohort 1 
6.0  
(160/2661) 
- 
6.7  
(143/2147) 
- 
9.0  
(118/1307) 
- 
  Cohort 2 
7.6  
(182/2405) 
- 
6.2  
(117/1889) 
- 
9.9  
(117/1179) 
- 
  Cohort 3 
7.7  
(181/2363) 
- 
8.9  
(152/1709) 
- 
7.3  
(85/1171) 
- 
Any TE 
83.3 
(5802/6963) 
100.66 *** 
50.0 
(2826/5723) 
668.45 *** 
37.8 
(1364/3613) 
88.74 *** 
  Cohort 1 
89.2 
(2189/2453) 
- 
69.9 
(1497/2141) 
- 
47.9 
(620/1294) 
- 
  Cohort 2 
81.4 
(1842/2263) 
- 
47.0 
(883/1877) 
- 
31.7 
(370/1168) 
- 
  Cohort 3 
78.8 
(1771/2247) 
- 
28.3 
(482/1705) 
- 
32.5 
(374/1151) 
- 
Probable-PTSD 
36.0 
(1683/4671) 
8.32 * 
26.6 
(920/3459) 
47.86 *** 
37.5 
(503/1341) 
14.04 ** 
  Cohort 1 
36.1 
(601/1664) 
- 
22.5 
(377/1678) 
- 
32.2 
(196/609) 
- 
  Cohort 2 
33.5 
(509/1520) 
- 
26.8 
(292/1089) 
- 
40.6 
(147/362) 
- 
  Cohort 3 
38.5 
(573/1487) 
- 
36.3 
(251/692) 
- 
43.2 
(160/370) 
- 
Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use 
of prescription drugs, TE = trauma exposure, probable-PTSD = probable posttraumatic stress disorder, Y1F = fall 
assessment period in reference to NMUPD, TE, and probable-PTSD prior to college, Y1S = spring assessment period 
in reference to NMUPD, TE, and probable-PTSD freshman year, Y2S = spring assessment period in reference to 
NMUPD, TE, and probable-PTSD sophomore year. 
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Longitudinal associations between TE and NMUPD-E.  To examine the longitudinal 
associations between TE and NMUPD-E, autoregressive cross lag models were conducted with 
sex and cohort included as covariates.  The first (saturated) model, serving as the basis for 
comparison, included all potential paths (Figure 1 [see page 36; Model 1.1 in Table 3).  
For parsimony, Figure 2 presents a simplified figure wherein the covariates, sex and cohort, 
are not included pictorially (but are included in the modeling). Figure 2 also provides path 
notations which will be referenced throughout the results section. 
 
Figure 2. Simplified autoregressive cross lag model examining the longitudinal association 
between trauma exposure and experimental non-medical use of prescription drugs. 
 
 
 
 
 
Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = fall assessment 
period in reference to the time period prior to college, Y1S = spring assessment period in reference to freshman year, 
Y2S = spring assessment period in reference to sophomore year.  Double headed arrows indicate correlation and single 
headed arrows indicate regression. Sex and cohort excluded from figure included in analyses. 
 
Model comparisons:  TE and NMUPD-E.  Next, a series of sub-models were fitted by 
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were compared to the saturated model (Model 1.1, Table 3).  Two models examining the self-
medication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 3) were 
compared to the saturated model.  In Model 2.1 (Table 3), cross lag paths from TE to NMUPD-E 
across time points (h, k, and l paths) were constrained to zero to test the self-medication model 
across time.  This model was not significantly different from the saturated model (p = .44) 
indicating that these paths could be dropped without significantly effecting the fit.  In Model 3.1 
(Table 3), cross lag paths from NMUPD-E to TE across time points (i, j, and m paths) were 
constrained to zero to test the high risk model across time.  This model was significantly different 
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit 
with the data.  In short, the results of the model fitting procedures provide support for the high risk 
hypothesis (i.e., prior NMUPD-E is associated with heightened risk for TE).   
TE and NMUPD-E best fitting model results.  Following comparisons between the 
Longitudinal Effects Models (Table 3, Models 2.1 [self-medication model] and 3.1 [high risk 
model]) to the saturated model (Table 3, Model 1.1), the fit indices from Model 2.1 indicate that 
paths from TE to NMUPD-E across time can be constrained to zero without significantly 
impacting model fit.  Path estimates with these paths dropped are reported in Table 4.   
The covariates of cohort and sex were consistently significantly associated with NMUPD-
E and TE (with female sex being associated with greater report of TE but lower NMUPD-E and 
cohort being positively associated with NMUPD-E at baseline but negatively associated 
sophomore year, ps < .05) with the exception of sex not being a significant predictor of NMUPD-
E during sophomore year and cohort not being a significant predictor of NMUPD-E occurring 
freshman year.  When examining TE and NMUPD-E, prior TE and NMUPD-E were significant 
predictors of future TE and NMUPD-E, respectively.  Specifically, TE prior to college was 
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associated with TE freshman year (B = .12, p < .001 [path a]) and TE in freshman year was 
significantly associated with TE sophomore year (B = .22, p < .001 [path b]).  NMUPD-E prior to 
college was associated with freshman year NMUPD-E (B = 1.16, p < .001 [path c]) and freshman 
year NMUPD-E was also significantly associated with sophomore year NMUPD-E (B = .57, p < 
.001 [path d]).   Potential long term associations between TE and NMUPD-E occurring prior to 
college and TE and NMUPD-E, respectively, occurring in sophomore year were also examined.  
TE prior to college was associated with TE sophomore year (B = .15, p = .001 [path n) and 
NMUPD-E prior to college was also significantly associated with NMUPD-E sophomore year (B 
= .54, p = .001 [path o]). 
Given that model fitting results suggested that TE was not a significant predictor of 
NMUPD-E across time, these paths were not included in the final model and thus only the cross 
paths between NMUPD-E and TE across time are presented.  NMUPD-E prior to college served 
as a significant predictor of TE freshman year (B = .06, p = .04); however, NMUPD-E during 
freshman year did not serve as a significant predictor of TE sophomore year (B = .10, p = .05).  
NMUPD-E prior to college did not serve as a significant predictor of TE sophomore year (B = .01, 
p = .96).   To summarize, the results of the model fitting procedures provide support for the high 
risk hypothesis (i.e., prior NMUPD-E is associated with heightened risk for TE).
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Table 3. Model fitting results of autoregressive cross lag models between trauma exposure and experimental non-medical use of 
prescription drugs. 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.1 a 57773.13 48193 -38612.87 -- -- -- 
Longitudinal Effects Models  
2.1 b 57775.84 48196 -38616.16 2.71 3 0.44 
3.1 c 57799.89 48196 -38592.11 26.77 3 <.001 
Note:  a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-E’, ‘freshman TE to sophomore NMUPD-E’, and ‘pre college TE to 
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman TE’, ‘freshman NMUPD-E to sophomore TE’, and ‘pre college 
NMUPD-E to sophomore TE’ constrained to zero. 
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Figure 3. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between trauma exposure and experimental non-
medical use of prescription drugs. 
 
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  TE = 
trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college, Y1S = 
freshman year, Y2S = sophomore year. 
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Table 4. Path estimates, p values, and standard errors for the best-fitting trauma exposure and 
experimental non-medical use of prescription drugs autoregressive cross lag model. 
 
Path Estimate p value SE 
Correlations    
   TE Y1F           NMUPD-E Y1F (e) .12 <.001 .03 
   TE Y1S           NMUPD-E Y1S (f) .17 <.001 .04 
   TE Y2S           NMUPD-E Y2S (g) .10 .04 .05 
   Sex         TE Y1F .10 <.001 .02 
   Sex         NMUPD-E Y1F -.10 <.001 .02 
   Cohort           TE Y1F -.19 <.001 .02 
   Cohort           NMUPD-E Y1F .07 <.001 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       TE Y1S .13 <.001 .02 
   Sex       NMUPD-E Y1S -.10 .004 .03 
   Sex       NMUPD-E Y2S -.05 .24 .05 
   Sex       TE Y2S .09 .007 .03 
   Cohort        TE Y1S -.52 <.001 .02 
   Cohort        NMUPD-E Y1S -.04 .23 .03 
   Cohort        NMUPD-E Y2S -.12 .003 .04 
   Cohort        TE Y2S -.06 .10 .03 
 Autoregressive paths 1    
   TE Y1F        TE Y1S (a) .12 <.001 .03 
   TE Y1S        TE Y2S (b) .22 <.001 .04 
  Experimental  NMUPD Y1F       NMUPD-E Y1S (c) 1.16 <.001 .05 
   NMUPD-E Y1S       NMUPD-E Y2S (d) .57 <.001 .07 
 Autoregressive paths 2    
   TE Y1F         TE Y2S (n) .15 .001 .03 
   NMUPD-E Y1F       NMUPD-E Y2S (o) .54 .001 .09 
 Cross lag paths 1    
   TE Y1F          NMUPD-E Y1S (h) - - - 
   TE Y1S          NMUPD-E Y2S (k) - - - 
   NMUPD-E Y1F      TE Y1S (i) .06 .04 .03 
  NMUPD-E Y1S       TE Y2S (j) .10 .05 .07 
Cross lag paths 2    
   TE Y1F          NMUPD-E Y2S (l) - - - 
  NMUPD-E Y1F        TE Y2S (m) .01 .96 .10 
Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college, 
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 3) indicated that these paths could be 
dropped. 
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Longitudinal Associations between TE and NMUPD-R.  To examine the longitudinal 
associations between TE and NMUPD-R, a similar set of autoregressive cross lag models as 
described above for NMUPD-E were also conducted with sex and cohort as covariates.  The first 
(saturated) model, serving as the basis for comparison, is presented in Figure 1 (Model 1.2 in Table 
5).  Figure 4 presents a simplified figure with path notations wherein the covariates, sex and cohort, 
are not included pictorially (but are included in the modeling).  
Model comparisons:  TE and NMUPD-R.  A series of sub-models were fitted by 
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model 
were compared to the saturated model (Model 1.2, Table 5).  Two models examining the self-
medication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 5) were 
compared to the saturated model.  In Model 2.2 (Table 5), cross lag paths from TE to NMUPD-R 
across time points (h, k, and l paths) were constrained to zero to test the self-medication model 
across time.  This model was not significantly different from the saturated model (p = .11) 
indicating that these paths could be dropped without significantly effecting the fit.  In Model 3.2 
(Table 5), cross lag paths from NMUPD-R to TE across time points (i, j, and m paths) were 
constrained to zero to test the high risk model across time.  This model was significantly different 
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit 
with the data.  In short, the results of the model fitting procedures provide support for the high risk 
hypothesis (i.e., prior NMUPD-R is associated with heightened risk for TE).   
TE and NMUPD-R best fitting model results.  Following comparisons between the 
Longitudinal Effects Models (Table 5, Models 2.2 [self-medication model] and 3.2 [high risk 
model]) to the saturated model (Table 5, Model 1.2), the fit indices from Model 2.2 indicate that 
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paths from TE to NMUPD-R across time can be constrained to zero.  Path estimates with these 
paths dropped are located in Table 6.   
The covariates of cohort and sex were consistently significantly associated with NMUPD-
R and TE (with female sex being associated with greater report of TE but lower report of NMUPD-
R, and cohort being negatively associated NMUPD-R, ps < .05) with the exception of sex not 
being a significant predictor of NMUPD-R during sophomore year and cohort not being a 
significant predictor of NMUPD-R occurring freshman year.  When examining TE and NMUPD-
R, prior TE and NMUPD-R were significant predictors of future TE and NMUPD-R, respectively.  
Specifically, TE prior to college was associated with TE freshman year (B = .12, p < .001 [path a]) 
and TE in freshman year was significantly associated with TE sophomore year (B = .21, p < .001 
[path b]).  Repeated use NMUPD-R prior to college was associated with freshman year NMUPD-
R (B = 1.10, p < .001 [path c]) and freshman year NMUPD-R was also significantly associated 
with sophomore year NMUPD-R (B = .45, p < .001 [path d]).   Potential long term associations 
between TE and NMUPD-R occurring prior to college and TE and NMUPD-R, respectively, 
occurring in sophomore year were also examined.  TE prior to college was associated with TE 
sophomore year (B = .16, p < .001 [path n) and NMUPD-R prior to college was also significantly 
associated with NMUPD sophomore year (B = .55, p < .001 [path o]). 
Given that model fitting results suggested that TE was not a significant predictor or 
NMUPD-R across time, these paths were not included in the final model and thus only the cross 
paths between NMUPD-R and TE across time are presented. NMUPD-R prior to college served 
as a significant predictor of TE freshman year (B = .10, p = .002) and NMUPD-R during freshman 
year also served as a significant predictor of TE sophomore year (B = .19, p = .005). NMUPD-R 
prior to college did not serve as a significant predictor of TE sophomore year (B = -.08, p = .36).  
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In summary, the results of the model fitting procedures provide support for the high risk hypothesis 
(i.e., prior NMUPD-R heightens risk for TE).   
The high risk hypothesis was found to be the best fitting model across both forms of 
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model.   When 
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was 
significantly associated with TE freshman year. However, significant associations between 
NMUPD freshman year and TE sophomore year were only identified when examining NMUPD-
R.  This path was not significant when examining the association between NMUPD-E freshman 
year and TE sophomore year.  Thus, although the high risk hypothesis best fits the data in both 
models examining TE and NMUPD (-E, -R), NMUPD serving as a significant predictor across 
each time point is inconsistent.
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Table 5. Model fitting results of autoregressive cross lag models between trauma exposure and repeated use non-medical use of 
prescription drugs. 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.2 a 52528.67 48204 -43879.33 -- -- -- 
Longitudinal Effects Models  
2.2 b 52534.65 48207 -43879.35 5.98 3 0.11 
3.2 c 52572.34 48207 -43841.66 43.66 3 < .001 
Note:  a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-R’, ‘freshman TE to sophomore NMUPD-R’, and ‘pre college TE to 
sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman TE’, ‘freshman NMUPD-R to sophomore TE’, and ‘pre college 
NMUPD-R to sophomore TE’ constrained to zero. 
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Figure 4. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between trauma exposure and repeated use non-
medical use of prescription drugs. 
 
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  TE = 
trauma exposure, NMUPD-R = repeated use non-medical use of prescription drugs, Y1F = prior to college, Y1S = 
freshman year, Y2S = sophomore year. 
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Table 6. Path estimates, p values, and standard errors for the best-fitting trauma exposure and 
repeated use non-medical use of prescription drugs autoregressive cross lag model. 
 
Path Estimate p value SE 
Correlations    
   TE Y1F           NMUPD-R Y1F (e) .09 .004 .03 
   TE Y1S           NMUPD-R Y1S (f) .14 .001 .05 
   TE Y2S           NMUPD-R Y2S (g) .06 .27 .15 
   Sex         TE Y1F .10 <.001 .02  
   Sex         NMUPD-R Y1F -.11 <.001 .03 
   Cohort           TE Y1F .05 <.001 .03 
   Cohort          NMUPD-R Y1F -.19 .04 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       TE Y1S .14 <.001 .02 
   Sex       NMUPD-R Y1S -.12 .002 .05 
   Sex       NMUPD-R Y2S -.04 .50 .11 
   Sex       TE Y2S .10 .01 .03 
   Cohort         TE Y1S -.53 <.001 .02 
   Cohort         NMUPD-R Y1S .04 .30 .05 
   Cohort         NMUPD-R Y2S -.12 .01 .06 
   Cohort         TE Y2S -.07 .01 .04 
 Autoregressive paths 1    
   TE Y1F        TE Y1S (a) .12 <.001 .03 
   TE Y1S        TE Y2S (b) .21 <.001 .03 
   NMUPD-R Y1F       NMUPD-R Y1S (c) 1.10 <.001 .12 
   NMUPD-R Y1S       NMUPD-R Y2S (d) .45 <.001 .12 
 Autoregressive paths 2    
   TE Y1F         TE Y2S (n) .16 <.001 .04 
   NMUPD-R Y1F       NMUPD-R Y2S (o) .55 <.001 .09 
 Cross lag paths 1    
   TE Y1F         NMUPD-R Y1S (h) - - - 
   TE Y1S         NMUPD-R Y2S (k) - - - 
  NMUPD-R Y1F      TE Y1S (i) .10 .002 .04 
   NMUPD-R Y1S       TE Y2S (j) .19 .005 .06 
Cross lag paths 2    
   TE Y1F         NMUPD-R Y2S (l) - - - 
  NMUPD-R Y1F        TE Y2S (m) -.08 .36 .06 
Note: TE = trauma exposure, NMUPD-R = repeated use non-medical use of prescription drugs, Y1F = prior to college, 
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 5) indicated that these paths could be 
dropped. 
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Follow-up Phenotypic Analyses 
 Given that posttraumatic distress following TE may be more relevant to substance misuse 
than the exposure alone and in an effort to further refine the phenotypic analyses, follow-up 
analyses were conducted examining longitudinal associations between probable-PTSD and 
NMUPD (-E, -R). 
Longitudinal associations between probable-PTSD and NMUPD-E.   To examine the 
longitudinal associations between probable-PTSD and NMUPD-E, autoregressive cross lag 
models were conducted with sex and cohort as covariates, via the same steps as described above 
for the primary analyses using TE in association with NMUPD (-E, -R).  The first (saturated) 
model, serving as the basis for comparison, included all potential paths and is presented in Figure 
1 (Model 1.3 in Table 7).  Figure 5 presents a simplified figure with path notations wherein the 
covariates, sex and cohort, is not included pictorially (but is included in the modeling).  
Model comparisons:  probable-PTSD and NMUPD-E.  A series of sub-models were fitted 
by constraining paths.  The fit statistics (AIC and change in -2 log likelihood) from each sub-model 
were compared to the saturated model (Model 1.3, Table 7). Two models examining the self-
medication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 7) were 
compared to the saturated model.  In Model 2.3 (Table 7), cross lag paths from probable-PTSD to 
NMUPD across time points (h, k, and l paths) were constrained to zero to test the self-medication 
model across time.  This model was not significantly different from the saturated model (p = .46) 
indicating that these paths could be dropped without significantly effecting the fit.  In Model 3.3 
(Table 7), cross lag paths from NMUPD to probable-PTSD across time points (i, j, and m 
paths) were constrained to zero to test the high risk model across time.  This model was 
significantly different from the saturated model (p < .001) suggesting that dropping these paths 
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would result in worse fit with the data.  In short, the results of the model fitting procedures provide 
support for the high risk hypothesis (i.e., prior NMUPD-E is associated with heightened risk for 
probable-PTSD). 
 Probable-PTSD and NMUPD-E best fitting model results.  Following comparisons 
between the Longitudinal Effects Models (Table 7, Models 2.3 [self-medication model] and 3.3 
[high risk model]) to the saturated model (Table 7, Model 1), the fit indices from Model 2.3 
indicate that paths from probable-PTSD to NMUPD-E across time can be constrained to zero.  Path 
estimates with these paths dropped are located in Table 8.   
The covariates of cohort and sex were consistently significantly associated with NMUPD-
E and probable-PTSD (with female sex being associated with greater report of probable-PTSD and 
lower report of NMUPD-E and cohort being positively associated with probable-PTSD at baseline 
but negatively associated sophomore year, ps < .05) with the exception of sex not being a 
significant predictor of NMUPD-E during sophomore year and cohort not being a significant 
predictor of NMUPD-E occurring freshman year.  Moreover, cohort and probable-PTSD were not 
significantly correlated at baseline. When examining probable-PTSD and NMUPD-E, prior 
probable-PTSD and NMUPD-E were significant predictors of future probable-PTSD and 
NMUPD-E, respectively.  Specifically, probable-PTSD prior to college was associated with 
probable-PTSD freshman year (B = .50, p < .001 [path a]) and probable-PTSD in freshman year 
was significantly associated with probable-PTSD sophomore year (B = .40, p < .001 [path b]).  
NMUPD-E prior to college was associated with freshman year NMUPD-E (B = 1.17, p < .001 
[path c]) and freshman year NMUPD-E was also significantly associated with sophomore year 
NMUPD-E (B = .57, p < .001 [path d]).   Potential long term associations between probable-PTSD 
and NMUPD occurring prior to college and probable-PTSD and NMUPD, respectively, occurring 
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in sophomore year were also examined.  probable-PTSD prior to college was associated with 
probable-PTSD sophomore year (B = .28, p < .001 [path n) and NMUPD prior to college was 
associated with NMUPD sophomore year (B = .54, p < .001 [path o]). 
Given that model fitting results suggested that TE was not a significant predictor or 
NMUPD-E across time, these paths were not included in the final model and thus only the cross 
paths between NMUPD-E and TE across time are presented.  NMUPD-E prior college served as 
a significant predictor of probable-PTSD freshman year (B = .17, p < .001); however, NMUPD-E 
during freshman year did not serve as a significant predictor of probable-PTSD sophomore year 
(B = -.04, p = .62).  Moreover, NMUPD-E prior to college did not serve as a significant predictor 
of probable-PTSD sophomore year (B = .05, p = .67).   To summarize, the results of the model 
fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPD-E is associated 
with heightened risk for probable-PTSD).   
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Table 7. Model fitting results of autoregressive cross lag models between probable posttraumatic stress disorder and experimental non-
medical use of prescription drugs. 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.3 a 51041.51 41365 -31688.49 -- -- -- 
Longitudinal Effects Models  
2.3 b 51044.08 41368 -31691.92 2.57 3  0.46 
3.3 c 51058.23 41368 -31677.77 16.72 3  .001 
Note:  a = model includes all paths; b = paths ‘pre college PTSD to freshman NMUPD-E’, ‘freshman PTSD to sophomore NMUPD-E’, and ‘pre college PTSD 
to sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman PTSD’, ‘pre college NMUPD-E to sophomore PTSD’, and 
‘freshman NMUPD-E to sophomore experimental PTSD’ constrained to zero. 
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Figure 5. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between probable posttraumatic stress disorder and 
experimental non-medical use of prescription drugs.         
 
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  probable-
PTSD = probable posttraumatic stress disorder, NMUPD-E = experimental non-medical use of prescription drugs, 
Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. 
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Table 8. Path estimates, p values, and standard errors for the best-fitting probable posttraumatic 
stress disorder and experimental non-medical use of prescription drugs autoregressive cross lag 
model. 
Path Estimate p value SE 
Correlations    
   Probable-PTSD Y1F           NMUPD-E Y1F (e) .21 <.001 .02 
   Probable-PTSD Y1S           NMUPD-E Y1S (f) .04 .44 .03 
   Probable-PTSD  Y2S           NMUPD-E Y2S (g) .16 .04  .07 
   Sex         Probable-PTSD Y1F .32 <.001 .02 
   Sex         NMUPD-E Y1F -.11 <.001 .02 
   Cohort           Probable-PTSD Y1F .01 .71 .02 
   Cohort           NMUPD-E Y1F .08 <.001 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       Probable-PTSD Y1S .16 <.001 .05 
   Sex       NMUPD-E Y1S -.09 .007 .03 
   Sex       NMUPD-E Y2S -.05 .28 .04 
   Sex       Probable-PTSD Y2S .20 .002 .07 
   Cohort         Probable-PTSD Y1S .16 <.001 .04 
   Cohort         NMUPD-E Y1S -.03 .32 .03 
   Cohort         NMUPD-E Y2S -.12 .002 .04 
   Cohort         Probable-PTSD Y2S .05 .27 .05 
 Autoregressive paths 1    
   Probable-PTSD Y1F        Probable-PTSD Y1S (a) .50   <.001 .05 
   Probable-PTSD Y1S        Probable-PTSD Y2S (b) .40 <.001 .07 
  NMUPD-E Y1F       NMUPD-E Y1S (c) 1.17 <.001 .04 
   NMUPD-E Y1S       NMUPD-E Y2S (d) .57 <.001 .05 
 Autoregressive paths 2    
   Probable-PTSD Y1F         Probable-PTSD Y2S (n) .28 <.001 .08 
  NMUPD-E Y1F       NMUPD-E Y2S (o) .54 <.001 .07 
 Cross lag paths 1    
  Probable-PTSD Y1F          NMUPD-E Y1S (h) - - - 
  Probable-PTSD Y1S          NMUPD-E Y2S (k) - - - 
   NMUPD-E Y1F      Probable-PTSD Y1S (i) .17 <.001 .04 
  NMUPD-E Y1S       Probable-PTSD Y2S (j) -.04 .62 .09 
Cross lag paths 2    
   Probable-PTSD Y1F          NMUPD-E Y2S (l) - - - 
   NMUPD-E Y1F        Probable-PTSD Y2S (m) .05 .67 .15 
Note: probable-PTSD = probable posttraumatic stress disorder, NMUPD-E = experimental non-medical use of 
prescription drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. - = best fitting model 
indicated that these paths could be dropped. 
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Longitudinal associations between probable-PTSD and NMUPD-R.   To examine the 
longitudinal associations between probable-PTSD and NMUPD-R, autoregressive cross lag 
models were conducted with sex and cohort as covariates.  The first (saturated) model, serving as 
the basis for comparison, is presented in Figure 1 (Model 1.4 in Table 9).  Figure 6 presents a 
simplified figure wherein the covariates, sex and cohort, are not included pictorially (but are 
included in the modeling).  
Model comparisons:  probable-PTSD and NMUPD-R. The fit statistics (AIC and change 
in -2 log likelihood) from each sub-model were compared to the saturated model (Model 1.4, Table 
9).  Two models examining the self-medication and the high risk hypotheses (i.e., Longitudinal 
Effects Models in Table 9) were compared to the saturated model.  In Model 2.4 (Table 9), cross 
lag paths from probable-PTSD to NMUPD across time points (h, k, and l paths) were constrained 
to zero to test the self-medication model across time.  This model was not significantly different 
from the saturated model (p = .29) indicating that these paths could be dropped without 
significantly effecting the fit.  In Model 3.4 (Table 9), cross lag paths from NMUPD to probable-
PTSD across time points (i, j, and m paths) were constrained to zero to test the high risk model 
across time.  This model was significantly different from the saturated model (p = .02) suggesting 
that dropping these paths would result in worse fit with the data. In summary, the results of the 
model fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPD-R is 
associated with heightened risk for probable-PTSD). 
Probable-PTSD and NMUPD-R best fitting model.  Following comparisons between the 
Longitudinal Effects Models to the saturated model (Table 9, Model 1.4), the fit indices from 
Model 2.4 indicate that paths from TE to NMUPD-R across time can be constrained to zero.  Path 
estimates with these paths dropped are located in Table 10.   
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The covariates of cohort and sex were consistently significantly associated with NMUPD-
R and probable-PTSD (ps < .05), with female sex being associated with greater report of probable-
PTSD but lower report of NMUPD-E and cohort being positively associated with NMUPD-R at 
baseline but negatively associated sophomore year, with the exception of sex not being a 
significant predictor of NMUPD-R during sophomore year and cohort not being a significant 
predictor of NMUPD-R occurring freshman year.  Moreover, cohort and probable-PTSD were not 
significantly correlated at baseline. When examining probable-PTSD and NMUPD-R, prior 
probable-PTSD and NMUPD-R were significant predictors of future probable-PTSD and 
NMUPD-R, respectively.  Specifically, probable-PTSD prior to college was associated with 
probable-PTSD freshman year (B = .49, p < .001 [path a]) and probable-PTSD in freshman year 
was significantly associated with TE sophomore year (B = .40, p < .001 [path b]).  Repeated use 
NMUPD prior to college was associated with freshman year NMUPD-R (B = 1.12, p < .001 [path 
c]) and freshman year NMUPD-R was also significantly associated with sophomore year 
NMUPD-R (B = .45, p < .001 [path d]).   Potential long term associations between probable-PTSD 
and NMUPD occurring prior to college and probable-PTSD and NMUPD, respectively, occurring 
in sophomore year were also examined.  probable-PTSD prior to college was associated with 
probable-PTSD sophomore year (B = .27, p < .001 [path n) and NMUPD prior to college was also 
associated with NMUPD sophomore year (B = .56, p < .001 [path o]). 
 Given that model fitting results suggested that TE was not a significant predictor or 
NMUPD-R across time, these paths were not included in the final model and thus only the cross 
paths between NMUPD-R and probable-PTSD across time are presented.  Repeated use NMUPD 
prior college served as a significant predictor of probable-PTSD freshman year (B = .16, p = .002); 
however, NMUPD-R during freshman year did not serve as a significant predictor of probable-
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PTSD sophomore year (B = -.03, p = .83).  Moreover, NMUPD-R prior to college did not serve as 
a significant predictor of probable-PTSD sophomore year (B = .09, p = .62).  In short, the results 
of the model fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPD-
R is associated with heightened risk for probable-PTSD).   
The high risk hypothesis was found to be the best fitting model across both forms of 
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model.  When 
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was 
significantly associated with probable-PTSD freshman year. However, significant associations 
between NMUPD freshman year and probable-PTSD sophomore year were only identified when 
examining NMUPD-R.  This path was not significant when examining the association between 
NMUPD-E freshman year and probable-PTSD sophomore year.  Thus, although the high risk 
model best fits the data in both models examining probable-PTSD and NMUPD (-E, -R), NMUPD 
serving as a significant predictor across each time point is inconsistent.
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Table 9. Model fitting results of autoregressive cross lag models between probable posttraumatic stress disorder and repeated use non-
medical use of prescription drugs. 
 
Note:  a = model includes all paths; b = paths ‘pre college probable-PTSD to freshman NMUPD-R’, ‘freshman probable-PTSD to sophomore NMUPD-R’, and 
‘pre college probable-PTSD to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman probable-PTSD’, ‘freshman NMUPD-
R to sophomore probable-PTSD’, and ‘pre college NMUPD-R to sophomore probable-PTSD’ constrained to zero. 
 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.4 a 45801.39 41376 -36950.61 -- -- -- 
Longitudinal Effects Models  
2.4 b 45811.22 41379 -36952.82 3.79 3 0.29 
3.4 c 45811.22 41379 -36946.78 9.83 3 0.02 
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Figure 6. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between probable posttraumatic stress disorder and 
repeated use non-medical use of prescription drugs.         
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  
probable-PTSD = posttraumatic stress disorder, NMUPD-E = experimental non-medical use of prescription drugs, 
Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. 
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Table 10. Path estimates, p values, and standard errors for the best-fitting probable posttraumatic 
stress disorder and repeated use non-medical use of prescription drugs autoregressive cross lag 
model. 
Path Estimate p 
value 
SE 
Correlations    
   Probable-PTSD Y1F           NMUPD-R Y1F (e) .21 <.001 .03 
   Probable-PTSD Y1S           NMUPD-R Y1S (f) .06 .36 .06 
   Probable-PTSD Y2S           NMUPD-R Y2S (g) .09 .31 .09 
   Sex         TE Y1F .32 <.001 .02 
   Sex         NMUPD-R Y1F -.11 <.001 .03 
   Cohort           TE Y1F .01 .68 .02 
   Cohort           NMUPD-R Y1F .05 .03 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       Probable-PTSD Y1S .16 <.001 .04 
   Sex       NMUPD-R Y1S -.12 .03 .04 
   Sex       NMUPD-R Y2S -.02 .68 .05 
   Sex       Probable-PTSD Y2S .22 .001 .07 
   Cohort         Probable-PTSD Y1S .18 <.001 .03 
   Cohort         NMUPD-R Y1S .05 .24 .04 
   Cohort         NMUPD-R Y2S -.13 .006 .04 
   Cohort         Probable-PTSD Y2S .05 .23 .05 
 Autoregressive paths 1    
   Probable-PTSD Y1F        Probable-PTSD Y1S (a) .49 <.001 .05 
   Probable-PTSD Y1S        Probable-PTSD Y2S (b) .40 <.001 .07 
   NMUPD-R Y1F       NMUPD-R Y1S (c) 1.12 <.001 .08 
   NMUPD-R Y1S       NMUPD-R Y2S (d) .45 <.001 .07 
 Autoregressive paths 2    
   Probable-PTSD Y1F       Probable-PTSD Y2S (n) .27 <.001 .08 
   NMUPD-R Y1F       NMUPD-R Y2S (o) .56 <.001 .10 
 Cross lag paths 1    
   Probable-PTSD Y1F          NMUPD-R Y1S (h) - - - 
   Probable-PTSD Y1S          NMUPD-R Y2S (k) - - - 
   NMUPD Y1F      Repeated Probable-PTSD Y1S (j) .16 .002 .05 
   NMUPD Y1S       Repeated Probable-PTSD Y2S (j) -.03 .83 .13 
Cross lag paths 2    
   Probable-PTSD Y1F          NMUPD-R Y2S (l) - - - 
   NMUPD Y1F        Probable-PTSD Y2S (m) .09 .62 .19 
Note: probable-PTSD = probable posttraumatic stress disorder, NMUPD-R = repeated non-medical use of prescription 
drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. - = best fitting model indicated that these 
paths could be dropped. 
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Longitudinal Associations Summary 
Within each longitudinal model, prior TE, probable-PTSD, and NMUPD (-E, -R) served 
as a significant predictor of future TE, probable-PTSD, and NMUPD (-E, -R) across time, 
respectively, as indicated by the significant autoregressive paths identified in each model. In the 
examination of longitudinal relationships between TE and NMUPD (-E, -R) similar patterns 
emerged.  When comparing each of the two models to the saturated model, (Longitudinal Effects 
Models representing the self-medication hypothesis and high risk hypothesis), the model 
representing the self-medication hypotheses, (which dropped cross lag paths from TE to NMUPD 
[-E, -R] across time) was consistently not significantly different from the saturated model which 
included all potential paths.  Thus, the findings overall, do not lend support for the self-medication 
hypothesis which posits that NMUPD may serve as a method of coping post trauma exposure.  
Rather, the overall findings from each of the models suggests that NMUPD (-E, -R) heightens risk 
for TE over time. This pattern was additionally demonstrated within the follow-up analyses 
(examining the longitudinal associations between probable-PTSD and both forms of NMUPD) 
which also suggested that the high risk model may best capture the associations between NMUPD 
(-E, -R) and probable-PTSD across time within this sample1.   
Aim 2: Genotypic Results 
Determining molecular heritability of NMUPD (experimental and repeated use) and 
TE.  To determine the SNP-based heritability (h2SNP) of each variable of interest, univariate 
GCTAs were conducted within each ancestral group.  As reviewed in the QC portion of the 
 
1When the analyses were further refined to examine the longitudinal associations between IPV and 
both forms of NMUPD, the same pattern emerged (Appendix II).  However, this pattern did not 
hold when the analyses were restricted to natural disaster (Appendix III).   Please see Appendices 
for results for each of these models. 
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Methods section of the present document, each participant was classified into their respective super 
population resulting in five ancestral groups:  AFR (n = 1,339), AMR (n = 582), EAS (n = 557), 
EUR (n = 3,018), and SAS (n = 455).  It is important to note that the ns within each ancestral group 
vary by phenotype (i.e., all participants may not have responded to every item); thereby resulting 
in different ancestral group ns in each set of analyses. 
Prior to conducting these analyses, power calculations were performed for each phenotype 
(NMUPD-E, NMUPD-R, and TE) within each ancestral group (Table 11).  Power analyses suggest 
that overall, there is limited power to detect effects (with the exception of GCTAs conducted within 
the EUR ancestry group for phenotypes with high heritability [h2SNP
 = 0.50]).  When examining 
the h2SNP of each phenotype by super population, most of the findings were not significant, as 
confidence intervals for estimates frequently included 0 (Table 12).  Some of the SNP-based 
heritability estimates were significant; however, interpretation is problematic given the unusually 
high estimates identified (e.g., h2SNP estimate of .99 within EAS super population for NMUPD-E). 
In accordance with standard practice set forth by the PGC 
(https://github.com/Nealelab/ricopili), results were also meta-analyzed across ancestry groups.  
The h2SNP estimate derived from the meta-analysis for NMUPD-E was .15 (SE = .01, CI = .12-.17) 
and for NMUPD-R was .22 (SE = .01, CI = .19-.24).  The h2SNP estimates identified for NMUPD-
E was significantly lower than that derived for NMUPD-R (F = 2.10, p < .001).   The h2SNP estimate 
for TE was .02 (SE = .01, CI = .001-.04).  Despite the h2SNP estimates for NMUPD-E and NMUPD-
R being within a range reasonably consistent with the broader substance use literature (with a 
higher estimate identified for the more refined NMUPD-R phenotype, compared to the NMUPD-
E phenotype), these findings should be interpreted cautiously.  Although the meta-analytic 
approach increases the power to detect effects, the estimates produced are likely influenced by low 
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prevalence rates (limited number of cases) for NMUPD (-E, -R) and limited number of controls 
within the TE phenotype. Moreover, interpretability is limited given the heterogeneity present 
within each of the phenotypes.  Specifically, NMUPD (-E, -R) can capture a range of use 
presentations (e.g., a single experiential use, problematic use) and the TE phenotype consists of a 
broad range of potentially traumatic events (e.g., motor vehicle accidents, sexual assault) collapsed 
into a single binary variable.  
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Table 11.  Power calculations within each phenotype (nonmedical use of prescription drugs 
[experimental and repeated use] and trauma exposure) by ancestral group. 
          Power 
Phenotypic 
Outcome 
Ancestry 
Group N Prevalence Controls Cases 
h2SNP  
= 0.50 
h2SNP   
= 0.20 
h2SNP = 
0.10 
Experimental 
NMUPD 
AFR 1325 14% 1144 181 .14 .06 .05 
AMR 573 27% 417 156 .08 .06 .05 
EAS 545 15% 462 83 .07 .05 .05 
EUR 2956 34% 1963 993 .79 .20 .09 
SAS 442 16% 371 71 .06 .05 .05 
Repeated Use 
NMUPD  
AFR 1325 5% 1264 61 .07 .05 .05 
AMR 574 12% 507 67 .06 .05 .05 
EAS 546 7% 510 36 .06 .05 .05 
EUR 2957 18% 2427 530 .58 .14 .07 
SAS 442 7% 413 29 .05 .05 .05 
TE 
AFR 1322 87% 176 1146 .13 .06 .05 
AMR 570 86% 79 491 .07 .05 .05 
EAS 546 81% 105 441 .07 .05 .05 
EUR 2953 87% 375 2578 .44 .11 .06 
SAS 442 82% 81 361 .06 .05 .05 
Note: NMUPD = non-medical use of prescription drugs, TE = trauma exposure, AMF = African ancestry, AMR = 
Americas ancestry, EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, h2SNP = SNP-
based heritability. 
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Table 12. Estimates of SNP-based heritability for non-medical use of prescription drugs 
(experimental and repeated use) and trauma exposure phenotypes (controlling for population 
stratification, sex, and cohort) generated from genome-wide complex trait analyses. 
Super population Covariates Sample Prevalence h2SNP SE p-value 
NMUPD-E 
AFR PCs, cohort, sex 14% .11 .26 .30 
AMR PCs, cohort, sex 27% .33 .45 .20 
EAS PCs, cohort, sex 15% .99 .63 .05 
EUR PCs, cohort, sex 34% .08 .13 .30 
SAS PCs, cohort, sex 16% .85 .72 .10 
NMUPD-R 
AFR PCs, cohort, sex 5% .71 .28 .01 
AMR PCs, cohort, sex 12% .52 .49 .20 
EAS PCs, cohort, sex 7% 1.00 .61 .01 
EUR PCs, cohort, sex 18% .06 .13 .30 
SAS PCs, cohort, sex 7% < .001 .74 .50 
TE 
AFR PCs, cohort, sex 87% .14 .26 .30 
AMR PCs, cohort, sex 86% .01 .42 .50 
EAS PCs, cohort, sex 81% <.001 .61 .50 
EUR PCs, cohort, sex 87% <.001 .13 .50 
SAS PCs, cohort, sex 82% < .001 .74 .50 
Note:  NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use 
of prescription drugs, h2SNP = SNP-based heritability estimate, PCs = principle components, AMF = African ancestry, 
AMR = Americas ancestry, EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up analyses. Given concerns regarding the univariate GCTAs conducted for 
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NMUPD (-E, -R) and TE associated with imbalance between cases and controls and with 
interpretability, univariate GCTAs were also conducted for probable-PTSD within each ancestral 
group in an effort to derive h2SNP estimates for a more refined phenotype. Again, prior to these 
analyses, power calculations were conducted for probable-PTSD within each ancestry group 
(Table 13).  Results from the power analyses suggest that there is limited power to detect effects. 
Determining the SNP-based heritability of probable-PTSD.  No significant findings were 
identified for univariate GCTAs for probable-PTSD, as confidence intervals for estimates 
frequently included 0 (Table 14).  Results were meta-analyzed across ancestry groups.  However, 
difficulties associated with limited power resulted in the inability to calculate the h2SNP for the 
probable-PTSD phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13.  Power calculations within the probable posttraumatic stress disorder phenotype by 
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ancestral group. 
          Power 
Phenotypic 
Outcome 
Ancestry 
Group N Prevalence Controls Cases 
h2SNP
 
 = 
0.50 
h2SNP
 
 = 
0.20 
h2SNP  
= 0.10 
Probable-
PTSD 
AFR 1139 39% 691 448 .20 .07 .05 
AMR 488 43% 278 210 .08 .05 .05 
EAS 435 32% 295 140 .07 .05 .05 
EUR 2548 42% 1481 1067 .71 .17 .08 
SAS 355 32% 241 114 .06 .05 .05 
Note: Probable-PTSD = posttraumatic stress disorder, AMF = African ancestry, AMR = Americas ancestry, EAS = 
East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, h2SNP = SNP-based heritability estimate. 
 
 
 
Table 14. Estimates of SNP-based heritability for probable posttraumatic stress disorder phenotype 
(controlling for population stratification, sex, cohort) generated from genome-wide complex trait 
analyses. 
Super population Covariates Sample Prevalence h2SNP SE p-value 
Probable-PTSD 
AFR PCs, cohort, sex 39% <.001 .29 .50 
AMR PCs, cohort, sex 43% <.001 .45 .50 
EAS PCs, cohort, sex 32% <.001 .81 .50 
EUR PCs, cohort, sex 42% <.001 .15 .50 
SAS PCs, cohort, sex 32% < .001 .90 .50 
Note: Probable-PTSD = probable posttraumatic stress disorder, h2SNP = SNP based heritability estimate, Ca = cases, 
Co = controls, PCs = principle components, AMF = African ancestry, AMR = Americas ancestry, EAS = East Asian 
ancestry, EUR = European ancestry, AMF = South Asian ancestry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP-based heritability results summary.  Overall, the findings from the meta-analyses 
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resulted in significant h2SNP estimates for NMUPD-E and NMUPD-R.  However, meta-analyses 
for TE and probable-PTSD did not reveal significant h2SNP estimates.  Moreover, additional 
attempts to refine the analyses resulted in mixed findings (significant h2SNP estimate identified for 
IPV [h2SNP = .05, SE = .01, CI = .03-.07] but not NMUPD-E when the covariates of TE and 
probable-PTSD were included)2.  The lack of significant results among the TE and probable-PTSD 
phenotypes is likely attributable to limited statistical power to detect effects and limitations 
associated with phenotypic assessment, which will be reviewed in detail within the discussion.   
Despite the limited evidence of aggregate molecular influence provided by h2SNP for some of the 
phenotypes, GWAS analyses were conducted to examine the potential influence of individual 
variants in relation to study constructs. Justification for conducting GWAS despite the lack of 
significant h2SNP estimates identified is reviewed within the discussion. 
Identifying Genetic Variants Associated with Phenotypes of Interest.   
Phenotype selection justification for GWAS.  Prior to conducting these GWAS, power 
analyses were completed using the Genetic Association Study Power Calculator 
(http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html).   Power was calculated 
for several MAFs (i.e., .05, .25, .50) and genotype relative risks (i.e., 1.05, 1.10, 1.15, 1.20).  As 
demonstrated in the table below, the NMUPD-R phenotype were underpowered for GWAS.   
Power calculations for the TE phenotype was also attempted; however, the calculations could not 
be calculated likely due to the imbalance between cases and controls.  Given the limited power to 
detect effects for NMUPD-R and TE, likely associated with lack of balance between cases and 
 
2 These attempts to refine the analyses included (1) conducting a GCTA on the more nuanced 
phenotype of IPV, and (2) conducting a GCTA on NMUPD-E incorporating TE and probable-
PTSD as covariates in the most highly powered subsample (European ancestral group). Please see 
Appendices VI and VII for results of these refined analyses. 
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controls (low prevalence of cases in NMUPD-R and low prevalence of controls in TE), GWAS 
were not performed for these phenotypes.   Although not ideal, NMUPD-E was selected for GWAS 
given the greater power to detect significant genetic effects (MAF > .25%, genotype relative risk 
> 1.20, prevalence of 25%) and better balance with regard to case/control status relative to the 
NMUPD-R and TE phenotypes (Table 15).   
In addition to NMUPD-E, GWAS were conducted for probable-PTSD and IPV.  There was 
adequate power to detect common variants at MAF >.50% and genotype relative risk > 1.15 and 
MAF >.25% and genotype relative risk > 1.20 for the probable-PTSD phenotype (prevalence of 
40%) and to detect common variants at MAF > .25% and genotype relative risk > 1.15 (prevalence 
of 46%). 
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Table 15. Power to detect variants in GWAS across phenotypes. 
NMUPD-E (1890 cases and 5610 controls) 
 Genotype Relative Risk 
MAF 1.05 1.10 1.15 1.20 
.05 0 .01 .01 .06 
.25 0 .06 .44 .88 
.50 0 .13 .68 .98 
NMUPD-R (933 cases and 6569 controls) 
 Genotype Relative Risk 
MAF 1.05 1.10 1.15 1.20 
.05 0 0 0 0 
.25 0 0 .04 .20 
.50 0 .01 .10 .38 
Probable-PTSD (1979 cases and 2986 controls) 
 Genotype Relative Risk 
MAF 1.05 1.10 1.15 1.20 
.05 0 0 .03 .14 
.25 0 .14 .71 .98 
.50 .01 .27 .88 1.00 
IPV (2673 cases and 3141 controls) 
 Genotype Relative Risk 
MAF 1.05 1.10 1.15 1.20 
.05 0 .01 .10 .40 
.25 .01 .38 .96 1.00 
.50 .02 .60 .99 1.00 
Note:  NMUPD-E = experimental non-medical use of prescriptions drugs, NMUPD-R = repeated non-medical use of 
prescription drugs, probable-PTSD = probable posttraumatic stress disorder, IPV = interpersonal violence, MAF = 
minor allele frequency. 
 
GWAS results overview.  GWAS for NMUPD-E, probable-PTSD, and IPV were 
conducted with each phenotype treated as a binary variable (case/control).  Moreover, GWAS were 
conducted separately by ancestry (i.e., AFR, AMR, EAS, EUR, SAS) with PCs, sex, and cohort 
included as covariates and then meta-analyzed using METAL (Willer, Li, & Abecases, 2010), 
which uses a fixed effect model and inverse variance weighting based on sample size. Results 
(sample size, number of markers, lambdas [λ and λ1000]) for each phenotype are presented in 
Table 16.  Manhattan plots and Q-Q plots are also presented for NMUPD-E (Figures 7 and 8, 
respectively), probable-PTSD (Figures 9 and 10, respectively), and IPV (Figures 11 and 12, 
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respectively).   
GWAS results for NMUPD-E.  No evidence of genomic inflation was identified (λ = 
1.006, concern regarding potential bias associated with population stratification arises when λ is 
greater than 1.1; Winkler et al., 2014), thus, no adjustments were made.  Eight genomic bins 
contained at least one SNP with a p-value that reached genome-wide significance (5x10-8) for 
NMUPD-E; however, only five genomic bins passed the FDR correction (method of controlling 
for Type 1 errors while maximizing power compared to standard Bonferroni type corrections; 
Benjamini & Hochberg, 1995) threshold of .05 (Table 17).  Information regarding the significant 
SNPs identified for NMUPD-E is provided in Table 20.  Moreover, Figures 13-17 present regional 
association plots, which visually displays the strength of association between the SNP of interest 
and other nearby markers within the region (+/- 200 kb [kilobase; one kb is equal to 1000 base 
pairs of DNA]), for each of the five genomic bins with at least one genome wide significant SNP 
passing FDR correction. 
The SNPs with the lowest p-values passing FDR correction for NMUPD-E meta analyzed 
across super populations were located on chromosome 20, chromosome 16, chromosome 13, 
chromosome 11, and chromosome 3.  The SNP located on chromosome 20 (rs73241778) mapped 
onto the PAK7, a protein coding gene, while the SNP located on chromosome 16 (rs138647543) 
mapped onto LINC00922, a noncoding RNA gene. The remaining three SNPs (rs142738451, 
rs74901044, rs9578774) did not map onto any specific gene although they were close (within 5000 
bp) to multiple genes including ATP12A, RNF17, AK095081, and LOC283177.  The direction of 
effect was similar across SNPs (minor allele [allele 1, listed at A1 in tables] being negatively 
associated with NMUPD-E case status) with the exception of rs73241778 which was positively 
associated with NMUPD-E case status.  Each SNP was also a rare variant (MAF < .05) with the 
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exception of rs73241778 which is considered common (MAF = .10).  The regional association 
plots (Figures 13-17) revealed that rs142738451, rs73241778, rs9578774, and rs74901044 are lone 
SNPs or in weak LD with surrounding markers.  However, rs138647543 is in strong LD with other 
nearby markers suggesting that multiple SNPs within the region may be associated with NMUPD-
E.  It could also suggest that the identified SNP is not the true casual variant but may be in LD 
with the causal variant. 
GWAS results for probable-PTSD.  No evidence of genomic inflation was identified for 
the probable-PTSD phenotype (λ = 1.011), thus, no adjustments were made.  No SNPs had p-
values that reached genome-wide significance for the probable-PTSD phenotype meta analyzed 
across super populations (Table 18).  Although no SNPs reached genome wide significance for 
these phenotypes, suggestive markers with p-values below 5x10-5 were identified (Table 18 and 
19).  The majority of genomic bins with SNPs possessing the lowest p-values were located on 
chromosome 4 (rs10024355).  The SNP with the lowest p-value for probable-PTSD is considered 
common and were within or near KCNIP, which is a protein coding gene.  The direction of effect 
for rs10024355 with a minor allele of ‘a’ was negative for the probable-PTSD phenotype.  The 
regional association plots (Figure 18) revealed that rs10024355 was in strong LD with surrounding 
markers for probable-PTSD. 
GWAS results for IPV.  No evidence of genomic inflation was identified for the IPV 
phenotype (λ = 1.013), thus, no adjustments were made.  No SNPs had p-values that reached 
genome-wide significance for the IPV phenotype (Table 19).  The majority of genomic bins with 
SNPs possessing the lowest p-values were located on chromosome 6 (rs2764203).  The SNPs with 
the lowest p-value for IPV were also considered common and were within or near the two protein 
coding genes of SNRPC and UHRF1BP1 (other surrounding genes included C6orf106, 1BP, 
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ANKS1A, and TAF1).  The direction of effect for rs2764203 with a minor allele of ‘a’ was positive 
for the IPV phenotype.  The regional association plots (Figure 19) revealed that rs2764203 was in 
strong LD with nearby SNPs for IPV. 
GWAS results summary.  Two phenotypes (NMUPD-R, TE) were not examined due to 
limited power to detect genetic effects; however, GWAS were conducted for the phenotypes of 
NMUPD-E, probable-PTSD, and IPV.  Five genomic bins containing at least one genome wide 
significant SNP passing FDR correction were identified for NMUPD-E.  Significant SNPs were 
within or nearby PAK7 and LINC00922.  The majority of significant SNPs possessed the minor 
allele (‘t’ rather than ‘c’ for rs142738451 and rs73241778; ‘a’ rather than ‘g’ for rs9578774, 
rs138647543, and rs74901044) that was negatively associated with NMUPD-E case status and are 
considered rare; however, one SNP possessed a minor allele (‘a’ rather than ‘g’) that was positively 
associated with case status and considered a common variant.  Inspection of regional association 
plots revealed that only one SNP (rs138647543) was in high LD with surrounding markers, 
indicating that multiple other SNPs within this region may be associated with the NMUPD-E 
phenotype or the actual causal variant.  Although genome wide significant SNPs were identified 
for the NMUPD-E phenotype, no genome wide significant SNPs were identified for probable-
PTSD or IPV phenotypes.   However, suggestive SNPs within the KCNIP4 gene for probable-
PTSD and SNRPC and UHRF1BP1 genes (other surrounding genes included C6orf106, 1BP, 
ANKS1A, and TAF1) for IPV were identified.   
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Table 16. Sample sizes, number of markers, lambdas, and lambda 1000 information for GWAS 
results of experimental non-medical use of prescription drugs, probable posttraumatic stress 
disorder, and interpersonal violence phenotypes. 
  AFR AMR EAS EUR SAS Metal 
NMUPD-E 
N 1325 573 545 2956 442 >1000 
n 
markers 
14443339 8022304 6807786 10327163 7311043 16591911 
λ 
1.003 
1.018 1.032 1.003 1.014 1.006 
λ1000 1.001 1.003 1.005 1.001 1.002 1.000 
Probable-
PTSD 
N 1139 488 435 2548 355 >1000 
n 
markers 
13865404 7699002 6526178 10123812 6924055 16257569 
λ 1.002 1.017 1.020 .999 1.006 1.011 
λ1000 1.000 1.003 1.004 1.000 1.001 1.000 
IPV 
N 1314 568 542 2949 441 >1000 
n 
markers 
14430840 8009501 6813103 10328147 7311426 16908762 
λ 1.010 1.022 1.015 1.002 1.014 1.013 
λ1000 1.002 1.003 1.003 1.001 1.002 1.000 
Note:  NMUPD-E = experimental non-medical use of prescription drugs, probable-PTSD = probable posttraumatic 
stress disorder, IPV = interpersonal violence. 
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Figure 7: Q-Q plot of experimental non-medical use of prescription drugs results within each super 
population and meta-analyzed across super populations.  
 
 
Note:  The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from 
GWAS of experimental non-medical use of prescription drugs is shown on the y-axis. All p-values are represented as 
–log10(P). The red lines to the sides represent 95% confidence intervals. 
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Figure 8.  Manhattan plot for meta-analyzed results of experimental non-medical use of 
prescription drugs. 
 
 
Note: This figure plots the –log10(p) values of associations for experimental non-medical use of prescription drugs 
by chromosome. The red line represents genome-wide significance (p = 5x10E-08), while the blue line indicates 
nominal significance (p = 10-5). 
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Figure 9: Q-Q plot of probable posttraumatic stress disorder meta-analyzed results within each 
super population and meta-analyzed across super populations.  
 
 
 
Note: The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from 
GWAS of probable posttraumatic stress disorder is shown on the y-axis. All p-values are represented as –log10(P). 
The red lines to the sides represent 95% confidence intervals. 
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Figure 10.  Manhattan plot for meta-analyzed results of probable posttraumatic stress disorder.  
 
 
Note:  This figure plots the –log10(p) values of associations for probable posttraumatic stress disorder by chromosome. 
The red line represents genome-wide significance (p = 5x10E-08), while the blue line indicates nominal significance 
(p = 10-5). 
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Figure 11: Q-Q plot of interpersonal violence results within each super population and meta-
analyzed across super populations.  
 
 
Note:  The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from 
GWAS of interpersonal violence is shown on the y-axis. All p-values are represented as –log10(P). The red lines to 
the sides represent 95% confidence intervals. 
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Figure 12.  Manhattan plot for meta-analyzed results of interpersonal violence.  
 
 
 
Note:  This figure plots the –log10(p) values of associations for interpersonal violence by chromosome. The red line 
represents genome-wide significance (p = 5x10E-08), while the blue line indicates nominal significance (p = 10-5). 
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Table 17. Annotated top 20 clusters of SNPs for experimental non-medical use of prescription 
drugs phenotype using results from meta-analyses. 
Chr Start BP End BP # of 
SNPs 
Min P Min Q Genes Local genes 
3 22753786 22753786 1 6.13E-09 0.03 None None 
20 9541486 9541486 1 7.12E-09 0.03 PAK7 LAMP5,PAK7 
13 25301501 25313166 3 1.02E-08 0.03 None 
ATP12A,RNF1
7 
16 65445551 65463312 3 1.02E-08 0.03 LINC00922 
JB153694,LIN
C00922 
11 134390129 134392003 2 1.53E-08 0.04 None 
AK095081,LO
C283177 
20 9552989 9557791 2 2.57E-08 0.05 PAK7 LAMP5,PAK7 
8 125229715 125230709 2 3.10E-08 0.05 None AK057332 
20 9521828 9527903 5 4.38E-08 0.07 PAK7 LAMP5,PAK7 
15 69953475 69956198 3 7.64E-08 0.08 None AK097902 
16 65424997 65434757 3 8.18E-08 0.08 LINC00922 
JB153694,LIN
C00922 
8 125171598 125195866 18 9.10E-08 0.08 AK057332 
AK057332,FE
R1L6 
12 66130101 66143059 3 1.69E-07 0.11 None RPSAP52 
16 65474561 65540007 22 1.78E-07 0.11 LINC00922 None 
8 55755894 55755894 1 1.88E-07 0.11 None None 
1 1390226 1396458 2 2.89E-07 0.11 ATAD3C 
ANKRD65,AT
AD3B,ATAD3
C,MRPL20,TM
EM88B,VWA1 
9 104478986 104500980 5 2.23E-07 0.11 GRIN3A None 
8 2174033 2175104 4 2.40E-07 0.11 None AX747124 
9 134478679 134479696 3 3.16E-07 0.11 RAPGEF1 None 
11 458441 540005 80 3.25E-07 0.11 
HRAS,LRR
C56,PTDSS
2,RNH1 
ANO9,AX7483
30,BC031953,
C11orf35,HRA
S,LOC143666,
LRRC56,Metaz
oa_SRP,MIR21
0,MIR210HG,
PHRF1,PTDSS
2,RASSF7,RN
H1,SIGIRR 
5 171596395 171603750 4 3.47E-07 0.11 STK10 
EFCAB9,STK1
0,UBTD2 
Note: BP = base position; Chr = chromosome number; Min = minimum.  
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Table 18. Annotated top clusters of SNPs for probable posttraumatic stress disorder using results 
from meta-analyses. 
Chr Start BP End BP # of 
SNPs 
Min P Min 
Q 
Genes Local genes 
2 153957506 153957512 2 1.06E-06 0.43 None None 
3 162247037 162254016 4 1.98E-07 0.15 None None 
4 21228079 21250060 26 9.00E-08 0.15 KCNIP4 None 
4 190031837 190031837 1 1.85E-07 0.15 None None 
10 15513474 15518328 3 4.01E-07 0.26 None ITGA8 
10 78098586 78098586 1 1.27E-07 0.15 C10orf11 None 
12 18276779 18285577 2 5.39E-07 0.29 None RERGL 
14 102804409 102804409 1 1.19E-06 0.46 ZNF839 
CINP,MOK,T
ECPR2,TRNA
_Ile,ZNF839 
18 70493335 70493335 1 8.99E-07 0.38 NETO1 None 
Note: BP = base position; Chr = chromosome number; Min = minimum.  
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Table 19. Annotated top clusters of SNPs for interpersonal violence using results from meta-
analyses. 
Chr Start BP End BP # of 
SNPs 
Min P Min 
Q 
Genes Local genes 
6 34708901 34724815 6 1.01E-07 0.17 None 
C6orf106,SNRP
C,UHRF1BP1 
6 34738990 34747409 4 1.08E-07 0.17 SNRPC 
SNRPC,UHRF
1BP1 
6 34777401 34795102 7 1.15E-07 0.17 UHRF1BP1 
SNRPC,UHRF
1BP1 
6 34759502 34763982 2 1.33E-07 0.17 UHRF1BP1 
SNRPC,UHRF
1BP1 
6 34805296 34825662 8 1.69E-07 0.17 UHRF1BP1 
ANKS1A,TAF11
,UHRF1BP1 
6 34689126 34692474 2 1.92E-07 0.17 None 
C6orf106,SNR
PC 
2 6794065 6794065 1 4.98E-07 0.29 None None 
12 117381060 117381060 1 5.45E-07 0.31 FBXW8 None 
6 165895697 165895697 1 8.26E-07 0.43 PDE10A None 
6 165906181 165906181 1 8.43E-07 0.43 PDE10A None 
12 117425695 117425695 1 9.09E-07 0.44 FBXW8 
AK055849,FB
XW8 
6 34623905 34623905 1 1.02E-06 0.48 C6orf106 None 
Note: BP = base position; Chr = chromosome number; Min = minimum. 
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Table 20. Significant SNPs associated with the experimental non-medical use of prescription drugs phenotype, following false 
discovery rate correction. 
SNP CHR A1 A2 INFO MAF HWE z-score p Direction Q_1k 
 
rs142738451 3 t c 0.612 0.016 1 5.813 6.13E-09 +???? 0.033 
rs73241778 20 t c 0.586 0.021 0.436 -5.788 7.12E-09 -???? 0.033 
rs9578774 13 a g 0.650 0.020 1 -5.728 1.02E-08 -???? 0.034 
rs138647543 16 a g 0.929 0.030 1 -5.728 1.02E-08 -???? 0.034 
rs74901044 11 a g 0.749 0.101 1 -5.658 1.53E-08 -???? 0.042 
Note:  CHR = chromosome; A1 = allele 1; A2 = allele 2; INFO = imputation quality; MAF = minor allele frequency; HWE = Hardy Weinberg Equilibrium; p = 
p-value; Q_1k = q-value.  
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Table 21. Suggestive SNPs associated with the probable posttraumatic stress disorder and interpersonal violence phenotypes. 
SNP CHR A1 A2 INFO MAF HWE z-score p Direction Q_1k 
 
Probable-PTSD 
rs10024355 4 a g 0.950 0.098 0.822 -5.346 9.00E-08 ----- 0.150 
IPV 
rs2764203 6 a g 0.997 0.154 0.888 5.324 1.01E-07 ++?++ 0.173 
Note:  Probable-PTSD = probable posttraumatic stress disorder, IPV = interpersonal violence, CHR = chromosome; A1 = allele 1; A2 = allele 2; INFO = 
imputation quality; MAF = minor allele frequency; HWE = Hardy Weinberg Equilibrium; p = p-value; Q_1k = q-value.  
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Figure 13: Locus Zoom plot for rs142738451 on chromosome 3, associated with experimental 
non-medical use of prescription drugs. 
 
Note:  Associations for SNPs near rs14273851 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
 
 
 
 
 
 
 93 
Figure 14: Locus Zoom plot for rs73241778 on chromosome 20, associated with experimental 
nonmedical use of prescription drugs. 
 
Note:  Associations for SNPs near rs73241778 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
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Figure 15: Locus Zoom plot for rs9578774 on chromosome 13, associated with experimental 
non-medical use of prescription drugs. 
 
Note:  Associations for SNPs near rs9578774 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
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Figure 16: Locus Zoom plot for rs138647543 on chromosome 16, associated with experimental 
non-medical use of prescription drugs. 
 
Note:  Associations for SNPs near rs138647543 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP (r2) is represented by different colors (red being highest and blue being lowest). 
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Figure 17: Locus Zoom plot for rs74901044 on chromosome 11, associated with experimental 
non-medical use of prescription drugs. 
 
Note:  Associations for SNPs near rs74901044 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
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Figure 18: Locus Zoom plot for rs10024355 on chromosome 4, associated with probable 
posttraumatic stress disorder. 
 
Note:  Associations for SNPs near rs10024355 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
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Figure 19: Locus Zoom plot for rs2764203 on chromosome 4, associated with interpersonal 
violence. 
 
Note:  Associations for SNPs near rs2764203 (the SNP with the smallest p-value [reference SNP]) are presented in 
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p). 
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue 
being lowest). 
 
 
 
 
 
 
 
 
 99 
Discussion 
 The aims of the present study were threefold: 1) examine the longitudinal associations 
between NMUPD (-E, -R) and TE, 2) determine the SNP-based heritability of the NMUPD-E, 
NMUPD-R, and TE phenotypes via GCTA, and 3) identify specific variants associated with 
NMUPD-E, probable-PTSD, and IPV phenotypes by means of GWAS methodologies.  Additional 
follow-up analyses were also conducted with the potentially more refined phenotypes of probable-
PTSD and IPV (i.e., greater phenotypic specificity, greater balance between cases and controls).  
The present discussion is divided broadly into phenotypic and genotypic sections which each 
contain relevant discussion of results, limitation, and clinical implications.   
Phenotypic Discussion 
Prevalence of NMUPD (-E, -R).  Prior to conducting longitudinal analyses, the prevalence of 
each phenotype (NMUPD-E, NMUPD-R, TE, and probable-PTSD) was calculated. Both 
NMUPD-E and NMUPD-R remained relatively stable across assessment periods with estimates 
varying between approximately 16.7%-17.9% and 7.0%-8.8%, respectively. Within the extant 
literature, prevalence estimates vary widely across studies due to definitional variability (e.g., 
recreational use vs. DSM-IV-TR criteria [abuse/dependence]) and differences in samples assessed 
(Barrett et al., 2008); however, the prevalence identified within the present sample are consistent 
with those presented by SAMHSA (2016) for the 18-25-year-old age group (~15% lifetime use, 
paralleling the present definition of experimental use).  Moreover, studies assessing lifetime use 
derive similar prevalence estimates (ranging between approximately 13% and 25%) when focused 
specifically on college student samples (McCabe et al., 2016; McCabe et al., 2009; Meisel & 
Goodie, 2015). It is critical to note that in addition to definitional variability and differences in 
sample characteristics, that the binning of illicit substances with NMUPD in assessment 
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measures/analyses also contributes to the variation within rates demonstrated across studies (please 
see commentary regarding these concerns by Boyd & McCabe, 2007). The present study also 
suffers from this concern which is a significant limitation.  Additional research is warranted to 
further discern the prevalence rates of NMUPD independent of other forms of substance use.  
Comparing the prevalence identified for NMUPD-R in the present study (7.0%-8.8% 
depending on year) in relation to rates identified within the literature is also methodologically 
challenging.  The definition used in the assessment of NMUPD-R in the present study focused on 
six or more uses within one’s lifetime (or past 12 months depending on assessment period).  
Although this variable may serve as a proxy for potentially problematic use, it is not thorough 
enough to adequately capture consequences associated with use or the DSM-5 (APA, 2013) criteria 
for a substance use disorder.  However, given that adolescents/young adults are likely in the 
beginning, yet critical, stages of their potential substance use (Chambers, Taylor, & Potenza, 
2003), it may be helpful to identify an index of use that may be predictive of future problematic 
NMUPD.  Additional examination is warranted to elucidate the potential utility of an intermediate 
phenotype that may successfully predict problematic use.  
 Prevalence of each form of NMUPD (sedatives, stimulants, and opioids).  Stimulants were 
the most frequently misused substance within this sample, followed by opioids and then sedatives.  
A decreasing trend over time for sedatives and opioids (experimental [8.2% prior to college to 
5.3% sophomore year, 5.6% prior to college to 4.3% sophomore year, respectively] and repeated 
use [2.6% prior to college to 1.9% sophomore year, 1.9% prior to college to 1.5% sophomore year, 
respectively]) was present; however, stimulant use (experimental and repeated use [13.5% prior to 
college to 15.8% sophomore year, 5.6% prior to college to 7.4% sophomore year, respectively]) 
increased across time points.  Stimulant use has been noted to be a particularly relevant concern 
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among college aged students (McCabe, West, Teter, & Boyd, 2014; Ford & Pomykacz, 2016). 
Given the potentially competitive nature of academia and pressure to perform, students may resort 
to external means of increasing focus/attention in order to improve academic performance (Arria 
et al., 2010).  Studies explicitly examining stimulant use motives have noted a link between both 
interest in enhanced performance and perceptions of undiagnosed attentional difficulties with 
stimulant misuse (Judson & Langdon, 2009).  Moreover, non-medical stimulant use among 
students has also been associated with greater likelihood of skipping classes and poly substance 
use (Arria et al., 2008, Arria et al., 2010). Although less common, heightened social pressure 
regarding weight and body image within this age range may also contribute to stimulant use as a 
weight management tool (Rabiner et al., 2009; Jeffers, Benotsch, & Koester, 2013). Thus, future 
studies would benefit from not only assessing specific forms of NMUPD, but motivations behind 
such use.  Moreover, substance use and motives may show critical patterns by developmental 
stage. Specifically, stimulant use is more prevalent among adolescents/young adults.  Increased 
exposure to other substances (e.g., sedatives and opioids) may occur in later developmental periods 
(greater than 30 years of age, Han et al., 2017) potentially given the heightened opportunity to 
experience pain and/or stressful life events as a function of time. Additional disaggregated 
examination of NMUPD is necessary to further explicate differential associations between specific 
forms of prescriptions drug use and environmentally/developmentally influenced motives. 
Prevalence of TE and probable-PTSD.  Prevalence of TE demonstrated within the present 
study are higher than recent prevalence identified in epidemiological studies of TE (~85% in the 
present study compared to ~70% in an epidemiological study of adults by Benjet et al., 2015).  
However, the rate identified within the present study does fall within the range of prevalence 
estimates (52% - 94%) identified in previous studies examining the prevalence of trauma exposure 
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among college students specifically (Watson & Haynes, 2007; Vrana & Lauterbach, 1994; Owens 
& Chard, 2006; Ford & Arrastia, 2008).   The lower prevalence identified in some studies has been 
linked to differences regarding what constitutes an event being classified as traumatic (e.g., not 
including unexpected/sudden death as a traumatic; Frazier et al., 2009). It is important to note that 
the report of natural disaster is likely inflated in the present study due to a mild earthquake that 
occurred within the area in 2011, thereby impacting the overall reporting of TE (85.5% including 
natural disaster vs. 76.8% excluding natural disaster occurring prior to college). Prevalence of IPV 
(approximately 20% across freshman and sophomore year within the present sample) was similar 
to rates identified within the extant the literature concerning exposure among college students 
(Coker, Follingstad, Bush, & Fisher, 2016).  The high prevalence of trauma, particularly IPV, 
among college students highlights the need for continued investigation of correlates and efforts 
aimed at prevention and intervention post exposure.   
The probable-PTSD prevalence identified within the preset study, as assessed by a single item 
screener within the present study (39.1% collapsed across all time points), was higher than that 
identified within the literature for PTSD diagnosis (13.6% of those reporting symptoms based upon 
their self-reported “worst event”; Breslau et al., 2004). Moreover, the screener item used within 
the present study merged all of the Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD; 
Prins & Ouimette, 2004) items into a single item, thus likely contributing to the inflated rates 
identified within the present study vs. those identified when utilizing the four item screener of 
probable-PTSD (26.4%; Prins et al., 2016).   The Life Experiences and Alcohol Use S4S spin-off 
study (P50AA022537 PI Amstadter, F31AA025820 PI Hawn) utilized the full Posttraumatic Stress 
Disorder Checklist (Weathers et al., 2013), which mirrors PTSD symptoms specified by the DSM-
5 (APA, 2013), and derived a probable PTSD prevalence of 15.8%.  Thus, there are significant 
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concerns associated with specificity of the screener item utilized in the present study in that it may 
capture a large proportion of false positives. However, sensitivity to sub clinical distress may 
remain useful in identifying those at heightened risk of substance misuse. Future research 
endeavors would benefit from a more refined approach in assessing post traumatic symptoms.  
Longitudinal Analyses of TE/probable-PTSD and NMUPD (experimental and repeated 
use).  Given the cross-sectional associations identified within the literature between NMUPD and 
TE/probable-PTSD (Walsh et al., 2014; Ham et al., 2016), we aimed to further clarify the 
directionality of these relationships by conducting longitudinal comparisons to test multiple 
models of comorbidity.  Specifically, we compared a saturated model which included all potential 
paths (sex and cohort included as covariates) to two Longitudinal Effects models (i.e., self-
medication model and high risk model).  Broadly, and contrary to our hypothesis that the self-
medication model (TE/probable-PTSD precedes NMUPD [-E, -R]) would best fit the data, the 
longitudinal models consistently yielded results that supported the high risk hypothesis, which 
posits that substance use may place an individual at risk for experiencing distress (perhaps via 
heightened risk of being exposed to trauma; Cottler et al., 1992).  Evidence of the high risk model 
has been identified within the literature broader substance use and TE/PTSD literature (Cottler et 
al., 1992; Kilpatrick, Acierno, Resnick, Saunders, & Best, 1997; Haller & Chassin, 2014).  
However, results from some of the aforementioned studies (Kilpatrick et al., 1997; Haller & 
Chassin, 2014) additionally provide support for the self-medication model which posits that 
individuals use substances as a method of coping with negative affect (negative reinforcement 
model; Keane & Kaloupek, 1997).  Thus, the casual pathways between TE/PTSD and substance 
use may be multifactorial and warrant further study. 
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Although the self-medication model is intuitively appealing (substances provide an escape 
from distress and delayed consequences may be discounted in an effort to achieve immediate relief, 
resulting in a cycle of sustained use), it is likely problematic to subsume all forms of substance use 
post exposure under this umbrella (Khantzian, 1997; Lembke, 2012).  Moreover, although the self-
medication framework is frequently considered the prevailing means of conceptualizing 
comorbidity, the preponderance of evidence is inconsistent and does not fully support this 
hypothesis.  This literature is wrought with methodological limitations, including few longitudinal 
designs, analyses conducted under the assumption of self-medication (e.g., substance use set as an 
outcome in mediator/moderator analyses [Tomaka, Morales-Monks, & Shamaley, 2017;  Ullman, 
Relyea, Peter-Hagene, and Vasquez, 2013), and lack of consideration of confounding factors (e.g., 
comorbid disorders, trauma type, sociodemographic variables).  Similar concerns exist across 
various forms of substance use and highlight continued uncertainty with regard to causal 
directionality with support existing for multiple pathways (Kessler, 2004; Kassel, Stroud, & 
Paronis, 2003; Goldenberg et al., 1995).  Thus, rather than relying on the self-medication 
hypothesis, consideration of multiple etiological pathways is necessary to further clarify our 
understanding of putative causal associations between TE/PTSD and substance use broadly. 
To our knowledge, the present study represents the first study to examine this association 
specifically with regard to NMUPD and support was not present for the self-medication 
hypothesis.  It may be that this causal phenotypic pathway may be associated with the form of 
substance use examined (e.g., alcohol; Leeis et al., 2010).  However, given the findings of the 
present study, greater consideration of the high risk model of comorbidity is warranted.  Rather 
than framing substance use and TE/PTSD comorbidity within the context of the self-medication 
hypothesis, the field would benefit from further conceptualization and longitudinal testing of this 
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assumption.  It is important to note that the follow-up analyses examining longitudinal associations 
between NMUPD-R and IPV provided some support for the self-medication model (significantly 
different from the saturated model), however, the fit was superior for the high risk model.  Taken 
together, the findings highlight the relevance of the high risk model while indicating that 
consideration of the self-medication model remains necessary. 
Consistently strong and significant autoregressive estimates were identified within each model.  
These results suggest that NMUPD (-E, -R) prior to college is a significant predictor of NMUPD 
(-E, -R) in the future.  This has been demonstrated within the broader substance misuse literature 
(Jordan & Andersen, 2017; Schulenberg et al., 2017) and indicates that assessment of prior use 
may serve as a method of identifying those at heightened risk of use in the future.  Moreover, the 
strong path estimates linking prior TE to future TE (a pattern which was also present when 
examining IPV and probable-PTSD) supports the extensive revictimization literature (Messman-
Moore & Long, 2000; Classen, Palesh, & Aggarwal, 2005).  Given the heightened likelihood of 
revictimization post exposure, the importance for assessing trauma history is underscored.   
Demographic factors were also relevant to risk of TE, probable-PTSD, and both forms of 
NMUPD.  Associations between cohort and each phenotype were inconsistent across models; 
however, sex was consistently associated with all three phenotypes.  Specifically, female sex was 
positively associated with probable-PTSD while male sex was associated with greater risk of 
NMUPD.  Differential findings based on sex regarding probable-PTSD are consistent with the 
extant literature (Breslau, 2002).  The present findings are consistent with some studies regarding 
the associations between male sex and NMUPD (McCabe et al., 2014); however, the literature on 
this topic is mixed (Simoni-Wastilla et al., 2004).  Additional examination of demographic factors 
in the association between TE/probable-PTSD and NMUPD are warranted, particularly given that 
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consideration of sex in addition to other potential risk factors may serve as a useful means of 
identifying vulnerable populations.  
Longitudinal Analyses of IPV/natural disaster and NMUPD (-E, -R).  Despite the ability 
to examine the relationship between TE/probable-PTSD and NMUPD longitudinally, the 
assessment of these phenotypes was relatively limited in the present study. Thus, efforts were made 
to refine analyses by restricting the trauma exposure phenotype to IPV.  The same pattern of 
findings was identified as the prior models reviewed.  However, the effect sizes within the 
autoregressive components of the models were stronger (IPV pre college to IPV in freshman year 
and sophomore year) which is consistent with the literature regarding revictimization (Walker et 
al., 2019; Breitenbecher, 2001).  Additionally, the NMUPD-R and IPV model revealed some 
support for the self-medication model (significantly different from the saturated model); however, 
similar to the previously described modeling results, the fit was superior for the high risk model.  
However, these findings indicate that multiple pathways likely play a role in the comorbidity 
between NMUPD and IPV and consideration of the various individual factors that may contribute 
to each specific pathway is necessary. 
Another potential limitation addressed includes the assessment of TE which may be somewhat 
inflated due to higher than usual report of natural disaster associated with a low grade earthquake 
experienced within the area in 2011. Although this event was likely not considered traumatic by 
most, report of this event inflated TE rates overall which may have obscured the relationship 
between TE/probable-PTSD and NMUPD (-E, -R).  Given that natural disasters may be considered 
more random in nature than other forms of traumatic events, it may be expected that if the 
longitudinal examination were restricted to the association between natural disaster and NMUPD 
we would either be unable to identify clear support for any specific model or greater support for 
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the self-medication model.  When these additional analyses were conducted for NMUPD-E, the 
pattern of findings was not consistent with previous models such that all paths between NMUPD-
E and natural disaster.  Although this may serve as a form of general model validation, it is critical 
to note that prior research suggests that exposure to trauma is not entirely random and that certain 
factors (e.g., personality) may increase risk of trauma exposure with underlying genetic factors 
influencing environment selection (Jang et al., 2003).  Moreover, consistent with this literature, 
the model examining the longitudinal association between NMUPD-R (the more refined NMUPD 
phenotype) and natural disaster provided further support for the high risk model. 
Phenotypic Analyses Limitations.  Given the focus on college students, there are numerous 
concerns regarding generalizability; however, the sample is generalizable to the home institution 
(VCU) as a whole (Dick et al., 2014).  It is also critical to note that the analyses within the present 
study focused on specific and narrow windows of time.  Albeit longitudinal, the timeframe is 
truncated and thus introduces limitations in generalizing across longer durations of time.  
Additional examination throughout college and into adulthood is warranted.  Moreover, the 
associations identified within the present study may be less applicable to older individuals. For 
example, young adults may be more impulsive and willing to engage in in riskier activities (Romer, 
2010; Rolison, Hanoch, Wood, & Liu, 2013) than those in later developmental periods while self-
medication may be more relevant at later developmental periods.  It is also important to note 
attrition as a limitation, a common issue present in longitudinal research (Barry et al., 2005; Miller 
& Wright, 1995). Future research would also benefit from focusing on specific classes of 
prescription medications as this may be a key factor in determining the relevant model of 
comorbidity.  For example, stimulant misuse may be more relevant to the high risk model whereas 
the self-medication model may better capture the association between opioid misuse and 
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TE/probable-PTSD.  More broadly, considering other forms of substance use (e.g., alcohol use) is 
necessary as continued efforts are made to determine the relationships between TE/PTSD and 
substance use phenotypes.  For example, polysubstance use may be driving associations between 
these variables, therefore additional research is necessary to control for other forms of substance 
use or parse out unique effects related to substance type. Finally, more thorough phenotypic 
assessment overall would aid in further understanding of the relationship between NMUPD and 
TE/probable-PTSD.  Single items aimed at adequately assessing these complex phenotypes 
(NMUPD and PTSD) possess a significant concern and additional effort placed on capturing 
consequences of misuse (along the substance use disorder continuum) and probable-PTSD 
symptoms via multiple items would greatly improve future analyses of these phenotypes.  
Phenotypic summary and clinical implications.  Overall, the phenotypic analyses further 
support literature suggesting that NMUPD, TE, and trauma related symptoms are concerns 
relevant to college aged students (McCabe, West, & Wechsler, 2007; Breslau et al., 1998; Read, 
Ouimette, White, Colder & Farrow, 2011).  Given the high prevalence of these phenotypes, 
consistent screening of substance use, specifically NMUPD, and trauma history may aid in 
identification of individuals at particularly heightened risk of substance use difficulties and 
revictimization. Students may be less inclined to report this form of substance use given 
definitional uncertainty (Boyd & McCabe, 2008).  Moreover, students with a trauma history may 
avoid or delay disclosing their experience particularly if it is interpersonal in nature (Smith et al., 
2000).  Thus, direct assessment may prove beneficial in providing early intervention to individuals 
that would otherwise not receive it.  Results from the longitudinal models support the high risk 
hypothesis (although some limited support for the self-medication model was also identified) and 
these findings have important clinical implications for prevention and intervention efforts.  Given 
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the associations noted, inclusion of assessment and psychoeducation regarding TE and PTSD when 
an individual presents with a history of NMUPD may aid in the identification of at risk individuals 
and serve as a form of risk reduction.  Consideration of demographic factors, particularly sex, may 
also prove beneficial in identifying those at heightened risk, in light of the sex differences 
identified within the present study (i.e., females at heightened risk of probable-PTSD; males 
associated with NMUPD).   
Although the present study provides support for the high risk hypothesis, the associations 
between NMUPD (in addition to substance use more broadly) and TE/PTSD are likely 
multifactorial in nature and more emphasis should be placed on understanding the factors that may 
contribute to these differential pathways (e.g., personality factors, emotion regulation). NMUPD 
and TE/PTSD do not occur within a vacuum, thus conceptual and analytical inclusion of other 
variables potentially implicated in the development, maintenance, and interrelations between each 
is critical in better understanding the complex relationship between NMUPD and TE/PTSD.  As 
statistical approaches become more sophisticated, the field is increasingly more equipped to 
address these complex empirical questions.  One potential method of elucidating the association 
between NMUPD and TE/PTSD includes incorporating propensity score matching methodologies 
(Rosenbaum & Rubin, 1983), which would control for a multitude of covariates (e.g., personality, 
peer deviance), providing a more refined examination of the association between these phenotypes.  
Moreover, given that many studies have conducted analyses under the assumption of the self-
medication model, it may prove beneficial to re-analyzed this existing data to compare other 
potential models of comorbidity.  Support may exist for the high risk model within these datasets; 
however, such associations may have been overlooked due to the emphasis on the self-medication 
model. 
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A multitude of treatment options exist aimed at ameliorating symptoms of substance use (e.g., 
motivational interviewing), distress post trauma exposure (e.g., prolonged exposure) and 
comorbidity between the two (Seeking Safety, Najavitz, 2002; Concurrent Treatment of PTSD and 
SUDs using Prolonged Exposure [COPE], Back et al., 2014).  Greater emphasis over time has 
been placed on prevention, particularly with regard to interpersonal violence.  Initiatives include 
bystander intervention and mandatory education regarding sexual assault (Cares et al., 2014; Zapp, 
Buelow, Soutiea, Berkowitz, & Dejong, 2018).  Prevention efforts have also been aimed at 
reducing substance use among adolescents via parent and teacher interventions (Webster-Stratton 
& Taylor, 2001; Kuntsche & Kuntsche, 2016).  Given the temporal associations noted within the 
present study, increased focus on substance use prevention may aid in reduction of TE and 
associated sequelae. 
Genotypic Discussion 
 
 Another important consideration in the etiology of these phenotypes includes a third factor 
that may serve as a potential pathway contributing to the co-occurrence of substance use and 
TE/PTSD.  For example, Breslau and colleagues (2003) did not find evidence to support the self-
medication hypothesis but suggested that a third factor may be contributing to the comorbidity 
between PTSD and substance use. One such factor could include genetic influences, thus, the 
present study aimed to determine if NMUPD (-E, -R), TE, and probable-PTSD were heritable via 
GCTA methodologies and to identify specific variants that may be associated with each of these 
phenotypes of interest. 
SNP-based heritability of NMUPD (-E, -R) and TE/probable-PTSD.  Univariate GCTAs 
were conducted for each phenotype (NMUPD-E, NMUPD-R, TE, probable-PTSD) within each 
ancestral group (AFR, AMR, EAS, EUR, and SAS) and then meta-analyzed.  GCTA is a SNP 
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based method of estimating the heritability of a particular trait among unrelated individuals.  This 
is accomplished by assigning a code of 0 or 1 based on case status (control or case, respectively) 
and creating a genetic relatedness matrix whereby correlations are computed among individuals 
and then regressed onto the phenotype of interest (Yang et al., 2011).  Similar to other genetic 
methods, GCTA has limitations with regard to not accounting for rare variants and being sample 
dependent.  Moreover, the use of GCTA to examine binary traits (case/control status) is also a 
limitation given that this method is better suited for phenotypes more quantitative in nature (Yang 
et al., 2011).  Use of GCTA for binary traits violates multiple assumptions under the restricted 
maximum likelihood method including (a) that the distribution underlying the trait is normally 
distributed and (b) that genetic and environmental influences are not correlated.  The traits 
examined in the present study are not normally distributed and are correlated; therefore, the 
estimates derived from GCTA are likely biased.  Thus, although the benefit of GCTA lies within 
the ability to apply the analyses to non-related individuals (which proves beneficial in obtaining 
adequate sample sizes), limitations remain and may remain even when all assumptions have been 
met per analyses conducted by Kumar and colleagues (2016).  These aforementioned limitations 
may contribute to the gap between estimates derived from GCTAs and twin studies.  The estimates 
identified within the twin literature are typically higher than those identified via GCTA (for 
example, 42-58% heritability when utilizing twin methodologies for multiple forms of substance 
use vs. 10-30% when GCTA is employed; Vrieze, McGue, Miller, Hicks, & Iacono, 2013).  This 
has been a topic of ongoing debate within the field and is likely due to some of the limitations 
described above and that GCTA only takes into account additive effects, thus excluding effects 
associated with dominance, epistasis (genetic interactions), and gene by environment interactions 
(Wray et al., 2013). 
 112 
Within the present study, meta-analyses revealed significant SNP-based heritability (h2SNP) 
estimates for NMUPD-E (h2SNP = .15, SE = .01), NMUPD-R (h
2
SNP = .22, SE = .01), and IPV (h
2
SNP 
= .05, SE = .01).  Moreover, h2SNP estimate identified for NMUPD-E was significantly lower than 
that derived for NMUPD-R.  However, these estimates should be considered within the context of 
limited power as demonstrated by the power calculations.  SNP based heritability estimates could 
not be derived for the probable-PTSD phenotype, likely due to limited power.  Limited power is a 
common concern within the field of genetics.  Thus, consortia based approaches are on the rise 
which include much larger sample sizes (>20,000 participants), greatly improving the ability to 
determine the heritability of substance use phenotypes (e.g., alcohol use; Walters et al., 2018) and 
trauma related phenotypes (e.g., PTSD; Nievergelt et al., 2018). 
GCTAs of substance use more broadly consistently fall within the 25%-36% range (Palmer et 
al., 2015).  Moreover, Vrieze and colleagues (2013) identified h2SNP estimates within 
approximately the 10-30% range depending on substance use phenotype (21% for alcohol 
dependence, 36% nicotine use, and 45% for illicit drug dependence).  The SNP based heritability 
estimates for NMUPD in the present study fell close the ranges identified within the literature, 
particularly as the phenotype became more refined (lifetime use [NMUPD-E] vs. repeated use 
[NMUPD-R]). This benefit in refined phenotype can be seen in other GCTAs of substance use 
such as cannabis initiation age (Minica et al., 2015) which identified a significant SNP-based 
heritability estimate of 25%.  Use of more refined assessment methods (e.g., DSM criteria, 
problematic use) will likely provide a more nuanced picture of heritability as it relates to this 
specific form of substance use. To our knowledge, no h2SNP estimates have been identified for 
NMUPD and future research endeavors would benefit from examination in very large samples, in 
addition to investigation of the potential overlap between NMUPD and other substances and 
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possible overlap between TE/probable-PTSD and NMUPD (bi-variate GCTAs).  Bi-variate GCTA 
provides an opportunity to not only examine the genetic variance within a specific trait but also 
the co-variance between two traits, thereby serving as an index of shared common genetic variance 
(Lee, Yang, Goddard, Visscher, & Wray, 2012).  Moreover, additional statistical approaches (e.g., 
Cholesky decomposition) could aid in determining whether a latent common factor (e.g., genetic 
influences) accounts for the covariance shared between phenotypes (Neale & Cardon, 1992).  
Previous GCTAs of interpersonal trauma and PTSD have identified moderate h2SNP estimates 
(Duncan et al., 2017; Palmer et al., 2016).  Moreover, the recent PGC – PTSD Freeze 2 identified 
h2SNP estimates ranging between 10-30% across ancestries; however, significant SNP-based 
heritability estimates were only identified for females (female h2SNP = .10, p = 8.03 x 10
-11, male 
h2SNP = .01, p = .63 [Nievergelt et al., 2018]).  Similar to the substance use literature, there is a 
discrepancy between estimates identified when utilizing GCTA versus twin modeling 
methodologies (with twin studies identifying estimates falling between 23.5% [True et al., 1993] 
and 71% [Sartor et al., 2011] relative to the aforementioned ranges identified via GCTAs).   
Overall, although significant h2SNP estimates should be interpreted cautiously (due to concerns 
regarding power and limitations inherent to GCTAs of case/controls), GWAS remained a 
worthwhile venture given the multiple reasons as to why GWAS may identify significant SNPs in 
the absence of significant h2SNP estimates derived by GCTA.  Aggregate methods, such as GCTA, 
do not identify the independent contribution of specific SNPs.  Moreover, given the concern of 
missing heritability identified within the literature (i.e., twin and GCTA), specific variants may be 
captured within GWAS not otherwise subsumed within GCTA estimates (e.g., variants with non-
additive effects, Kumar, Feldman, Rehkopf, & Tuljapurkar, 2016). 
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Identifying specific risk variants.  A series of GWAS were conducted to identify specific 
variants associated with heighten risk of NMUPD-E, IPV, and probable-PTSD. These phenotypes 
were selected for GWAS given the greater balance between cases and controls and greater power 
to detect an effect relative to NMUPD-R and TE phenotypes which were both underpowered and 
lacked case/control balance.  
 Genetic Variants associated with NMUPD-E.  Five genomic bins having at least one SNP 
possessing a p-value < 5x10-8 and passing FDR correction for NMUPD-E (rs142738451 [minor 
allele ‘t’], rs73241778 [minor allele ‘t’], rs9578774 [minor allele ‘a’], rs74901044 [minor allele 
‘a’], and rs138647543 [minor allele ‘a’]) were identified.  The direction of effect was similar across 
SNPs, with the presence of the minor allele (less frequently occurring allele for a particular SNP) 
being negatively associated with NMUPD-E case status, with the exception of rs73241778 which 
was positively associated with NMUPD-E case status.  Most significant SNPs identified were lone 
markers or in weak LD with other SNPs in the region which suggests that the finding is likely 
spurious in nature.  The regional association plots show that there are a few SNPs near 
rs138647543 that reach significance and are in strong LD with each other, which is suggestive of 
other potential SNPs that may be associated with the NMUPD-E phenotype.  
The present study represents the first GWAS of NMUPD.  Significant SNPs on the PAK7 (a 
protein coding gene [SNP rs73241778]) and LINC00922 (a noncoding RNA gene [SNP 
rs138647543]) genes emerged following GWAS of NMUPD-E.  The regional association plot for 
rs73241778 revealed that it is a lone SNP, in weak LD with surrounding markers.  However, 
rs138647543 was in high LD with surrounding markers per the regional association plot, 
suggesting that multiple SNPs within the region may be linked with NMUPD-E or that the 
identified SNP is not the casual variant but may be in high LD with the true casual variant. Of 
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these identified SNPs, rs73241778 (minor allele ‘t’) was a common variant (MAF = .10) positively 
associated with NMUPD-E case status, while rs138647543 (minor allele ‘t’) was a rare variant 
(MAF > .05) negatively associated with case status. 
Although the PAK7 gene has been linked with physical concerns including cancer (pancreatic 
cancer [Giroux, Iovanna, Garcia, & Dagorn, 2009], melanoma [LaPak et al., 2016], breast cancer 
[Li et al., 2018]), the literature with regard to mental health is limited.  However, Morris and 
colleagues (2014) identified an association between a PAK7 duplication and psychosis (bipolar 
disorder and schizophrenia) in an Irish discovery sample and replicated in the International 
Schizophrenia Consortium (ISC, 2008).  The LINC00922 gene has also been implicated in cancer 
risk (Drak Alsibai & Meseure, 2018); however, to our knowledge, an association between the gene 
and any metal health phenotype has not been identified within the literature.  Given the limited 
literature, both replication and additional GWAS of the NMUPD phenotype are necessary to 
further explicate specific variants associated with case status. 
The present study did not find genome wide significant SNPs in genes that have been 
previously identified in the literature.  Although a paucity of genetic association studies exists with 
regard to NMUPD, multiple GWAS have been conducted for other substance use phenotypes 
including illicit substance use which frequently includes NMUPD (multiple forms of illicit 
substance use, including NMUPD, aggregated into a single binary or symptom count variable).  
Additionally, multiple GWAS have focused on opioid use phenotypes (e.g., dependence, symptom 
count) and have identified several genome-wide markers present within the following genes: 
NCK2 [Liu et al., 2013], KCNG2, KCNC1, APBB2, PARVA [Gelertner et al., 2014], and CNIH3 
[Nelson et al., 2016].  Genome wide significant SNPs have also been identified within the FAM53B 
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for cocaine dependence (Gelernter et al., 2014) and Uhl and colleagues (2008) identified SNPs in 
genes CDH13 and CSMD1 that almost reached genome-wide significance.  
Genetic Variants associated with probable-PTSD and IPV.  GWAS were also conducted 
for probable-PTSD and IPV; however, no genome wide significant markers emerged.  Although 
no SNPs reached genome wide significance, strong signals were identified for each phenotype 
meeting a less conservative threshold of p < 5x10-5 and are considered suggestive SNPs of interest.  
As discussed in the results, KCNIP4 (SNP rs100243550 [minor allele ‘a’]) emerged as a gene 
associated with probable-PTSD and has been associated with personality disorders and ADHD.   
SNRPC and UHRF1BP1 (SNP rs2764203 [minor allele ‘a’]) protein coding genes were associated 
with IPV case status.  SNRPC has been linked with certain forms of cancer (myeloma; 
Shaughnessy et al., 2011) while UHRF1BP1 has been associated with systemic lupus 
erythematosus (Gateva et al., 2013). The SNP with the lowest p-value for probable-PTSD was 
negatively associated with the phenotype and is considered common variant.  The SNP with 
the lowest p-value for IPV was positively associated with the phenotype and is also 
considered a common variant. 
Although more extensive than the NMUPD molecular literature, only twelve GWAS to 
date have focused on PTSD; however, multiple genes with genome wide significant SNPs have 
been identified.  These genes include RORA (Logue et al., 2013), lincRNA AC068718.1 (Guffanti 
et al., 2013), ANKRD55, ZNF626 (Stein et al., 2016), PRTFDC1 (Nievergelt et al., 2015), IL2RA 
(Powers et al., 2016), NLGN1 (Kilaru et al., 2016), and KLHL1 (Duncan et al., 2018).  Novel loci 
have also been identified on chromosome 7p12 (Xie et al., 2013) and 4p15 (Almli et al., 2015).  
Additionally, a nominally significant finding was identified by Xie and collogues (2013) in the 
Tolloid-Like 1 gene.  However, two studies (Wolf et al., 2014; Ashley-Koch et al., 2015) were 
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unable to find genome-wide significant SNPs (likely due to low sample size).  Results from Freezes 
1 and 2 of the PGC – PTSD have also identified potential variants of interest.  Duncan and 
colleagues (2011) identified a variant in the KLHL1 gene among the African ancestral group during 
Freeze 1; however, cautioned that the finding may be spurious due to the decreased significance 
when meta-analyzed.  Upon examination of Freeze 2 data, which included approximately ten-fold 
the number of participants than Freeze 1), multiple genes were identified including ZDHHC14, 
PARK2, KAZN, TMRM51-AS1, SH3RF3, PODXL, and ZNF813 within the European ancestral 
group and LINC02335, MIR5007, TUC338, LINC02571, and HLA-B within the African ancestral 
group (Nievergelt et al., 2018).  The present study identified several genes with suggestive p-values 
that may be associated with probable-PTSD and IPV. 
Despite identifying strong signals above the p < 5x10-5 threshold, these effects did not reach 
genome-wide significance (p < 5x10-8).  The lack a genome-wide significant results could be 
attributable to lack of true effect, in addition to several other factors associated with power and 
phenotypic assessment.  For GWAS, multiple factors effect power including sample size, effect 
size, and minor allele frequency. With small sample sizes, it becomes more difficult to identify 
less common variants and/or variants with smaller effects.  Thus, obtaining large samples improves 
the ability to detect affects.  Aspects of the phenotype are also relevant to power, as those with 
relatively lower heritability estimates will need larger sample sizes to detect effects (Visscher et 
al., 2017).  Only probable-PTSD and IPV phenotypes were adequately powered to identify an 
effect and the NMUPD-E phenotype was underpowered but better powered relative to the 
phenotypes of NMUPD-R and TE.  Both NMUPD-R and TE lacked balance as far as proportion 
of cases and controls were concerned, thus, no attempt to complete a GWAS was made given the 
heightened likelihood of questionable results.  Given these concerns, additional examination in a 
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large balanced dataset (cases/controls) would be beneficial.  
Genotypic analyses limitations.  The present study represents a novel contribution to the 
field with regard to genetic influences on NMUPD and associated phenotypes.  However, it is not 
without many notable limitations that will be discussed in turn.   
 Phenotypic assessment. There are multiple concerns associated with the assessment of 
each of the phenotypes which impact the analyses/results.  NMUPD-E provides a broad assessment 
of the phenotype; however, the degree to which any use represents a form of problematic use 
remains uncertain and likely lacks the nuance necessary to identify specific environmental 
correlates and genetic factors that may be contributing to use.  NMUPD-R may serve as a proxy 
for more problematic use; however, additional examination is necessary to determine whether it 
provides a sufficiently refined phenotype.  Probable-PTSD also suffers from the same assessment 
concerns.  The four items of the PC-PTSD were merged into a single item thereby reducing 
specificity in identifying those with potential PTSD at a diagnostic level (probable-PTSD in 
present sample was 39.1% vs. data using a national sample of U.S. adults suggesting a lifetime 
prevalence of 8.3% based on DSM 5 criteria; Kilpatrick et al., 2013).  Thus, this item likely serves 
as a crude screener of a heterogeneous disorder.  Finally, TE was assessed in a much more thorough 
manner with five separate trauma types being queried (natural disaster, physical assault, sexual 
assault, any other unwanted and/or uncomfortable sexual experience, and motor vehicle accident).  
Although assessment of these phenotype was an improvement relative to the other phenotypes, the 
binning of each separate form of trauma into a single dichotomous TE variable introduced 
significant heterogeneity.  However, by implementing a more refined IPV variable, a more 
homogeneous group was created.  Yet, it is certainly worth noting that a significant degree of event 
variability remains even within the IPV variable.  Given these assessment concerns, a more 
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thorough approach to phenotypic assessment should be applied.  Large-scale genetic studies are 
frequently confronted with finding the balance between adequate assessment and feasibility.  
Given that researchers are often interested in assessing thousands of participants (to increase power 
to detect effects), reducing both researcher and participant burden by simplifying assessment 
makes this task more manageable.  However, multiple approaches are being taken to tackle this 
issue including “deep” phenotyping (more nuanced phenotypic assessment) and the rise of 
consortia which provide the opportunity to merge data across multiple datasets for genetic analyses 
and address concerns regarding heterogeneous sample populations (by increasing power). 
 Power.  Many of the genetic analyses in the present study were underpowered.  This is a 
large issue within the field of behavioral genetics and as studies become better powered (via the 
aforementioned consortia) the ability to detect the small effects across an array of different SNPs 
associated with mental health phenotypes will continue to improve.  Given that the field works 
under the hypothesis of polygenetic risk (Vissher et al., 2017), many common variants likely have 
small effects and thousands (upon thousands) of participants will be needed to detect such small 
effects.  The use of larger samples improves the ability to identify variants with smaller effect sized 
and also increases the ability to detect less common variants.  For example, with each successive 
inclusion of large numbers of participants in the Schizophrenia Working Group of the Psychiatric 
Genomics Consortia, the ability to detect small effect among many genes increases (Ripke et al., 
2014).  As presented within the GWAS power calculations of the present study, the ability to detect 
variants with lower MAFs and genotype relative risks was limited (for example, MAF > .25%, 
genotype relative risk > 1.20, for NMUPD-E).  
 Method.   Limitations regarding method employed encompass multiple concerns.  First, 
the use of binary variables creates limitations both statistically and conceptually.  Use of 
 120 
quantitative variables aid in the performance of models and provide a more nuanced view of the 
phenotype (diagnoses are indeed dichotomous yet concerns exist regarding the view of mental 
health in binary terms, please see Timimi, 2014 for additional details).  Moreover, the field of 
behavioral genetics is rapidly changing and the use of methods such as polygenic risk scores (PRS; 
aggregates the effects across risk alleles into a single risk score) may better capture the effects of 
many variants when under the constraints of limited power.  PRS has been successfully used to 
examine associations between PTSD and other mental health conditions (e.g., major depressive 
disorder; Duncan et al., 2018) and the relationships between substance use related phenotypes 
including alcohol use (Taylor et al., 2016; Mies et al., 2018) and cannabis initiation (Vink et al., 
2014).  However, it is important to note that these emerging techniques also present challenges 
similar to those described for GCTA regarding assumptions of normal distribution and 
independence of markers (Dudbridge, 2013; Lewis & Vassos, 2017). 
Genotypic summary and clinical implications.  In an effort to examine the genetic 
liability contributing to the etiology of comorbid NMUPD and TE/probable-PTSD, genetic 
methods (GCTAs and GWAS) were utilized to determine the h2SNP of these phenotypes and 
putative variants associated with case status. Meta-analyses revealed significant SNP-based 
heritability (h2SNP) estimates for NMUPD-E and IPV.   Although significant molecular heritability 
estimates were not identified for probable-PTSD, GWAS were conducted for NMUPD-E, 
probable-PTSD, and IPV.  Given power concerns and imbalance with regard to cases and controls, 
GWAS were not conducted for the NMUPD-R and TE phenotypes; however, GWAS were 
performed for the phenotypes of NMUPD-E, probable-PTSD, and IPV.  Following the GWAS of 
NMUPD-E, five genomic bins with SNPs reaching genome wide significance and passing FDR 
correction (method of controlling for Type 1 errors while maximizing power compared to standard 
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Bonferroni type corrections; Benjamini & Hochberg, 1995) threshold of .05 were identified.  
Genes associated with genome wide significant SNPs for NMUPD-E included PAK7 and 
LINC00922.  Suggestive SNPs within the KCNIP4 gene for probable-PTSD and SNRPC and 
UHRF1BP1 genes (other surrounding genes included C6orf106, 1BP, ANKS1A, and TAF1) for 
IPV were identified; however, these SNPs did not reach genome wide significance.  Despite 
finding genome wide significant or suggestive hits, the SNPs/genes did not overlap across 
phenotypes.  Additional investigation is needed to better understand the potential unique and 
overlapping influence of genes on NMUPD, probable-PTSD, and IPV. 
 These findings may have important clinical implications as the field continues to strive 
towards personalized medicine.  The aim of personalized medicine is to take into consideration the 
various factors (environmental and genetic) that may account for individual differences in physical 
and mental health (Ginsberg & Willard, 2009).  In doing so, more targeted therapeutic 
interventions may be undertaken, ranging from identification of individuals at heightened risk to 
determining the most appropriate psychopharmacological method of treatment.  Although 
personalized medicine would be ideal, there is a significant amount of work that needs to be 
completed prior to this aspiration becoming a reality within the realm of mental health.  Although 
personalized medicine with regard to genetics has seen success, particularly single gene, single 
disorder phenotypes (e.g., Huntington disease), it is far more difficult to take this approach with 
mental health phenotypes due to their polygenetic and multifactorial etiology (Chatterjee, Shi, & 
Garcia-Closas).  However, recent research has made significant strides in determining the 
predictive utility of genetic information (particularly via polygenic risk scores [PRS]) in the 
identification of vulnerable populations (Khera et al., 2018).  The focus of the aforementioned 
work involved medical concerns (e.g., diabetes, cardiovascular disease) yet application of PRS to 
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other polygenic disorders (e.g., mental health concerns) is promising.  Particularly promising is 
that PRS could be used for targeted intervention.  Khera and colleagues (2018) noted the benefits 
of encouraging lifestyle interventions among those identified to be at-risk through PRS, given the 
previous success noted with the implementation of such intervention for common diseases 
(Knowler et al., 2002; Khera et al., 2016).  Similarly, use of PRS could be helpful in the promotion 
of certain interventions among individuals at heightened risk of developing psychiatric symptoms. 
Given the complicated nature of psychiatric phenotypes, additional genetic research, 
replication, and use of multifactorial models is warranted and consideration must be placed in how 
this information is disseminated to both clinicians and the general population.  Concerns regarding 
potential fatalistic views associated with genetic risk (i.e., if an individual possesses a specific risk 
variant, they may believe they have limited control with regard to prevention/intervention [Claasen 
et al., 2010) need to be considered in the ways in which genetic information is disseminated to 
patients in the future.  Moreover, additional psychoeducation for the public regarding the role of 
genes in mental health is needed to address misperceptions and cultivate better understanding of 
biological influences. 
Conclusions.  The present study aimed to examine the multiple etiological pathways (self-
medication, high risk, and third factor [genetic influences]) hypothesized to contribute to the 
comorbidity and/or etiology of NMUPD and TE/probable-PTSD.  Although the self-medication 
model is frequently assumed to be the model best explaining the substance use TE/PTSD 
comorbidity, the present study lends support to the extant literature suggesting that the high risk 
model plays an important role.  The present study also identified significant heritability estimates 
for NMUPD (-E, -R) and IPV although caution is warranted when attempting to interpret the 
estimates given power concerns.  Moreover, genetic variants associated with NMUPD-E and 
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suggestive variants for probable-PTSD and IPV were also identified; however, the SNPs/genes 
identified were specific to each phenotype (not overlapping).  Although the self-medication model 
and shared liability model received limited support within the present study, it is critical to note 
that each of these pathways is likely important yet partially dependent on a multitude of other 
factors including developmental period and class of NMUPD substance. Moreover, limited power 
greatly restricted the ability to adequately examine these phenotypes from a genetic perspective.   
Although additional examination is needed to better take into consideration nuances 
associated with context and reduce issues associated with power and assessment, the present study 
addresses a significant gap within the extant literature.  To our knowledge, the present study is the 
first to 1) longitudinally examine NMUPD and TE/probable-PTSD longitudinally, 2) attempt to 
determine h2SNP estimates for NMUPD, and 3) conduct GWAS for the phenotype of NMUPD.  
These novel contributions mark the next step in the growing empirical literature addressing 
etiological factors (environmental and genetic) contributing to NMUPD, trauma exposure, and 
traumatic stress. 
 
 
 
 
 
 
 
 
 
 
 124 
References 
Afifi, T. O., Asmundson, G. J., Taylor, S., & Jang, K. L. (2010). The role of genes and 
environment on trauma exposure and posttraumatic stress disorder symptoms: a review of 
twin studies. Clinical psychology review, 30(1), 101-112. 
Agrawal, A., & Lynskey, M. T. (2009). Candidate genes for cannabis use disorders: findings, 
challenges and directions. Addiction, 104(4), 518-532. 
Agrawal, A., & Lynskey, M. T. (2008). Are there genetic influences on addiction: evidence from 
family, adoption and twin studies. Addiction, 103(7), 1069-1081. 
Agrawal, A., Neale, M. C., Jacobson, K. C., Prescott, C. A., & Kendler, K. S. (2005). Illicit drug 
use and abuse/dependence: modeling of two-stage variables using the CCC 
approach. Addictive Behaviors, 30(5), 1043-1048. 
Almli, L.M., Stevens, J.S., Smith, A.K., Kilaru, V., Meng, Q., Flory, J., Abu‐Amara, D., 
Hammamieh, R., Yang, R., Mercer, K.B. & Binder, E.B. (2015). A genome‐wide identified 
risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical 
activation to fearful faces. American Journal of Medical Genetics Part B: 
Neuropsychiatric Genetics, 168(5), 327-336. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders 
(5th ed.). Washington, DC: Author. 
Amos, W., Driscoll, E., & Hoffman, J. I. (2010). Candidate genes versus genome-wide 
associations: which are better for detecting genetic susceptibility to infectious disease? 
Proceedings of the Royal Society of London B: Biological Sciences, rspb20101920. 
Arria, A. M., Caldeira, K. M., Vincent, K. B., O’Grady, K. E., & Wish, E. D. (2008). Perceived 
 125 
harmfulness predicts non-medical use of prescription drugs among college students: 
interactions with sensation-seeking. Prevention Science, 9(3), 191-201. 
Arria, A. M., & DuPont, R. L. (2010). Non-medical prescription stimulant use among college 
students: why we need to do something and what we need to do. Journal of addictive 
diseases, 29(4), 417-426. 
Arria, A. M., Caldeira, K. M., Kasperski, S. J., O’Grady, K. E., Vincent, K. B., Griffiths, R. R.,  
& Wish, E. D. (2010). Increased alcohol consumption, non-medical prescription drug use, 
and illicit drug use are associated with energy drink consumption among college 
students. Journal of addiction medicine, 4(2), 74. 
Azimi, A. M., & Daigle, L. E. (2017). Promising Avenues for Prevention: Confronting Sexual 
Victimization on College Campuses. In Preventing Crime and Violence (pp. 243-260). 
Springer International Publishing. 
Back, S., Dansky, B. S., Coffey, S. F., Saladin, M. E., Sonne, S., & Brady, K. T. (2000). Cocaine 
dependence with and without posttraumatic stress disorder: A comparison of substance 
use, trauma history and psychiatric comorbidity. The American Journal on 
Addictions, 9(1), 51-62. 
Barrett, S. P., Meisner, J. R., & Stewart, S. H. (2008). What constitutes prescription drug 
misuse? Problems and pitfalls of current conceptualizations. Current drug abuse
 reviews, 1(3), 255-262. 
Barry, A. E. (2005). How attrition impacts the internal and external validity of longitudinal 
research. Journal of School Health, 75(7), 267-271. 
Becker, W. C., Sullivan, L. E., Tetrault, J. M., Desai, R. A., & Fiellin, D. A. (2008). Non 
medical use, abuse and dependence on prescription opioids among US adults: psychiatric, 
 126 
medical and substance use correlates. Drug and alcohol dependence, 94(1), 38-47. 
Benjet, C., Bromet, E., Karam, E.G., Kessler, R.C., McLaughlin, K.A., Ruscio, A.M., Shahly, 
V., Stein, D.J., Petukhova, M., Hill, E. & Alonso, J. (2016). The epidemiology of traumatic 
event exposure worldwide: results from the World Mental Health Survey 
Consortium. Psychological medicine, 46(02), 327-343. 
Berenson, A. B., & Rahman, M. (2011). Prevalence and correlates of prescription drug misuse 
among young, low-income women receiving public healthcare. Journal of addictive 
diseases, 30(3), 203-215. 
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. 
(2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United 
States. Pain Medicine, 12(4), 657-667. 
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., et 
al. (1995). The development of a Clinician-Administered PTSD Scale. Journal of 
Traumatic Stress, 8, 75-90. 
Bohnert, A. S., Ilgen, M. A., Ignacio, R. V., McCarthy, J. F., Valenstein, M., & Blow, F. C. 
(2012). Risk of death from accidental overdose associated with psychiatric and substance 
use disorders. American Journal of Psychiatry, 169(1), 64-70. 
Bousman, C. A., Glatt, S. J., Everall, I. P., & Tsuang, M. T. (2009). Genetic association studies 
of methamphetamine use disorders: a systematic review and synthesis. American Journal 
of Medical Genetics Part B: Neuropsychiatric Genetics, 150(8), 1025-1049. 
Boyd, C. J., & McCabe, S. E. (2008). Coming to terms with the non-medical use of prescription 
medications. Substance Abuse Treatment, Prevention, and Policy, 3(1), 22. 
Breitenbecher, K. H. (2001). Sexual revictimization among women: A review of the literature 
 127 
focusing on empirical investigations. Aggression and Violent Behavior, 6(4), 415-432. 
Breslau, N., Kessler, R. C., Chilcoat, H. D., Schultz, L. R., Davis, G. C., & Andreski, P. (1998). 
Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey 
of Trauma. Archives of general psychiatry, 55(7), 626-632. 
Breslau, N. (2001). Gender differences in trauma and posttraumatic stress disorder. The journal 
of gender-specific medicine: JGSM: the official journal of the Partnership for Women's 
Health at Columbia, 5(1), 34-40. 
Breslau, N., Davis, G. C., & Andreski, P. (1995). Risk factors for PTSD-related traumatic events: 
a prospective analysis. The American journal of psychiatry, 152(4), 529. 
Bruenig, D., Lurie, J., Morris, C. P., Harvey, W., Lawford, B., Young, R. M., & Voisey, J. 
(2016). A case-control study and meta-analysis reveal BDNF Val66Met is a possible risk 
factor for PTSD. Neural Plasticity, 2016. 
Cai, R., Crane, E., Poneleit, K. & Paulozzi, L. (2010). Emergency Department Visits Involving 
Non-medical Use of Selected Prescription Drugs in the United States, 2004–2008. Journal 
of Pain and Palliative Care Pharmacotherapy, 24, 293-297. 
Cares, A. C., Banyard, V. L., Moynihan, M. M., Williams, L. M., Potter, S. J., & Stapleton, J. G. 
(2015). Changing attitudes about being a bystander to violence: Translating an in-person 
sexual violence prevention program to a new campus. Violence Against Women, 21(2), 
165-187. 
Center for Disease Control and Prevention, National Center for Health Statistics, National Vital
 Statistics System, Mortality File. (2015). Number and Age-Adjusted Rates of Drug
 Poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014.
 Atlanta, GA: Center for Disease Control and Prevention.  
 128 
Chambers, R. A., Taylor, J. R., & Potenza, M. N. (2003). Developmental neurocircuitry of 
motivation in adolescence: a critical period of addiction vulnerability. American Journal 
of Psychiatry, 160(6), 1041-1052. 
Chatterjee, N., Shi, J., & García-Closas, M. (2016). Developing and evaluating polygenic risk 
prediction models for stratified disease prevention. Nature Reviews Genetics, 17(7), 392. 
Chilcoat, H. D., & Breslau, N. (1998). Investigations of causal pathways between PTSD and 
drug use disorders. Addictive behaviors, 23(6), 827-840. 
Chilcoat, H. D., & Breslau, N. (1998). Posttraumatic stress disorder and drug disorders: testing 
causal pathways. Archives of general psychiatry, 55(10), 913-917. 
Classen, C. C., Palesh, O. G., & Aggarwal, R. (2005). Sexual revictimization: A review of the 
empirical literature. Trauma, Violence, & Abuse, 6(2), 103-129. 
Claassen, L., Henneman, L., De Vet, R., Knol, D., Marteau, T., & Timmermans, D. (2010). 
Fatalistic responses to different types of genetic risk information: exploring the role of 
self-malleability. Psychology and Health, 25(2), 183-196. 
Cochran, G., Rubinstein, J., Bacci, J. L., Ylioja, T., & Tarter, R. (2015). Screening community 
pharmacy patients for risk of prescription opioid misuse. Journal of addiction 
medicine, 9(5), 411. 
Cochran, G. T., Engel, R. J., Hruschak, V. J., & Tarter, R. E. (2016). Prescription Opioid Misuse 
Among Rural Community Pharmacy Patients Pilot Study for Screening and Implications 
for Future Practice and Research. Journal of Pharmacy Practice, 0897190016656673. 
Coker, A. L., Follingstad, D. R., Bush, H. M., & Fisher, B. S. (2016). Are interpersonal violence 
rates higher among young women in college compared with those never attending 
college?. Journal of interpersonal violence, 31(8), 1413-1429. 
 129 
Cottler, L. B., Compton, W. M., Mager, D., Spitznagel, E. L., & Janca, A. (1992). Posttraumatic 
stress disorder among substance users from the general population. American journal of 
Psychiatry, 149(5), 664-670. 
Cromer, L. D., & Smyth, J. M. (2010). Making meaning of trauma: Trauma exposure doesn’t tell 
the whole story. Journal of Contemporary Psychotherapy, 40(2), 65-72. 
Dick, D. M., & Foroud, T. (2003). Candidate genes for alcohol dependence: a review of genetic
 evidence from human studies. Alcoholism: clinical and experimental research, 27(5), 
868-879. 
Dick, D., Nasim, A., Edwards, A.C., Salvatore, J., Cho, S.B., Adkins, A., Meyers, J., Yan, J., 
Cooke, M., Clifford, J. & Goyal, N. (2014). Spit for Science: launching a longitudinal study 
of genetic and environmental influences on substance use and emotional health at a large 
US university. Frontiers in genetics, 5, 47. 
Drak Alsibai, K., & Meseure, D. (2018). Tumor microenvironment and noncoding RNAs as co 
drivers of epithelial–mesenchymal transition and cancer metastasis. Developmental 
Dynamics, 247(3), 405-431. 
Dudbridge, F. (2013). Power and predictive accuracy of polygenic risk scores. PLoS 
genetics, 9(3),e1003348. 
Duncan, L.E., Ratanatharathorn, A., Aiello, A.E., Almli, L.M., Amstadter, A.B., Ashley-Koch, 
A.E., Baker, D.G., Beckham, J.C., Bierut, L.J., Bisson, J. & Bradley, B. (2018).  Largest 
GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences 
in heritability. Molecular Psychiatry. 00, 1-8. 
Filipas, H. H., & Ullman, S. E. (2006). Child sexual abuse, coping responses, self-blame, 
 130 
posttraumatic stress disorder, and adult sexual revictimization. Journal of Interpersonal 
Violence, 21(5), 652-672. 
Ford, J. A., & Arrastia, M. C. (2008). Pill-poppers and dopers: A comparison of non-medical
 prescription drug use and illicit/street drug use among college students. Addictive 
behaviors, 33(7), 934-941. 
Ford, J. A., & Pomykacz, C. (2016). Non-medical use of prescription stimulants: A comparison 
Of college students and their same-age peers who do not attend college. Journal of 
psychoactive drugs, 48(4), 253-260. 
Fortuna, R. J., Robbins, B. W., Caiola, E., Joynt, M., & Halterman, J. S. (2010). Prescribing of 
controlled medications to adolescents and young adults in the United States. Pediatrics, 
peds-2010. 
Frazier, P., Anders, S., Perera, S., Tomich, P., Tennen, H., Park, C., & Tashiro, T. (2009). 
Traumatic events among undergraduate students: Prevalence and associated 
symptoms. Journal of Counseling Psychology, 56(3), 450. 
 Friedman, R. A. (2006). The changing face of teenage drug abuse-the trend toward prescription 
drugs. The New England journal of medicine, 354(14), 1448. 
Gelernter, J., & Kranzler, H. R. (2010). Genetics of drug dependence. Dialogues Clinical 
Neuroscience, 12(1), 77-84. 
Gelernter, J., Kranzler, H. R., Sherva, R., Koesterer, R., Almasy, L., Zhao, H., & Farrer, L. A. 
(2014). Genome-wide association study of opioid dependence: multiple associations 
mapped to calcium and potassium pathways. Biological psychiatry, 76(1), 66-74. 
Gelernter, J., Sherva, R., Koesterer, R., Almasy, L., Zhao, H., Kranzler, H. R., & Farrer, L. 
 131 
(2014). Genome-wide association study of cocaine dependence and related traits: FAM53B 
identified as a risk gene. Molecular psychiatry, 19(6), 717-723. 
Gfroerer, J. C., Greenblatt, J. C., & Wright, D. A. (1997). Substance use in the US college-age 
population: differences according to educational status and living arrangement. American 
journal of public health, 87(1), 62-65. 
Ginsburg, G. S., & Willard, H. F. (2009). Genomic and personalized medicine: foundations and 
applications. Translational research, 154(6), 277-287. 
Giroux, V., Iovanna, J. L., Garcia, S., & Dagorn, J. C. (2009). Combined inhibition of PAK7, 
MAP3K7 and CK2α kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell 
xenografts. Cancer gene therapy, 16(9), 731. 
Goldenberg, I.M., Mueller, T., Fierman, E.J., Gordon, A., Pratt, L., Cox, K., Park, T., Lavori, P., 
Goisman, R.M. & Keller, M.B. (1995). Specificity of substance use in anxiety-disordered 
subjects. Comprehensive Psychiatry, 36(5), 319-328. 
Grant, B.F., Goldstein, R.B., Saha, T.D., Chou, S.P., Jung, J., Zhang, H., Pickering, R.P., Ruan, 
W.J., Smith, S.M., Huang, B. & Hasin, D.S. (2016). The epidemiology of DSM-5 
posttraumatic stress disorder in the United States: results from the National Epidemiologic 
Survey on Alcohol and Related Conditions-III. Social psychiatry and psychiatric 
epidemiology, 51(8), 1137-1148. 
Gratten, J., Wray, N. R., Keller, M. C., & Visscher, P. M. (2014). Large-scale genomics unveils 
the genetic architecture of psychiatric disorders. Nature neuroscience, 17(6), 782-790. 
Gray, M. J., Litz, B. T., Hsu, J. L., & Lombardo, T. W. (2004). Psychometric properties of the 
life events checklist. Assessment, 11(4), 330-341. 
Guffanti, G., Galea, S., Yan, L., Roberts, A.L., Solovieff, N., Aiello, A.E., Smoller, J.W., De 
 132 
Vivo, I., Ranu, H., Uddin, M. & Wildman, D.E. (2013). Genome-wide association study 
implicates a novel RNA gene, the lincRNA AC068718. 1, as a risk factor for post-traumatic 
stress disorder in women. Psychoneuroendocrinology, 38(12), 3029-3038. 
Hall, M. T., Golder, S., Higgins, G. E., & Logan, T. K. (2016). Non-medical prescription opioid 
use among victimized women on probation and parole. Addictive behaviors, 53, 113-119. 
Haller, M., & Chassin, L. (2014). Risk pathways among traumatic stress, posttraumatic stress 
disorder symptoms, and alcohol and drug problems: A test of four hypotheses. Psychology 
of Addictive Behaviors, 28(3), 841. 
Ham, L. S., Wiersma-Mosley, J. D., Feldner, M. T., Melkonian, A. J., Milner, L. A., & Lewis, S. 
F. (2016). Posttraumatic stress symptoms and non-medical prescription drug use among 
college students with trauma exposure. Journal of dual diagnosis, 12(1), 43-54. 
Han, B., Compton, W. M., Blanco, C., Crane, E., Lee, J., & Jones, C. M. (2017). Prescription 
opioid use, misuse, and use disorders in US adults: 2015 National Survey on Drug Use and 
Health. Annals of Internal Medicine, 167(5), 293-301. 
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research 
electronic data capture (REDCap)—a metadata-driven methodology and workflow process 
for providing translational research informatics support. Journal of biomedical 
informatics, 42(2), 377-381. 
Hawkins, J. D., Catalano, R. F., & Miller, J. Y. (1992). Risk and protective factors for alcohol 
and other drug problems in adolescence and early adulthood: implications for substance 
abuse prevention. Psychological bulletin, 112(1), 64. 
Hedtke, K. A., Ruggiero, K. J., Fitzgerald, M. M., Zinzow, H. M., Saunders, B. E., Resnick, H.  
 133 
S., & Kilpatrick, D. G. (2008). A longitudinal investigation of interpersonal violence in 
relation to mental health and substance use. Journal of consulting and clinical 
psychology, 76(4), 633. 
Hien, D., Cohen, L., & Campbell, A. (2005). Is traumatic stress a vulnerability factor for women 
with substance use disorders? Clinical Psychology Review, 25(6), 813-823. 
Himelein, M. J. (1995). Risk factors for sexual victimization in dating: A longitudinal study of 
college women. Psychology of Women Quarterly, 19(1), 31-48. 
Hirschhorn, J. N., & Daly, M. J. (2005). Genome-wide association studies for common diseases 
and complex traits. Nature Reviews Genetics, 6(2), 95-108. 
Huang, B., Dawson, D. A., Stinson, F. S., Hasin, D. S., Ruan, W. J., Saha, T. D., Smith, S. M. 
Goldstein, R. B., & Grant, B. F. (2006). Prevalence, correlates, and comorbidity of 
non-medical prescription drug use and drug use disorders in the United States: Results of 
the National Epidemiology Survey on Alcohol and Drug Related Conditions. Journal of 
Clinical Psychiatry, 67, 1062-1073. 
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001). Substance use disorders in patients 
with posttraumatic stress disorder: a review of the literature. American Journal of 
Psychiatry. 
Jang, K. L. (2005). The behavioral genetics of psychopathology: A clinical guide. Routledge. 
Jeffers, A., Benotsch, E. G., & Koester, S. (2013). Misuse of prescription stimulants for weight 
loss, psychosocial variables, and eating disordered behaviors. Appetite, 65, 8-13. 
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National 
Survey Results on Drug Use, 1975–2004. Volume II: College Students and Adults Ages 
19–45. Bethesda, MD: National Institute on Drug Abuse; 2005. NIH Publication 05-5728. 
 134 
Jordan, C. J., & Andersen, S. L. (2017). Sensitive periods of substance abuse: Early risk for the 
transition to dependence. Developmental cognitive neuroscience, 25, 29-44. 
Judson, R., & Langdon, S. W. (2009). Illicit use of prescription stimulants among college 
students: prescription status, motives, theory of planned behaviour, knowledge and self-
diagnostic tendencies. Psychology, Health & Medicine, 14(1), 97-104. 
Karkowski, L. M., Prescott, C. A., & Kendler, K. S. (2000). Multivariate assessment of factors 
influencing illicit substance use in twins from female‐female pairs. American journal of 
medical genetics, 96(5), 665-670. 
Kassel, J. D., Stroud, L. R., & Paronis, C. A. (2003). Smoking, stress, and negative affect: 
correlation, causation, and context across stages of smoking. Psychological bulletin, 
129(2), 270. 
Keane, T. M., & Kaloupek, D. G. (1997). Comorbid psychiatric disorders in PTSD. Annals of the 
New York Academy of Sciences, 821(1), 24-34. 
Kendler, K. S., Aggen, S. H., Tambs, K., & Reichborn-Kjennerud, T. (2006). Illicit psychoactive 
substance use, abuse and dependence in a population-based sample of Norwegian 
twins. Psychological medicine, 36(07), 955-962. 
Kendler, K. S., Prescott, C. A., Myers, J., & Neale, M. C. (2003). The structure of genetic and 
environmental risk factors for common psychiatric and substance use disorders in men and 
women. Archives of general psychiatry, 60(9), 929-937. 
Kennedy, J. N., Bebarta, V. S., Varney, S. M., Zarzabal, L. A., & Ganem, V. J. (2015). 
Prescription stimulant misuse in a military population. Military Medicine, 180(3S), 191-
194. 
Kessler, R. C. (2004). The epidemiology of dual diagnosis. Biological psychiatry, 56(10), 730 
 135 
737. 
Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a 
reconsideration and recent applications. Harvard review of psychiatry, 4(5), 231-244. 
Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Natarajan, P., 
Lander, E.S., Lubitz, S.A., Ellinor, P.T. & Kathiresan, S. (2018).  Genome-wide polygenic 
scores for common diseases identify individuals with risk equivalent to monogenic 
mutations. Nature genetics, 50(9), 1219. 
Khera, A.V., Emdin, C.A., Drake, I., Natarajan, P., Bick, A.G., Cook, N.R., Chasman, D.I., 
Baber, U., Mehran, R., Rader, D.J. & Fuster, V. (2016).  Genetic risk, adherence to a 
healthy lifestyle, and coronary disease. New England Journal of Medicine, 375(24), 2349-
2358. 
Kilaru, V., Iyer, S.V., Almli, L.M., Stevens, J.S., Lori, A., Jovanovic, T., Ely, T.D., Bradley, B., 
Binder, E.B., Koen, N. & Stein, D.J. (2016). Genome-wide gene-based analysis suggests 
an association between Neuroligin 1 (NLGN1) and post-traumatic stress 
disorder. Translational psychiatry, 6(5), e820. 
Kilpatrick, D. G., Acierno, R., Resnick, H. S., Saunders, B. E., & Best, C. L. (1997). A 2-year 
longitudinal analysis of the relationships between violent assault and substance use in 
women. Journal of consulting and clinical psychology, 65(5), 834. 
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., 
& Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle 
intervention or metformin. The New England journal of medicine, 346(6), 393-403. 
Koenen, K.C., Harley, R., Lyons, M.J., Wolfe, J., Simpson, J.C., Goldberg, J., Eisen, S.A. & 
 136 
Tsuang, M. (2002). A twin registry study of familial and individual risk factors for trauma 
exposure and posttraumatic stress disorder. The Journal of nervous and mental 
disease, 190(4), 209-218. 
Koenen, K.C., Hitsman, B., Lyons, M.J., Niaura, R., McCaffery, J., Goldberg, J., Eisen, S.A., 
True, W. & Tsuang, M. (2005). A twin registry study of the relationship between 
posttraumatic stress disorder and nicotine dependence in men. Archives of general 
psychiatry, 62(11), 1258-1265. 
Koenen, K.C., Lyons, M.J., Goldberg, J., Simpson, J., Williams, W.M., Toomey, R., Eisen, S.A., 
True, W. & Tsuang, M.T. (2003). Co‐twin control study of relationships among combat 
exposure, combat‐related PTSD, and other mental disorders. Journal of traumatic 
stress, 16(5), 433-438. 
Korte, A., & Farlow, A. (2013). The advantages and limitations of trait analysis with GWAS: a 
review. Plant methods, 9(1), 29. 
Kumar, S. K., Feldman, M. W., Rehkopf, D. H., & Tuljapurkar, S. (2016). Limitations of GCTA 
as a solution to the missing heritability problem. Proceedings of the National Academy of 
Sciences, 113(1), E61-E70. 
Kuntsche, S., & Kuntsche, E. (2016). Parent-based interventions for preventing or reducing 
adolescent substance use—A systematic literature review. Clinical Psychology Review, 45, 
89-101. 
Lander, E. S., & Schork, N. J. (1994). Genetic dissection of complex traits. SCIENCE-NEW 
YORK THEN WASHINGTON-, 2037-2037. 
LaPak, K. M., Gross, M. A., Vroom, D. C., Lesinski, G. B., Carson, W. E., & Burd, C. E. (2016). 
Defining the role of PAK7 variants in melanoma. 
 137 
Lee, S. H., Yang, J., Goddard, M. E., Visscher, P. M., & Wray, N. R. (2012). Estimation of 
pleiotropy between complex diseases using single-nucleotide polymorphism-derived 
genomic relationships and restricted maximum likelihood. Bioinformatics, 28(19), 2540-
2542. 
Leeies, M., Pagura, J., Sareen, J., & Bolton, J. M. (2010). The use of alcohol and drugs to self 
medicate symptoms of posttraumatic stress disorder. Depression and anxiety, 27(8), 731-
736. 
Lembke, A. (2012). Time to abandon the self-medication hypothesis in patients with psychiatric 
disorders. The American Journal of Drug and Alcohol Abuse, 38(6), 524-529. 
Lewis, C. M., & Vassos, E. (2017). Prospects for using risk scores in polygenic 
medicine. Genome medicine, 9(1), 96. 
Li, L., Bao, Y., He, S., Wang, G., Guan, Y., Ma, D., Wang, P., Huang, X., Tao, S., Zhang, D. & 
Liu, Q. (2016). The association between genetic variants in the dopaminergic system and 
posttraumatic stress disorder: A meta-analysis. Medicine, 95(11). 
Li, K., Xu, X., He, Y., Tian, Y., Pan, W., Xu, L., Ma, Y., Gao, Y., Gao, J., Qi, Y. & Wei, L. 
(2018). P21-activated kinase 7(PAK7) interacts with and activates Wnt/β-catenin signaling 
pathway in breast cancer. Journal of Cancer, 9(10), 1821. 
Liebschutz, J.M., Saitz, R., Weiss, R.D., Averbuch, T., Schwartz, S., Meltzer, E.C., Claggett 
Borne, E., Cabral, H. & Samet, J.H. (2010). Clinical factors associated with prescription 
drug use disorder in urban primary care patients with chronic pain. The Journal of 
Pain, 11(11), 1047-1055. 
Liu, Z., Guo, X., Jiang, Y., & Zhang, H. (2013). NCK2 is significantly associated with opiates 
addiction in African-origin men. The Scientific World Journal, 2013. 
 138 
Logue, M.W., Baldwin, C., Guffanti, G., Melista, E., Wolf, E.J., Reardon, A.F., Uddin, M., 
Wildman, D., Galea, S., Koenen, K.C. & Miller, M.W. (2013). A genome-wide association 
study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha 
(RORA) gene as a significant risk locus. Molecular psychiatry, 18(8), 937-942. 
Lyons, M. J., Goldberg, J., Eisen, S. A., True, W., Tsuang, M. T., Meyer, J. M., & Henderson, 
W. G. (1993). Do genes influence exposure to trauma? A twin study of combat. American 
journal of medical genetics, 48(1), 22-27. 
Lynskey, M. T., Agrawal, A., Henders, A., Nelson, E. C., Madden, P. A., & Martin, N. G. 
(2012). An Australian twin study of cannabis and other illicit drug use and misuse, and 
other psychopathology. Twin Research and Human Genetics, 15(05), 631-641. 
Mackesy-Amiti, M. E., Donenberg, G. R., & Ouellet, L. J. (2015). Prescription opioid misuse 
and mental health among young injection drug users. The American journal of drug and 
alcohol abuse, 41(1), 100-106. 
Maher, B. (2008). The case of the missing heritability. Nature, 456(7218), 18. 
Maxwell, J. C. (2011). The prescription drug epidemic in the United States: a perfect storm. 
Drug and alcohol review, 30(3), 264-270. 
Mahalanobis, P. C. (1936). On the generalized distance in statistics. Proceedings of the National 
Institute of Sciences (Calcutta), 2, 49-55. 
McCabe, S. E., Hughes, T. L., Bostwick, W. B., West, B. T., & Boyd, C. J. (2009). Sexual 
orientation, substance use behaviors and substance dependence in the United 
States. Addiction, 104(8), 1333-1345. 
McCabe, S. E., West, B. T., & Wechsler, H. (2007). Trends and college‐level characteristics 
 139 
associated with the non‐medical use of prescription drugs among US college students from 
1993 to 2001. Addiction, 102(3), 455-465. 
McCabe SE, Knight JR, Teter CJ, Wechsler H. (2005).  Non-medical use of prescription 
stimulants among US college students: prevalence and correlates from a national survey. 
Addiction. 100:96–106. 
McCabe, S. E., Teter, C. J., & Boyd, C. J. (2006). Medical use, illicit use and diversion of 
prescription stimulant medication. Journal of psychoactive drugs, 38(1), 43-56. 
McCabe, S. E., West, B. T., & Wechsler, H. (2007). Trends and college‐level characteristics 
associated with the non‐medical use of prescription drugs among US college students from 
1993 to 2001. Addiction, 102(3), 455-465. 
McCabe, S. E. (2008). Misperceptions of non-medical prescription drug use: A web survey of 
college students. Addictive behaviors, 33(5), 713-724. 
McCabe, S. E., West, B. T., Teter, C. J., & Boyd, C. J. (2014). Trends in medical use, diversion, 
and non-medical use of prescription medications among college students from 2003 to 
2013: Connecting the dots. Addictive behaviors, 39(7), 1176-1182. 
McCauley, J. L., Amstadter, A. B., Danielson, C. K., Ruggiero, K. J., Kilpatrick, D. G., & 
Resnick, H. S. (2009). Mental health and rape history in relation to non-medical use of 
prescription drugs in a national sample of women. Addictive behaviors, 34(8), 641-648. 
McCauley, J.L., Danielson, C.K., Amstadter, A.B., Ruggiero, K.J., Resnick, H.S., Hanson, R.F., 
Smith, D.W., Saunders, B.E. & Kilpatrick, D.G. (2010). The role of traumatic event 
history in non‐medical use of prescription drugs among a nationally representative sample 
of US adolescents. Journal of Child Psychology and Psychiatry, 51(1), 84-93. 
McCauley, J. L., Amstadter, A. B., Macdonald, A., Danielson, C. K., Ruggiero, K. J., Resnick, 
 140 
H. S., & Kilpatrick, D. G. (2011). Non-medical use of prescription drugs in a national 
sample of college women. Addictive behaviors, 36(7), 690-695. 
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P., & 
Hirschhorn, J. N. (2008). Genome-wide association studies for complex traits: consensus, 
uncertainty and challenges. Nature reviews genetics, 9(5), 356-369. 
McGue, M., Elkins, I., & Iacono, W. G. (2000). Genetic and environmental influences on 
adolescent substance use and abuse. American journal of medical genetics, 96(5), 671-677. 
McLeod, D. S., Koenen, K. C., Meyer, J. M., Lyons, M. J., Eisen, S., True, W., & Goldberg, J. 
(2001). Genetic and environmental influences on the relationship among combat exposure, 
posttraumatic stress disorder symptoms, and alcohol use. Journal of traumatic 
stress, 14(2), 259-275. 
Merikangas, K.R., Stolar, M., Stevens, D.E., Goulet, J., Preisig, M.A., Fenton, B., Zhang, H., 
O'malley, S.S. & Rounsaville, B.J. (1998). Familial transmission of substance use 
disorders. Archives of general psychiatry, 55(11), 973-979. 
Messman-Moore, T. L., Ward, R. M., & Brown, A. L. (2009). Substance use and PTSD 
symptoms impact the likelihood of rape and revictimization in college women. Journal of 
Interpersonal Violence, 24(3), 499-521. 
Messman-Moore, T. L., & Long, P. J. (2000). Child sexual abuse and revictimization in the form 
of adult sexual abuse, adult physical abuse, and adult psychological maltreatment. Journal 
of interpersonal violence, 15(5), 489-502. 
Meisel, M. K., & Goodie, A. S. (2015). Predicting prescription drug misuse in college students' 
social networks. Addictive behaviors, 45, 110-112. 
Miller, R. B., & Wright, D. W. (1995). Detecting and correcting attrition bias in longitudinal 
 141 
family research. Journal of Marriage and the Family, 921-929. 
Minică, C.C., Dolan, C.V., Hottenga, J.J., Pool, R., Fedko, I.O., Mbarek, H., Huppertz, C., 
Bartels, M., Boomsma, D.I., Vink, J.M. and Genome of the Netherlands Consortium 
(2015). Heritability, SNP-and gene-based analyses of cannabis use initiation and age at 
onset. Behavior genetics, 45(5), 503-513. 
Miranda, R., Meyerson, L. A., Long, P. J., Marx, B. P., & Simpson, S. M. (2002). Sexual assault 
and alcohol use: Exploring the self-medication hypothesis. Violence and victims, 17(2), 
205-217. 
Mistry, C., Bawor, M., Desai, D., C Marsh, D., & Samaan, Z. (2014). Genetics of opioid 
dependence: A review of the genetic contribution to opioid dependence. Current 
psychiatry reviews, 10(2), 156-167. 
Morris, D.W., Pearson, R.D., Cormican, P., Kenny, E.M., O'dushlaine, C.T., Perreault, L.P.L., 
Giannoulatou, E., Tropea, D., Maher, B.S., Wormley, B. and Kelleher, E. (2014). An 
inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor 
for psychosis. Human molecular genetics, 23(12), 3316-3326. 
Najavits, L. (2002). Seeking safety: A treatment manual for PTSD and substance abuse. Guilford 
Publications. 
Nargiso, J. E., Ballard, E. L., & Skeer, M. R. (2015). A systematic review of risk and protective 
factors associated with non-medical use of prescription drugs among youth in the United 
States: a social ecological perspective. Journal of studies on alcohol and drugs, 76(1), 5-
20. 
Neale, M. & Cardon, L. R. (2013). Methodology for genetic studies of twins and families (Vol. 
67). Springer Science & Business Media. 
 142 
Need, A. C., & Goldstein, D. B. (2006). Genome-wide tagging for everyone. Nature 
genetics, 38(11), 1227. 
Nelson, E.C., Agrawal, A., Heath, A.C., Bogdan, R., Sherva, R., Zhang, B., Al-Hasani, R., 
Bruchas, M.R., Chou, Y.L., Demers, C.H. & Carey, C.E. (2016). Evidence of CNIH3 
involvement in opioid dependence. Molecular psychiatry, 21(5), 608. 
Newcomb, M. D., & Felix-Ortiz, M. (1992). Multiple protective and risk factors for drug use 
and abuse: cross-sectional and prospective findings. Journal of personality and social 
psychology, 63(2), 280. 
Nievergelt, C.M., Maihofer, A.X., Mustapic, M., Yurgil, K.A., Schork, N.J., Miller, M.W., 
Logue, M.W., Geyer, M.A., Risbrough, V.B., O’Connor, D.T. & Baker, D.G. (2015). 
Genomic predictors of combat stress vulnerability and resilience in US Marines: a genome-
wide association study across multiple ancestries implicates PRTFDC1 as a potential 
PTSD gene. Psychoneuroendocrinology, 51, 459-471. 
Nugent, N. R., Amstadter, A. B., & Koenen, K. C. (2008, May). Genetics of post‐traumatic stress 
disorder: Informing clinical conceptualizations and promoting future research. 
In American Journal of Medical Genetics Part C: Seminars in Medical Genetics (Vol. 148, 
No. 2, pp. 127-132). Wiley Subscription Services, Inc., A Wiley Company. 
Oderda, G. M., Lake, J., Rüdell, K., Roland, C. L., & Masters, E. T. (2015). Economic Burden of
 Prescription Opioid Misuse and Abuse: A Systematic Review. Journal of pain &
 palliative care pharmacotherapy, 29(4), 388-400. 
Ouimette, P. C., Kimerling, R., Shaw, J., & Moos, R. H. (2000). Physical and sexual abuse 
among women and men with substance use disorders. Alcoholism Treatment 
Quarterly, 18(3), 7-17. 
 143 
Ouimette, P., Read, J. P., Wade, M., & Tirone, V. (2010). Modeling associations between 
posttraumatic stress symptoms and substance use. Addictive behaviors, 35(1), 64-67. 
Owens, G. P., & Chard, K. M. (2006). PTSD severity and cognitive reactions to trauma among a 
college sample: An exploratory study. Journal of Aggression, Maltreatment & 
Trauma, 13(2), 23-36. 
Palmer, R.H., Button, T.M., Rhee, S.H., Corley, R.P., Young, S.E., Stallings, M.C., Hopfer, C.J. 
& Hewitt, J.K. (2012). Genetic etiology of the common liability to drug dependence: 
evidence of common and specific mechanisms for DSM-IV dependence symptoms. Drug 
and alcohol dependence, 123, S24-S32. 
Palmer, R. H., Nugent, N. R., Brick, L. A., Bidwell, C. L., McGeary, J. E., Keller, M. C., & 
Knopik, V. S. (2016). Evidence of Shared Genome‐Wide Additive Genetic Effects on 
Interpersonal Trauma Exposure and Generalized Vulnerability to Drug Dependence in a 
Population of Substance Users. Journal of traumatic stress, 29(3), 197-204. 
Palmer, R. H., Brick, L., Nugent, N. R., Bidwell, L. C., McGeary, J. E., Knopik, V. S., & Keller, 
M. C. (2015). Examining the role of common genetic variants on alcohol, tobacco, 
cannabis and illicit drug dependence: genetics of vulnerability to drug 
dependence. Addiction, 110(3), 530-537. 
Parks, K. A., Levonyan-Radloff, K., Przybyla, S., & Hequembourg, A. (2015). College student 
opinions about the use of non-medical prescription drugs. Drug & Alcohol Dependence, 
146, e62-e63. 
Passik, S. D., Kirsh, K. L., & Webster, L. (2011). Pseudoaddiction revisited: a commentary on 
clinical and historical considerations. Pain, 1(3), 239-248. 
Perkins, H. (2012). Misperceptions of peer substance use among youth are 
 144 
real. Addiction, 107(5), 888-889. 
Plomin, R., DeFries, J. C., Knopik, V. S., & Neiderheiser, J. (2013). Behavioral genetics. 
Palgrave Macmillan. Price, A. L., Zaitlen, N. A., Reich, D., & Patterson, N. (2010). New 
approaches to population stratification in genome-wide association studies. Nature 
Reviews Genetics, 11(7), 459-463. 
Powers, A., Almli, L., Smith, A., Lori, A., Leveille, J., Ressler, K.J., Jovanovic, T. & Bradley, B. 
(2016). A genome-wide association study of emotion dysregulation: evidence for 
interleukin 2 receptor alpha. Journal of psychiatric research, 83, 195-202. 
Prentice, R. L. (1995). Design issues in cohort studies. Statistical methods in medical research, 
4(4), 273-292. 
Prins, A., & Ouimette, P. (2004). " The primary care PTSD screen (PC-PTSD): Development 
and operating characteristics".(vol 16, pg 257, 2003). Primary Care Psychiatry, 9(4), 151-
151. 
Prins, A., Bovin, M.J., Smolenski, D.J., Marx, B.P., Kimerling, R., Jenkins-Guarnieri, M.A., 
Kaloupek, D.G., Schnurr, P.P., Kaiser, A.P., Leyva, Y.E. & Tiet, Q.Q. (2016). The primary 
care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran 
primary care sample. Journal of general internal medicine, 31(10), 1206-1211. 
Psychiatric GWAS Consortium Coordinating Committee. (2009). Genomewide association 
studies: history, rationale, and prospects for psychiatric disorders. American Journal of 
Psychiatry. 
Quintero, G., Peterson, J., & Young, B. (2006). An exploratory study of socio-cultural factors 
contributing to prescription drug misuse among college students. Journal of Drug Issues, 
36(4), 903-931. 
 145 
Rabiner, D. L., Anastopoulos, A. D., Costello, E. J., Hoyle, R. H., Esteban McCabe, S., &  
Swartzwelder, H. S. (2009). The misuse and diversion of prescribed ADHD medications 
by college students. Journal of Attention Disorders, 13(2), 144-153. 
Read, J. P., Ouimette, P., White, J., Colder, C., & Farrow, S. (2011). Rates of DSM–IV–TR 
trauma exposure and posttraumatic stress disorder among newly matriculated college 
students. Psychological Trauma: Theory, Research, Practice, and Policy, 3(2), 148. 
Reich, D. E., Cargill, M., Bolk, S., Ireland, J., Sabeti, P. C., Richter, D. J., ... & Lander, E. S.  
(2001). Linkage disequilibrium in the human genome. Nature, 411(6834), 199-204. 
Rhoades, H., & Wenzel, S. L. (2013). Correlates of prescription drug misuse among 
heterosexually active homeless men. Substance abuse, 34(2), 143-149. 
Ripke, S., Neale, B.M., Corvin, A., Walters, J.T., Farh, K.H. and Holmans, P.A., & Pers, T.H. 
(2014). Biological insights from 108 schizophrenia-associated genetic 
loci. Nature, 511(7510), 421. 
Risch, N. & Marikangas, K. (1996). The future of genetic studies of complex human diseases. 
Science, 1516-1517. 
Roberts, A. L., Gilman, S. E., Breslau, J., Breslau, N., & Koenen, K. C. (2011). Race/ethnic 
differences in exposure to traumatic events, development of post-traumatic stress disorder, 
and treatment-seeking for post-traumatic stress disorder in the United 
States. Psychological medicine, 41(01), 71-83. 
Rolison, J. J., Hanoch, Y., Wood, S., & Liu, P. J. (2013). Risk-taking differences across the adult 
life span: a question of age and domain. Journals of Gerontology Series B: Psychological 
Sciences and Social Sciences, 69(6), 870-880. 
Romer, D. (2010). Adolescent risk taking, impulsivity, and brain development: Implications for 
 146 
prevention. Developmental Psychobiology: The Journal of the International Society for 
Developmental Psychobiology, 52(3), 263-276. 
Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in 
observational studies for causal effects. Biometrika, 70(1), 41-55. 
Saha, T.D., Kerridge, B.T., Goldstein, R.B., Chou, S.P., Zhang, H., Jung, J., Pickering, R.P., 
Ruan, W.J., Smith, S.M., Huang, B. and Hasin, D.S. (2016). Non-medical Prescription 
Opioid Use and DSM-5 Non-medical Prescription Opioid Use Disorder in the United 
States. The Journal of clinical psychiatry, 77(6), 772. 
Sartor, C.E., McCutcheon, V.V., Pommer, N.E., Nelson, E.C., Grant, J.D., Duncan, A.E., 
Waldron, M., Bucholz, K.K., Madden, P.A.F. & Heath, A.C. (2011). Common genetic and 
environmental contributions to post-traumatic stress disorder and alcohol dependence in 
young women. Psychological medicine, 41(07), 1497-1505. 
Sartor, C.E., Grant, J.D., Lynskey, M.T., McCutcheon, V.V., Waldron, M., Statham, D.J., 
Bucholz, K.K., Madden, P.A., Heath, A.C., Martin, N.G. & Nelson, E.C. (2012). Common 
heritable contributions to low-risk trauma, high-risk trauma, posttraumatic stress disorder, 
and major depression. Archives of general psychiatry, 69(3), 293-299. 
Scherrer, J.F., Xian, H., Lyons, M.J., Goldberg, J., Eisen, S.A., True, W.R., Tsuang, M., 
Bucholz, K.K. & Koenen, K.C. (2008). Posttraumatic stress disorder; combat exposure; 
and nicotine dependence, alcohol dependence, and major depression in male 
twins. Comprehensive psychiatry, 49(3), 297-304. 
Sheerin, C. M., Lind, M. J., Bountress, K. E., Nugent, N. R., & Amstadter, A. B. (2017). The 
genetics and epigenetics of PTSD: overview, recent advances, and future 
directions. Current Opinion in Psychology, 14, 5-11. 
 147 
Schulenberg, J. E., Johnston, L. D., O'Malley, P. M., Bachman, J. G., Miech, R. A., & Patrick, 
M. E. (2017). Monitoring the Future national survey results on drug use, 1975-2016: 
Volume II, college students and adults ages 19-55. 
Smith, D. W., Letourneau, E. J., Saunders, B. E., Kilpatrick, D. G., Resnick, H. S., & Best, C. L. 
(2000). Delay in disclosure of childhood rape: Results from a national survey. Child abuse 
& neglect, 24(2), 273-287. 
Smith, K. Z., Smith, P. H., Cercone, S. A., McKee, S. A., & Homish, G. G. (2016). Past year 
non-medical opioid use and abuse and PTSD diagnosis: Interactions with sex and 
associations with symptom clusters. Addictive behaviors, 58, 167-174. 
Stein, M. B., Jang, K. L., Taylor, S., Vernon, P. A., & Livesley, W. J. (2002). Genetic and 
environmental influences on trauma exposure and posttraumatic stress disorder symptoms: 
a twin study. American Journal of Psychiatry, 159(10), 1675-1681. 
Stein, M.B., Chen, C.Y., Ursano, R.J., Cai, T., Gelernter, J., Heeringa, S.G., Jain, S., Jensen, 
K.P., Maihofer, A.X., Mitchell, C. & Nievergelt, C.M. (2016). Genome-wide association 
studies of posttraumatic stress disorder in 2 cohorts of US Army soldiers. JAMA 
psychiatry, 73(7), 695-704. 
Sturza, M. L., & Campbell, R. (2005). An exploratory study of rape survivors’ prescription drug 
use as a means of coping with sexual assault. Psychology of Women Quarterly, 29(4), 353-
363. 
Substance Abuse and Mental Health Services Administration (2011). Results from the 2011 
National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: 
Substance Abuse and Mental Health Services Administration; 2012. HHS Publication No. 
(SMA) 12-4713, NSDUH Series H–44. 
 148 
Substance Abuse and Mental Health Services Administration (2016). Results from the 2016 
National Survey on Drug Use and Health: Summary of National Findings. Rockville, 
MD: Substance Abuse and Mental Health Services Administration; 2014. NSDUH Series 
H-48, HHS Publication No.(SMA) 14-4863. 
Substance Abuse and Mental Health Services Administration (2010). Results from the 2010 
National Survey on Drug Use and Health: summary of national findings, NSDUH Series 
H-41, HHS Publication No. (SMA) 11-4658. Rockville (MD): SAMHSA; 2011. 
Substance Abuse Mental Health Services Administration (2014). Results from the 2013 national 
survey on drug use and health: summary of national findings. NSDUH Series H-48, HHS 
Publication No.(SMA), 14-4863. 
Substance abuse and mental health services administration, center for behavioral health 
statistics and quality. The NSDUH Report: State Estimates of Non-medical Use of 
Prescription Pain Relievers Rockville, MD (January 8, 2013). 
Tabor, H. K., Risch, N. J., & Myers, R. M. (2002). Candidate-gene approaches for studying 
complex genetic traits: practical considerations. Nature Reviews Genetics, 3(5), 391-397. 
Tapscott, B. E., & Schepis, T. S. (2013). Non-medical Use of Prescription Medications in Young 
Adults. Adolescent medicine: state of the art reviews, 24(3), 597. 
Taylor, M., Simpkin, A. J., Haycock, P. C., Dudbridge, F., & Zuccolo, L. (2016). Exploration of 
a polygenic risk score for alcohol consumption: a longitudinal analysis from the ALSPAC 
cohort. PloS one, 11(11), e0167360. 
Testa, M., Livingston, J. A., & Leonard, K. E. (2003). Women's substance use and experiences 
of intimate partner violence: A longitudinal investigation among a community sample. 
Addictive behaviors, 28(9), 1649-1664. 
 149 
Timimi, S. (2014). No more psychiatric labels: Why formal psychiatric diagnostic systems 
should be abolished. International Journal of Clinical and Health Psychology, 14(3), 208-
215. 
Tolin, D. F., & Foa, E. B. (2006). Sex differences in trauma and posttraumatic stress disorder: a 
quantitative review of 25 years of research. Psychological bulletin, 132(6), 959. 
Tomaka, J., Morales‐Monks, S., & Shamaley, A. G. (2013). Stress and coping mediate 
relationships between contingent and global self‐esteem and alcohol‐related problems 
among college drinkers. Stress and Health, 29(3), 205-213. 
Treutlein, J., Cichon, S., Ridinger, M., Wodarz, N., Soyka, M., Zill, P., Maier, W., Moessner, R., 
Gaebel, W., Dahmen, N. & Fehr, C. (2009). Genome-wide association study of alcohol 
dependence. Archives of general psychiatry, 66(7), 773-784. 
True, W. R., Rice, J., Eisen, S. A., Heath, A. C., Goldberg, J., Lyons, M. J., & Nowak, J. (1993). 
A twin study of genetic and environmental contributions to liability for posttraumatic stress 
symptoms. Archives of general psychiatry, 50(4), 257-264. 
Uhl, G.R., Drgon, T., Liu, Q.R., Johnson, C., Walther, D., Komiyama, T., Harano, M., Sekine, 
Y., Inada, T., Ozaki, N. & Iyo, M. (2008). Genome-wide association for methamphetamine 
dependence: convergent results from 2 samples. Archives of general psychiatry, 65(3), 
345-355. 
Ullman, S. E., Relyea, M., Peter-Hagene, L., & Vasquez, A. L. (2013). Trauma histories, 
substance use coping, PTSD, and problem substance use among sexual assault 
victims. Addictive behaviors, 38(6), 2219-2223. 
Van Zee, A. (2009). The promotion and marketing of oxycontin: commercial triumph, public 
health tragedy. American Journal of Public Health, 99(2), 221-227. 
 150 
Ventola, C. L. (2011). Direct-to-consumer pharmaceutical advertising: therapeutic or toxic?. 
Pharmacy and Therapeutics, 36(10), 669. 
Verhulst, B., Neale, M. C., & Kendler, K. S. (2015). The heritability of alcohol use disorders: a 
meta-analysis of twin and adoption studies. Psychological medicine, 45(05), 1061-1072. 
Vink, J. M., Hottenga, J. J., de Geus, E. J., Willemsen, G., Neale, M. C., Furberg, H., & 
Boomsma, D. I. (2014). Polygenic risk scores for smoking: predictors for alcohol and 
cannabis use? Addiction, 109(7), 1141-1151. 
Vink, J. M., Willemsen, G., & Boomsma, D. I. (2005). Heritability of smoking initiation and 
nicotine dependence. Behavior genetics, 35(4), 397-406. 
Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J. 
(2017). 10 years of GWAS discovery: biology, function, and translation. The American 
Journal of Human Genetics, 101(1), 5-22. 
Volkow, N. D. (2005). Prescription drugs: Abuse and addiction. National Institute on Drug 
Abuse. 
Vrana, S., & Lauterbach, D. (1994). Prevalence of traumatic events and post-traumatic 
psychological symptoms in a nonclinical sample of college students. Journal of traumatic 
stress, 7(2), 289-302. 
 Vrieze, S. I., McGue, M., Miller, M. B., Hicks, B. M., & Iacono, W. G. (2013). Three mutually 
informative ways to understand the genetic relationships among behavioral disinhibition, 
alcohol use, drug use, nicotine use/dependence, and their co-occurrence: twin biometry, 
GCTA, and genome-wide scoring. Behavior genetics, 43(2), 97-107. 
Walker, H. E., Freud, J. S., Ellis, R. A., Fraine, S. M., & Wilson, L. C. (2019). The prevalence of 
sexual revictimization: A meta-analytic review. Trauma, Violence, & Abuse, 20(1), 67-80. 
 151 
Walsh, K., Resnick, H. S., Danielson, C. K., McCauley, J. L., Saunders, B. E., & Kilpatrick, D. 
G. (2014). Patterns of drug and alcohol use associated with lifetime sexual revictimization 
and current posttraumatic stress disorder among three national samples of adolescent, 
college, and household-residing women. Addictive behaviors, 39(3), 684-689. 
Walters, R.K., Polimanti, R., Johnson, E.C., McClintick, J.N., Adams, M.J., Adkins, A.E., Aliev, 
F., Bacanu, S.A., Batzler, A., Bertelsen, S. & Biernacka, J.M. (2018).  Transancestral 
GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric 
disorders. Nature neuroscience, 21(12), 1656. 
Watson, S. B., & Haynes, S. N. (2007). Brief screening for traumatic life events in female 
university health service patients. International Journal of Clinical and Health 
Psychology, 7(2). 
Warner, M., Chen, L. H. & Makuc, D. M. (2009). Increase in fatal poisonings involving 
opioid analgesics in the United States, 1999-2006. NCHS data brief, 1-8. 
Weathers, F. W., Litz, B. T., Keane, T. M., Palmieri, P. A., Marx, B. P., & Schnurr, P. P. (2013). 
The ptsd checklist for dsm-5 (pcl-5). Scale available from the National Center for PTSD 
at www. ptsd. va. gov. 
Webster-Stratton, C., & Taylor, T. (2001). Nipping early risk factors in the bud: Preventing 
substance abuse, delinquency, and violence in adolescence through interventions targeted 
at young children (0–8 years). Prevention science, 2(3), 165-192. 
Wessel, J. (2013). Common Disease-Common Variant. In Encyclopedia of Behavioral Medicin 
 (pp. 460-460). Springer New York  
White, A. G., Birnbaum, H. G., Schiller, M., Tang, J., & Katz, N. P. (2009). Analytic models to 
 152 
identify patients at risk for prescription opioid abuse. The American journal of managed 
care, 15(12), 897-906. 
Wilkening, S., Chen, B., Bermejo, J. L., & Canzian, F. (2009). Is there still a need for candidate 
gene approaches in the era of genome-wide association studies? Genomics, 93(5), 415-419. 
Wilsey, B. L., Fishman, S. M., Tsodikov, A., Ogden, C., Symreng, I., & Ernst, A. (2008). 
Psychological comorbidities predicting prescription opioid abuse among patients in 
chronic pain presenting to the emergency department. Pain Medicine, 9(8), 1107-1117. 
Wolf, E. J., Miller, M. W., Krueger, R. F., Lyons, M. J., Tsuang, M. T., & Koenen, K. C. (2010). 
Posttraumatic stress disorder and the genetic structure of comorbidity. Journal of abnormal 
psychology, 119(2), 320. 
Xie, P., Kranzler, H. R., Yang, C., Zhao, H., Farrer, L. A., & Gelernter, J. (2013). Genome-wide 
association study identifies new susceptibility loci for posttraumatic stress 
disorder. Biological psychiatry, 74(9), 656-663. 
Xian, H., Chantarujikapong, S.I., Scherrer, J.F., Eisen, S.A., Lyons, M.J., Goldberg, J., Tsuang, 
M. & True, W.R (2000). Genetic and environmental influences on posttraumatic stress 
disorder, alcohol and drug dependence in twin pairs. Drug and alcohol dependence, 61(1), 
95-102. 
Yan, J., Aliev, F., Webb, B.T., Kendler, K.S., Williamson, V.S., Edenberg, H.J., Agrawal, A., 
Kos, M.Z., Almasy, L., Nurnberger Jr, J.I. & Schuckit, M.A. (2014). Using genetic 
information from candidate gene and genome‐wide association studies in risk prediction 
for alcohol dependence. Addiction biology, 19(4), 708-721. 
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011). GCTA: a tool for genome-wide 
complex trait analysis. The American Journal of Human Genetics, 88(1), 76-82. 
 153 
Yehuda, R., Halligan, S. L., & Bierer, L. M. (2001). Relationship of parental trauma exposure 
and PTSD to PTSD, depressive and anxiety disorders in offspring. Journal of psychiatric 
research, 35(5), 261-270. 
Young, S. E., Corley, R. P., Stallings, M. C., Rhee, S. H., Crowley, T. J., & Hewitt, J. K. (2002). 
Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and 
correlates. Drug and alcohol dependence, 68(3), 309-322. 
Young, A. M., Glover, N., & Havens, J. R. (2012). Non-medical use of prescription medications 
among adolescents in the United States: a systematic review. Journal of Adolescent 
Health, 51(1), 6-17. 
Zapp, D., Buelow, R., Soutiea, L., Berkowitz, A., & Dejong, W. (2018). Exploring the potential 
campus-level impact of online universal sexual assault prevention education. Journal of 
interpersonal violence, 0886260518762449. 
Zhu, M., & Zhao, S. (2007). Candidate gene identification approach: progress and 
challenges. International Journal Biological Science, 3(7), 420-427. 
 
 
 
 
 
 
 
 
 
 
 154 
Appendix I 
NMUPD (Fall Freshman Year) 
Have you ever used any of the following drugs for non-medical use? Non-medical use means 
on your own, without a doctor's prescription, in greater amounts than prescribed, or for 
reasons other than your doctor recommended. Remember that all your responses are 
completely confidential.  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No [program: if no, skip all other sedatives questions] ( ) I choose not 
to answer [program: if choose not to answer, skip all other sedatives questions]  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other?  ( 
) Yes ( ) No [program: if no, skip all other stimulants questions] ( ) I choose not to answer 
[program: if choose not to answer, skip all other opioids questions] 
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip all other 
opioids questions] ( ) I choose not to answer [program: if choose not to answer, skip all other 
opioids questions]  
Have you used the following drugs 6 or more times in your life?  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other?   ( 
) Yes ( ) No ( ) I choose not to answer  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer  
 
 
STRESSFUL EVENTS (Fall Freshman Year) 
Listed below are a number of difficult or stressful things that sometimes happen to people. 
For each event check one or more of the boxes to indicate if the event happened to you ever 
in your lifetime, and if it happened to you in the past 12 months.  
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Ever ( ) 
Past 12 months ( ) Never happened to me ( ) I choose not to answer  
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( ) 
Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer  
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat 
of harm) ( ) Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer  
Other unwanted or uncomfortable sexual experience ( ) Ever ( ) Past 12 months ( ) Never 
happened to me ( ) I choose not to answer  
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( ) 
Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer  
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PTSD (Fall Freshman Year) 
Have any of these experiences resulted in any of the following symptoms: Nightmares about 
it, tried hard not to think about it or went out of your way to avoid situations that reminded 
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from 
others, activities, or your surroundings?  
( ) Yes ( ) No ( ) I choose not to answer  
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Appendix II 
NMUPD (Spring Freshman Follow-up) 
Since you started at VCU, have you used any of the following drugs for non-medical use? 
Non- medical use means on your own, without a doctor's prescription, in greater amounts 
than prescribed, or for reasons other than your doctor recommended. Remember that all 
your responses are completely confidential.  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes [program: if yes, ask b.1] ( ) No [program: if no, skip all other sedatives 
questions] ( ) I choose not to answer [program: if choose not to answer, skip all other sedatives 
questions]  
Have you used sedatives 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? ( 
) Yes [program: if yes, ask c.1] ( ) No [program: if no, skip all other stimulants questions] ( ) I 
choose not to answer [program: if choose not to answer, skip all other stimulants questions]  
Have you used stimulants 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes [program: if yes, ask e.1] ( ) No 
[program: if no, skip all other opioids questions] ( ) I choose not to answer [program: if choose 
not to answer, skip all other opioids questions]  
Have you used opioids 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer  
 
STRESSFUL EVENTS (Spring Freshman Follow-up) 
Listed below are a number of difficult or stressful things that sometimes happen to people. 
Please indicate whether you have experienced the following events since coming to VCU.  
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes ( ) 
No ( ) I choose not to answer  
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( ) 
Yes ( ) No ( ) I choose not to answer  
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat 
of harm) ( ) Yes ( ) No ( ) I choose not to answer  
Other unwanted or uncomfortable sexual experience ( ) Yes ( ) No ( ) I choose not to answer  
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( ) 
Yes ( ) No ( ) I choose not to answer  
 
PTSD (Spring Freshman Follow-up) 
Have any of these experiences resulted in any of the following symptoms: Nightmares about 
it, tried hard not to think about it or went out of your way to avoid situations that reminded 
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from 
others, activities, or your surroundings?  
( ) Yes ( ) No ( ) I choose not to answer  
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NMUPD (Spring Freshman NEW) 
Have you ever used any of the following drugs for non-medical use? Non-medical use means 
on your own, without a doctor's prescription, in greater amounts than prescribed, or for 
reasons other than your doctor recommended. Remember that all your responses are 
completely confidential. If you have used a particular drug both before and after starting 
school at VCU, please mark both boxes.  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes, before coming to VCU ( ) Yes, since coming to VCU ( ) No [program: if 
no, skip all other sedatives questions] ( ) I choose not to answer [program: if choose not to 
answer, skip all other sedatives questions]  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other?  ( 
) Yes, before coming to VCU ( ) Yes, since coming to VCU ( ) No [program: if no, skip all other 
stimulants questions] ( ) I choose not to answer [program: if choose not to answer, skip all other 
stimulants questions]  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes, before coming to VCU ( ) Yes, since 
coming to VCU ( ) No [program: if no, skip all other opioids questions] ( ) I choose not to answer 
[program: if choose not to answer, skip all other opioids questions]  
Have you used the following drugs 6 or more times in your life?  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other?  ( 
) Yes ( ) No ( ) I choose not to answer  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer  
 
STRESSFUL EVENTS (Spring Freshman NEW) 
Listed below are a number of difficult or stressful things that sometimes happen to people. 
For each event check one or more of the boxes to indicate if the event happened to you.  
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes, 
before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer  
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( ) 
Yes, before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer  
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat 
of harm) ( ) Yes, before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to 
answer  
Other unwanted or uncomfortable sexual experience ( ) Yes, before starting at VCU ( ) Yes, since 
starting at VCU ( ) No ( ) I choose not to answer  
Transportation accident (for example, car accident, boat accident, train wreck, plane crash)  ( ) Yes, 
before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer  
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PTSD (Spring Freshman Follow-up NEW) 
Have any of these experiences resulted in any of the following symptoms: Nightmares about 
it, tried hard not to think about it or went out of your way to avoid situations that reminded 
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from 
others, activities, or your surroundings?  
( ) Yes ( ) No ( ) I choose not to answer  
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Appendix III 
NMUPD (Spring Sophomore Follow-up) 
Have you used any of the following drugs for non-medical use? Non-medical use means on 
your own, without a doctor's prescription, in greater amounts than prescribed, or for reasons 
other than your doctor recommended. Remember that all your responses are completely 
confidential.  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No [program: if no, skip all other sedatives questions] ( ) I choose not 
to answer [program: if choose not to answer, skip all other sedatives questions]  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? ( 
) Yes ( ) No [program: if no, skip all other stimulants questions] ( ) I choose not to answer 
[program: if choose not to answer, skip all other stimulants questions]  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip all other 
opioids questions] ( ) I choose not to answer [program: if choose not to answer, skip all other 
opioids questions]  
Have you used any of the following drugs in the last 12 months?  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No [program: if no, skip question 98b]  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? ( 
) Yes ( ) No [program: if no, skip question 98c] ( ) I choose not to answer [program: if choose not 
to answer, skip question 98c]  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip question 
98e] ( ) I choose not to answer [program: if choose not to answer, skip question 98e]  
Have you used the following drugs 6 or more times in the past 12 months?  
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, 
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer  
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? ( 
) Yes ( ) No ( ) I choose not to answer  
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer  
 
STRESSFUL EVENTS (Spring Sophomore Follow-up) 
Listed below are a number of difficult or stressful things that sometimes happen to people. 
Please indicate whether you have experienced the following events over the past 12 months.  
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes ( ) 
No ( ) I choose not to answer  
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( ) 
Yes ( ) No ( ) I choose not to answer  
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat 
of harm) ( ) Yes ( ) No ( ) I choose not to answer  
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Other unwanted or uncomfortable sexual experience ( ) Yes ( ) No ( ) I choose not to answer  
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( ) 
Yes ( ) No ( ) I choose not to answer  
 
PTSD (Spring Sophomore Follow-up) 
Have any of these experiences resulted in any of the following symptoms: Nightmares about 
it, tried hard not to think about it or went out of your way to avoid situations that reminded 
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from 
others, activities, or your surroundings?  
( ) Yes ( ) No ( ) I choose not to answer  
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Appendix IV 
Longitudinal associations between IPV and NMUPD-E.  To examine the longitudinal 
associations between IPV (i.e., sexual assault, physical assault, any other unwanted and/or 
uncomfortable sexual experiences) and NMUPD-E, autoregressive cross lag models were 
conducted with sex and cohort included as covariates.  The first (saturated) model, serving as the 
basis for comparison, included all potential paths (Figure 1 [see page 36).  
Model comparisons:  IPV and NMUPD-E.  Next, a series of sub-models were fitted by 
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model 
were compared to the saturated model (Model 1.5, Table 22).  Two models examining the self-
medication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 22) were 
compared to the saturated model.  In Model 2.5 (Table 22), cross lag paths from IPV to NMUPD-
E across time points (h, k, and l paths) were constrained to zero to test the self-medication model 
across time.  This model was not significantly different from the saturated model (p = .59) 
indicating that these paths could be dropped without significantly effecting the fit.  In Model 3.5 
(Table 22), cross lag paths from NMUPD-E to IPV across time points (i, j, and m paths) were 
constrained to zero to test the high risk model across time.  This model was significantly different 
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit 
with the data.  In short, the results of the model fitting procedures provide support for the high risk 
hypothesis (i.e., prior NMUPD-E is associated with heightened risk for IPV).   
IPV and NMUPD-E best fitting model results.  Following comparisons between the 
Longitudinal Effects Models (Table 22, Models 2.5 [self-medication model] and 3.5 [high risk 
model]) to the saturated model (Table 22, Model 1.5), the fit indices from Model 2.5 indicate that 
paths from IPV to NMUPD-E across time can be constrained to zero.  Path estimates with these 
paths dropped are located in Table 23.   
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Regarding covariates, sex was significantly associated with IPV and NMUPD-E at all three 
time points (ps<.05), with female sex being associated with greater report of IPV but lower report 
of NMUPD-E, with the exception of NMUPD-E sophomore year.  Cohort was inconsistently 
associated with IPV and NMUPD-E, with significant associations only being identified at baseline 
and between cohort and NMUPD-E sophomore year.  Being a part of a later cohort was associated 
with lower report of IPV; however, cohort was positively associated with NMUPD-E at baseline 
but lower NMUPD-E sophomore year.  When examining IPV and NMUPD-E, prior IPV and 
NMUPD-E were significant predictors of future IPV and NMUPD-E, respectively.  Specifically, 
IPV prior to college was associated with IPV freshman year (B = .34, p < .001 [path a]) and IPV 
in freshman year was significantly associated with IPV sophomore year (B = .39, p < .001 [path 
b]).  NMUPD-E prior to college was associated with freshman year NMUPD-E (B = 1.17, p < .001 
[path c]) and freshman year NMUPD-E was also significantly associated with sophomore year 
NMUPD-E (B = .56, p < .001 [path d]).   Potential long term associations between IPV and 
NMUPD-E occurring prior to college and IPV and NMUPD-E, respectively, occurring in 
sophomore year were also examined.  IPV prior to college was associated with IPV sophomore 
year (B = .27, p = .001 [path n]) and NMUPD-E prior to college was also significantly associated 
with NMUPD-E sophomore year (B = .53, p = .001 [path o]). 
Given that model fitting results suggested that IPV was not a significant predictor or 
NMUPD-E across time, these paths were not included in the final model and thus only the cross 
paths between NMUPD-E and IPV across time are presented.  NMUPD-E prior to college served 
as a significant predictor of IPV freshman year (B = .17, p = <.001 [path i]); however, NMUPD-E 
during freshman year did not serve as a significant predictor of IPV sophomore year (B = .08, p = 
.001 [path j]).  NMUPD-E prior to college did not serve as a significant predictor of IPV 
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sophomore year (B = .05, p = .21 [path m]).   To summarize, the results of the model fitting 
procedures provide support for the high risk hypothesis (i.e., prior NMUPD-E is associated with 
heightened risk for IPV).
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Table 22. Model fitting results of autoregressive cross lag models between interpersonal violence and experimental non-medical use of 
prescription drugs. 
 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.5 a 56581.07 47462 -38342.93        -- -- -- 
Longitudinal Effects Models  
2.5 b 56583.01 47465 -38346.99 1.93 3 0.59 
3.5 c 56624.24 47465 -38305.76 43.17 3 < .001 
Note:  a = model includes all paths; b = paths ‘pre college IPV to freshman NMUPD-E’, ‘freshman IPV to sophomore NMUPD-E’, and ‘pre college IPV to 
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman IPV’, ‘freshman NMUPD-E to sophomore IPV’, and ‘pre college 
NMUPD-E to sophomore IPV’ constrained to zero. 
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Figure 20. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between interpersonal violence and experimental 
non-medical use of prescription drugs. 
 
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  TE = 
trauma exposure, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year, 
Y2S = sophomore year. 
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Table 23. Path estimates, p values, standard errors, and confidence intervals for the interpersonal 
violence and experimental non-medical use of prescription drugs longitudinal model. 
 
Path Estimate p value SE 
Correlations    
   IPV Y1F           NMUPD-E Y1F (e) .30 <.001 .02 
   IPV Y1S           NMUPD-E Y1S (f) .21 <.001 .04 
   IPV Y2S           NMUPD-E Y2S (g) .10 .05 .05 
   Sex         IPV Y1F .08 <.001 .02 
   Sex         NMUPD-E Y1F -.11 <.001 .02 
   Cohort           IPV Y1F -.12 .04 .02 
   Cohort           NMUPD-E Y1F .08 <.001 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       IPV Y1S .15 <.001 .03 
   Sex       NMUPD-E Y1S -.09 .006 .04 
   Sex       NMUPD-E Y2S -.05 .21 .04 
   Sex       IPV Y2S .10 .008 .04 
   Cohort        IPV Y1S -.02 .34 .02 
   Cohort        NMUPD-E Y1S -.03 .41 .03 
   Cohort        NMUPD-E Y2S -.11 .005 .04 
   Cohort        IPV Y2S .02 .56 .03 
 Autoregressive paths 1    
   IPV Y1F        IPV Y1S (a) .34 <.001 .03 
   IPV Y1S        IPV Y2S (b) .39 <.001 .05 
   NMUPD-E Y1F       NMUPD-E Y1S (c) 1.17 <.001 .05 
   NMUPD-E Y1S       NMUPD-E Y2S (d) .56 <.001 .06 
 Autoregressive paths 2    
   IPV Y1F         IPV Y2S (n) .27 <.001 .04 
   NMUPD-E Y1F       NMUPD-E Y2S (o) .53 <.001 .06 
 Cross lag paths 1    
   IPV Y1F         NMUPD-E Y1S (h) - - - 
   IPV Y1S         NMUPD-E Y2S (k) - - - 
  NMUPD-E Y1F      IPV Y1S (i) .17 <.001 .03 
   NMUPD-E Y1S       IPV Y2S (j) .08 .001 .06 
Cross lag paths 2    
   IPV Y1F          NMUPD-E Y2S (l) - - - 
   NMUPD-E Y1F        IPV Y2S (m) .05 .21 .08 
Note: IPV = interpersonal violence, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S = 
freshman year, Y2S = sophomore year. - = best fitting model (Table X) indicated that these paths could be dropped.
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Longitudinal Associations between IPV and NMUPD-R.  To examine the longitudinal 
associations between IPV and NMUPD-R, a similar set of autoregressive cross lag models as 
described above for NMUPD-E were also conducted with sex and cohort as covariates.  The first 
(saturated) model, serving as the basis for comparison, is presented in Figure 1 (Model 1.6 in Table 
24).   
Model comparisons:  IPV and NMUPD-R.  A series of sub-models were fitted by 
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model 
were compared to the saturated model (Model 1.6, Table 24).  Two models examining the self-
medication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 24) were 
compared to the saturated model. In Model 2.6 (Table 24), cross lag paths from IPV to NMUPD-
R across time points (h, k, and l paths) were constrained to zero to test the self-medication model 
across time.  This model was significantly different from the saturated model (p = .01) indicating 
that these paths could not be dropped without significantly effecting the fit.  In Model 3.6 (Table 
24), cross lag paths from NMUPD-R to IPV across time points (i, j, and m paths) were constrained 
to zero to test the high risk model across time.  This model was significantly different from the 
saturated model (p < .001) suggesting that dropping these paths would result in worse fit with the 
data.  The results of model fitting procedures suggest that dropping paths associated with the self-
medication and high-risk hypothesis resulted in worse model fit; however, Model 2.6 remained 
the worst fitting model between the two Longitudinal Effects Models, providing further support 
for the high risk hypothesis. 
IPV and NMUPD-R best fitting model results.  Following comparisons between the 
Longitudinal Effects Models (Table 24, Models 2.6 [self-medication model] and 3.6 [high risk 
model]) to the saturated model (Table 24, Model 1.6), the fit indices from Model 2.6 indicate that 
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paths from IPV to NMUPD-R across time can be constrained to zero.  Path estimates with these 
paths dropped are located in Table 25.   
Regarding covariates, sex was significantly associated with IPV and NMUPD-R at all three 
time points (ps<.05), with female sex being associated with greater report of IPV but lower report 
of NMUPD-E, with the exception of NMUPD-R sophomore year.  Cohort was inconsistently 
associated with IPV and NMUPD-R, with significant associations only being identified at baseline 
and between cohort and NMUPD-R sophomore year.  Being a part of a later cohort was associated 
with heightened report of IPV freshman year while cohort was negatively associated with 
NMUPD-E at baseline and sophomore year.     When examining IPV and NMUPD-R, prior IPV 
and NMUPD-R were significant predictors of future IPV and NMUPD-R, respectively.  
Specifically, IPV prior to college was associated with IPV freshman year (B = .34, p < .001 [path 
a]) and IPV in freshman year was significantly associated with IPV sophomore year (B = .39, p < 
.001 [path b]).  Repeated use NMUPD-R prior to college was associated with freshman year 
NMUPD-R (B = 1.13, p < .001 [path c]) and freshman year NMUPD-R was also significantly 
associated with sophomore year NMUPD-R (B = .43, p < .001 [path d]).   Potential long term 
associations between IPV and NMUPD-R occurring prior to college and IPV and NMUPD-R, 
respectively, occurring in sophomore year were also examined.  IPV prior to college was 
associated with IPV sophomore year (B = .29, p < .001 [path n) and NMUPD-R prior to college 
was also significantly associated with NMUPD sophomore year (B = .59, p < .001 [path o]). 
Given that model fitting results suggested that Model 2 (constraining paths between prior 
IPV to future NMUPD-R) was the worst fitting, these paths were not included in the final model 
and thus only the cross paths between NMUPD-R and IPV across time are presented.  Repeated 
use NMUPD prior to college served as a significant predictor of IPV freshman year (B = .25, p = 
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<.001 [path i]) and NMUPD-R during freshman year also served as a significant predictor of IPV 
sophomore year (B = .19, p = .01 [path j]).  Repeated use NMUPD prior to college did not serve 
as a significant predictor of IPV sophomore year (B = -.12, p = .27 [path m].  In summary, the 
results of the model fitting procedures provide support for the high risk hypothesis (i.e., prior 
NMUPD-R heightens risk for IPV).   
The high risk hypothesis was found to be the best fitting model across both forms of 
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model.   When 
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was 
significantly associated with IPV freshman year. However, significant associations between 
NMUPD freshman year and IPV sophomore year were only identified when examining NMUPD-
R.  This path was not significant when examining the association between NMUPD-E freshman 
year and IPV sophomore year.  Thus, although the high risk model best fits the data in both models 
examining IPV and NMUPD-E/NMUPD-R, NMUPD serving as a significant predictor across 
each time point is not consistent.  Interestingly, this is the same pattern that was noted when 
examining the associations between NMUPD-E/NMUPD-R and the primary phenotypes of 
interest (TE and probable-PTSD).  However, it is critical to note that dropping the paths from prior 
IPV to future NMUPD-R resulted in model fit significantly different from the saturated model and 
thus should be viewed as important paths to consider when investigating the longitudinal 
associations between IPV and NMUPD-R.
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Table 24. Model fitting results of autoregressive cross lag models between interpersonal trauma and repeated use non-medical    
use of prescription drugs. 
 
 Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.6 a 51448.55 47473 -43497.45        -- -- -- 
Longitudinal Effects Models  
2.6 b 51459.71 47476 -43492.29 11.16     3 0.01 
3.6 c 51497.27 47476 -43454.73 48.73      3 < .001 
Note:  a = model includes all paths; b = paths ‘pre college IPV to freshman NMUPD-R’, ‘freshman IPV to sophomore NMUPD-R’, and 
‘pre college IPV to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman IPV’, ‘freshman NMUPD-
R to sophomore IPV’, and ‘pre college NMUPD-R to sophomore IPV’ constrained to zero. 
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Figure 21. Visual representation of path significance for the best-fitting cross lag autoregressive 
model examining the longitudinal associations between interpersonal trauma and repeated use non-
medical use of prescription drugs. 
         
 
 
 
 
 
 
Note:  Significant paths are represented with black lines while grey lines represent non significant estimates.  TE = 
trauma exposure, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year, 
Y2S = sophomore year. 
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Table 25. Path estimates, p values, and standard errors for the best-fitting interpersonal trauma and 
repeated use non-medical use of prescription drugs autoregressive cross lag model. 
 
Path Estimate p value SE 
Correlations    
   IPV Y1F           NMUPD-R Y1F (e) .27  <.001  .03 
   IPV Y1S          NMUPD-R Y1S (f) .13 .01 .05 
   TE Y2S           NMUPD-R Y2S (g) .04 .46 .06 
   Sex         IPV Y1F .08 <.001 .02  
   Sex         NMUPD-R Y1F -.12 <.001 .03 
   Cohort           IPV Y1F .05 <.001 .02 
   Cohort           NMUPD-R Y1F -.12 <.001 .02 
Regressions    
 Controlling for sex and cohort    
   Sex       IPV Y1S .17 <.001 .03 
   Sex       NMUPD-R Y1S -.11 .01 .05 
   Sex       NMUPD-R Y2S -.02 .68 .07 
   Sex       IPV Y2S .11 .01 .05 
   Cohort         IPV Y1S -.53 .41 .02 
   Cohort         NMUPD-R Y1S .05 .25 .04 
   Cohort         NMUPD-R Y2S -.13 .01 .05 
   Cohort         IPV Y2S .02 .58 .043 
 Autoregressive paths 1    
   IPV Y1F        IPV Y1S (a) .34 <.001 .04 
   IPV Y1S        IPV Y2S (b) .39 <.001 .05 
   NMUPD-R Y1F       NMUPD-R Y1S (c) 1.13 <.001 .10 
   NMUPD-R Y1S       NMUPD-R Y2S (d) .43 <.001 .08 
 Autoregressive paths 2    
   IPV Y1F         IPV Y2S (n) .29 <.001 .04 
   NMUPD-R Y1F      NMUPD-R Y2S (o) .59 <.001 .11 
 Cross lag paths 1    
   IPV Y1F          NMUPD-R Y1S (h) - - - 
   TE Y1S          NMUPD-R Y2S (k) - - - 
   NMUPD-R Y1F      IPV Y1S (i) .25 <.001 .04 
   NMUPD-R Y1S       IPV Y2S (j) .19 .01 .04 
Cross lag paths 2    
   IPV Y1F          NMUPD-R Y2S (l) - - - 
  NMUPD-R Y1F        IPV Y2S (m) -.12 .27 .07 
Note: IPV = interpersonal victimization, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, 
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 5) indicated that these paths could be 
dropped. 
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Appendix V 
 Longitudinal associations between natural disaster and NMUPD (-E, -R).  As a 
potential proof of concept, exploratory models were also conducted examining the longitudinal 
associations between natural disaster, a form of trauma exposure considered potentially less 
influenced by substance use, including NMUPD (-E, -R).  Given that many participants may have 
reported natural disaster due to a small earthquake that occurred in the area in 2011, it was 
hypothesized that the high risk model (dropping all paths from TE to NMUPD [-E, -R]) would not 
fit the data better than the self-medication model as was found in the previous analyses. Given the 
exploratory nature of these models, only broad comparisons across models were conducted and 
thus, path estimates for the best-fitting models are not presented. 
Natural Disaster and NMUPD-E best fitting model results.  Following comparisons 
between the Longitudinal Effects Models (Table 26, Models 2.7 [self-medication model] and 3.7 
[high risk model]) to the saturated model (Table 26, Model 1.7), the results indicate that all paths 
with prior NMUPD-E predicting natural disaster could be dropped, as well as, all paths with prior 
natural disaster predicting NMUPD-E.   
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Table 26. Model fitting results of autoregressive cross lag models between natural disaster and experimental non-medical use of 
prescription drugs. 
 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.7 a 57783.41 47995 -38206.59 -- -- -- 
Longitudinal Effects Models  
2.7 b 57790.73 47998 -38205.27 7.31 3 .06 
3.7 c 57790.92 47998 -38205.08 7.50 3 .06 
Note:  a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-E’, ‘freshman TE to sophomore NMUPD-E’, and ‘pre college TE to 
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman TE’, ‘freshman NMUPD-E to sophomore TE’, and ‘pre college 
NMUPD-E to sophomore TE’ constrained to zero. 
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Natural Disaster and NMUPD-R best fitting model results.  Following comparisons 
between the Longitudinal Effects Models (Table 27, Models 2.8 [self-medication model] and 3.8 
[high risk model]) to the saturated model (Table 27, Model 1.8), the best fitting model was Model 
2.8 which constrained the paths from natural disaster to NMUPD-R across time to zero.  In short, 
the results of the model fitting procedures provide support for the high risk hypothesis (i.e., prior 
NMUPD-R is associated with heightened risk for natural disaster).   
The findings from these models were inconsistent, with the NMUPD-E model suggesting 
that all longitudinal paths could be dropped without significantly impacting model fit while the 
NMUPD-R model followed the same patterns identified in the analyses conducted for the primary 
phenotypes of interest (TE and probable-PTSD).  These findings, which is counter to the 
hypothesis that significant differences would not be identified across models, may lend additional 
support for the high risk model given that one would expect that prior NMUPD-E would not serve 
as a significant predictor of natural disaster, as it is perceived to be a “random” trauma type (with 
little influence from the individual exposed).  Overall, paths from NMUPD-E to natural disaster 
could be dropped without significantly effecting model fit.  However, the same pattern was not 
present when examining NMUPD-R, which demonstrated findings consistent with the high risk 
hypothesis. 
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Table 27. Results of autoregressive cross lag models for natural disaster and repeated use non-medical use of prescription drugs. 
 
 
 
Model Changes -2LL df AIC -2LL df p 
Saturated Model 
1.8 a 52506.44 48006 -43505.56 -- -- -- 
Longitudinal Effects Models  
2.8 b 52510.52 48009   -43507.48 4.09 3 .25 
3.8 c 52516.96 48009 -43501.04 10.53 3 .02 
Note:  a = model includes all paths; b = paths ‘pre college natural disaster to freshman NMUPD-R’, ‘freshman natural disaster to sophomore NMUPD-R’, and 
‘pre college natural disaster to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman natural disaster’, ‘freshman NMUPD-
R to sophomore natural disaster’, and ‘pre college NMUPD-R to sophomore natural disaster’ constrained to zero. 
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Appendix VI 
Determining the SNP-based heritability of IPV.  Given the lack of significant findings 
with regard to the univariate GCTAs conducted for NMUPD (-E, -R), TE, and probable-PTSD, 
GCTAs were also conducted for IPV within each ancestral group in an effort to derive molecular 
heritability estimates for a potentially more refined phenotype.  Prior to these analyses, power 
calculations were conducted for IPV within each ancestral group (Table 28).  Power analyses 
suggest that there is limited power to detect effects (with the exception of GCTAs within the EUR 
ancestry group for the IPV phenotype with high heritability [h2SNP
 = 0.50]). 
When univariate GCTAs were conducted, no significant findings were identified and 
standard errors for estimates frequently included 0 (Table 29).  In accordance with standard 
practice set forth by the PGC (https://github.com/Nealelab/ricopili), the results were meta-
analyzed across ancestry groups. The h2SNP estimate derived from the meta-analysis for IPV was 
.05 (SE = .01). 
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Table 28.  Power calculations for interpersonal violence phenotype by ancestral group. 
 
          Power 
Phenotypic 
Outcome 
Ancestry 
Group N Prevalence Controls Cases 
h2SNP 
= 0.50 
h2SNP 
= 0.20 
h2SNP = 
0.10 
IPV 
AFR 1314 39% 691 623 .26 .08 .06 
AMR 568 43% 295 273 .09 .06 .05 
EAS 542 32% 341 201 .08 .05 .05 
EUR 2949 42% 1518 1431 .84 .22 .09 
SAS 441 32% 296 145 .07 .05 .05 
Note: NMUPD = non-medical use of prescription drugs, TE = trauma exposure, probable-PTSD = posttraumatic stress 
disorder, h2 = SNP-based heritability estimate, h2SNP = SNP based heritability estimate. 
 
 
 
 
Table 29. Estimates of SNP-based heritability for interpersonal violence (controlling for 
population stratification, sex, cohort) phenotype generated from genome-wide complex trait 
analyses. 
 
Super population Covariates Sample prevalence h2SNP SE p-value 
IPV 
AFR PCs, cohort, 
sex 
47% .07 .27 .40 
AMR 
 
PCs, cohort, 
sex 
48% .53 .42 .10 
EAS PCs, cohort, 
sex 
37% .15 .63 .40 
EUR PCs, cohort, 
sex 
49% <.001 .13 .50 
SAS PCs, cohort, 
sex 
33% < .001 .73 .50 
Note: Ca = cases, Co = controls, PCs = principle components, AMF = African ancestry, AMR = Americas ancestry, 
EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, and h2SNP = SNP based 
heritability estimate. 
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Appendix VII 
In an additional effort to potentially refine the analyses, TE and probable-PTSD were 
included as covariates in a series of univariate GCTAs (in addition to PCs, sex, and cohort) of 
NMUPD (-E, -R).  These analyses were conducted only among the European ancestral group given 
the greater power of detecting an effect (larger sample size relative to the other ancestral groups).  
Results are shown in Table 30.  No significant SNP-based heritability estimates of NMUPD (-E,-
R) was identified.   
Overall, the findings from the additional GCTAs (IPV and NMUPD-E with inclusion of 
TE and probable-PTSD as covariates) did not identify significant h2SNP estimates. Similar concerns 
as those discussed within the molecular portion of the results section, lack of significant results is 
likely attributable to limited statistical power to detect effects and limitations associated with 
phenotypic assessment. 
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Table 30. Estimates of SNP-based heritability for nonmedical use of prescription drug use ([-E, -
R] while controlling for trauma exposure, probable posttraumatic stress disorder, population 
stratification, cohort, and sex) phenotypes generated from genome-wide complex trait analyses 
only among the European ancestral group. 
 
Super population N (Ca/Co) Covariates Sample 
prevalence 
h2SNP SE p-
value 
NMUPD-E 
EUR 988/1952 PCs, cohort, 
sex, TE 
34% .13 .13 .20 
EUR 892/1640 PCs, cohort, 
sex, TE, 
probable-PTSD 
35% .16 .15 .10 
NMUPD-R 
EUR 528/2413 PCs, cohort, 
sex, TE 
18% .07 .13 .30 
EUR 480/2053 PCs, cohort, 
sex, TE, 
probable-PTSD 
19% .04 .15 .40 
Note:  NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated non-medical use of 
prescription drugs, Ca = cases, Co = controls, PCs = principle components, TE = trauma exposure, probable-PTSD = 
probable posttraumatic stress disorder, h2SNP = SNP based heritability estimate. 
 
 
  
 
 
 
 
